% \documentclass[twocolumn]{article} \documentclass{report} \usepackage[section]{placeins} \usepackage[top=1in,left=1.5in,right=1in,bottom=1in]{geometry} \usepackage{siunitx} \usepackage{multicol} \setlength{\columnsep}{1cm} \usepackage[acronym]{glossaries} \usepackage[T1]{fontenc} \usepackage{enumitem} \usepackage{titlesec} \usepackage{titlecaps} \usepackage{upgreek} \usepackage{graphicx} \usepackage{subcaption} \usepackage{nth} \usepackage{hyperref} % must be before cleveref \usepackage[capitalize]{cleveref} \usepackage[version=4]{mhchem} \usepackage{pgfgantt} \usepackage{setspace} \usepackage{listings} %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% % my attempt to make MATLAB code look pretty \definecolor{dkgreen}{rgb}{0,0.6,0} \definecolor{gray}{rgb}{0.5,0.5,0.5} \definecolor{mauve}{rgb}{0.58,0,0.82} \lstset{frame=tb, language=Matlab, aboveskip=3mm, belowskip=3mm, showstringspaces=false, columns=flexible, basicstyle={\small\ttfamily}, numbers=none, numberstyle=\tiny\color{gray}, keywordstyle=\color{blue}, commentstyle=\color{dkgreen}, stringstyle=\color{mauve}, breaklines=true, breakatwhitespace=true, tabsize=3 } %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% % benevolently force figures stay in their own subsection % % NOTE the placeins package only has a 'section' option which puts % floatbarriers after every \section call; this does the same for \subsection \makeatletter \AtBeginDocument{% \expandafter\renewcommand\expandafter\subsection\expandafter {\expandafter\@fb@secFB\subsection}% \newcommand\@fb@subsecFB{\FloatBarrier \gdef\@fb@afterHHook{\@fb@topbarrier \gdef\@fb@afterHHook{}}}% \g@addto@macro\@afterheading{\@fb@afterHHook}% \gdef\@fb@afterHHook{}% } \makeatother %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% % header configuration % % NOTE glossary can't apparently be used in section header (even thought it % would be nice) \doublespacing{} \titleformat{\chapter}[block]{\filcenter\bfseries\large} {\MakeUppercase{\chaptertitlename} \thechapter: }{0pt}{\uppercase} % \titleformat{\chapter}[block]{\filcenter\bfseries\large}{}{0pt}{\uppercase} \titleformat{\section}[block]{\bfseries\large}{}{0pt}{\titlecap} \titleformat{\subsection}[block]{\itshape\large}{}{0pt}{\titlecap} \titleformat{\subsubsection}[runin]{\bfseries\itshape\/}{}{0pt}{\titlecap} \setlist[description]{font=$\bullet$~\textbf\normalfont} %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% % acronyms for the lazy % % adding as many as possible has the added benefit of making the thesis longer % and making me sound more sophisticated \renewcommand{\glossarysection}[2][]{} % remove glossary title \makeglossaries \newacronym{til}{TIL}{tumor infiltrating lymphocyte} \newacronym{tcr}{TCR}{T cell receptor} \newacronym{act}{ACT}{adoptive cell therapies} \newacronym{qc}{QC}{quality control} \newacronym{tn}{T\textsubscript{n}}{naive T cell} \newacronym{tcm}{T\textsubscript{cm}}{central memory T cell} \newacronym{tscm}{T\textsubscript{scm}}{stem-memory T cell} \newacronym{tem}{T\textsubscript{em}}{effector-memory T cell} \newacronym{teff}{T\textsubscript{eff}}{effector T cell} \newacronym{car}{CAR}{chimeric antigen receptor} \newacronym[longplural={monoclonal antibodies}]{mab}{mAb}{monoclonal antibody} \newacronym{ecm}{ECM}{extracellular matrix} \newacronym{cqa}{CQA}{critical quality attribute} \newacronym{cpp}{CPP}{critical process parameter} \newacronym{dms}{DMS}{degradable microscaffold} \newacronym{doe}{DOE}{design of experiments} \newacronym{adoe}{ADOE}{adaptive design of experiments} \newacronym{gmp}{GMP}{Good Manufacturing Practices} \newacronym{cho}{CHO}{Chinese hamster ovary} \newacronym{all}{ALL}{acute lymphoblastic leukemia} \newacronym{cll}{CLL}{chronic lymphoblastic leukemia} \newacronym{pdms}{PDMS}{polydimethylsiloxane} \newacronym{dc}{DC}{dendritic cell} \newacronym{il}{IL}{interleukin} \newacronym{il2}{IL2}{interleukin 2} \newacronym{il15}{IL15}{interleukin 15} \newacronym{il15r}{IL15R}{interleukin 15 receptor} \newacronym{rhil2}{rhIL2}{recombinant human interleukin 2} \newacronym{apc}{APC}{antigen presenting cell} \newacronym{mhc}{MHC}{major histocompatibility complex} \newacronym{elisa}{ELISA}{enzyme-linked immunosorbent assay} \newacronym{nmr}{NMR}{nuclear magnetic resonance} \newacronym{haba}{HABA}{4-hydroxyazobenene-2-carboxylic-acid} \newacronym{pbs}{PBS}{phosphate buffered saline} \newacronym{bca}{BCA}{bicinchoninic acid assay} \newacronym{bsa}{BSA}{bovine serum albumin} \newacronym{hsa}{HSA}{human serum albumin} \newacronym{stp}{STP}{streptavidin} \newacronym{stppe}{STP-PE}{streptavidin-phycoerythrin} \newacronym{snb}{SNB}{sulfo-nhs-biotin} \newacronym{cug}{CuG}{Cultispher G} \newacronym{cus}{CuS}{Cultispher S} \newacronym{pbmc}{PBMC}{peripheral blood mononuclear cells} \newacronym{macs}{MACS}{magnetic activated cell sorting} \newacronym{aopi}{AO/PI}{acridine orange/propidium iodide} \newacronym{igg}{IgG}{immunoglobulin G} \newacronym{pe}{PE}{phycoerythrin} \newacronym{fitc}{FITC}{Fluorescein} \newacronym{fitcbt}{FITC-BT}{Fluorescein-biotin} \newacronym{ptnl}{PTN-L}{Protein L} \newacronym{af647}{AF647}{Alexa Fluor 647} \newacronym{anova}{ANOVA}{analysis of variance} \newacronym{crispr}{CRISPR}{clustered regularly interspaced short palindromic repeats} \newacronym{mtt}{MTT}{3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide} \newacronym{bmi}{BMI}{body mass index} \newacronym{a2b1}{A2B1}{integrin $\upalpha$1$\upbeta$1} \newacronym{a2b2}{A2B2}{integrin $\upalpha$1$\upbeta$2} \newacronym{nsg}{NSG}{NOD scid gamma} \newacronym{colb}{COL-B}{collagenase B} \newacronym{cold}{COL-D}{collagenase D} \newacronym{tsne}{tSNE}{t-stochastic neighbor embedding} \newacronym{umap}{UMAP}{uniform manifold approximation and projection} \newacronym{anv}{AXV}{Annexin-V} \newacronym{pi}{PI}{propidium iodide} \newacronym{rt}{RT}{room temperature} \newacronym{cas37}{Cas3/7}{Caspase-3/7} \newacronym{bcl2}{BCL-2}{B cell lymphoma 2} \newacronym{tmb}{TMB}{3,3',5,5'-Tetramethylbenzidine} \newacronym{gvhd}{GVHD}{graft-vs-host disease} \newacronym{bcma}{BCMA}{B-cell maturation antigen} \newacronym{di}{DI}{deionized} \newacronym{moi}{MOI}{multiplicity of infection} \newacronym{ifng}{IFN$\upgamma$}{interferon-$\upgamma$} \newacronym{tnfa}{TNF$\upalpha$}{tumor necrosis factor-$\upalpha$} \newacronym{sql}{SQL}{structured query language} \newacronym{fcs}{FCS}{flow cytometry standard} \newacronym{ivis}{ivis}{in vivo imaging system} \newacronym{iacuc}{IACUC}{institutional animal care and use committee} \newacronym{hbss}{HBSS}{Hank's buffered saline solution} \newacronym{leaf}{LEAF}{low endotoxin, azide-free} \newacronym{cytof}{CyTOF}{cytometry time-of-flight} \newacronym{spade}{SPADE}{spanning-tree progression analysis of density-normalized events} \newacronym{ml}{ML}{machine learning} \newacronym{rf}{RF}{random forest} \newacronym{sr}{SR}{symbolic regression} \newacronym{gbm}{GBM}{gradient boosted trees} \newacronym{cif}{CIF}{conditional inference forests} \newacronym{lasso}{LASSO}{least absolute shrinkage and selection operator} \newacronym{svm}{SVM}{support vector machines} \newacronym{plsr}{PLSR}{partial least squares regression} \newacronym{mse}{MSE}{mean squared error} \newacronym{loocv}{LOO-CV}{leave-one-out cross validation} \newacronym{hsqc}{HSQC}{heteronuclear single quantum coherence} \newacronym{hla}{HLA}{human leukocyte antigen} \newacronym{zfn}{ZFN}{zinc-finger nuclease} \newacronym{talen}{TALEN}{transcription activator-like effector nuclease} \newacronym{qbd}{QbD}{quality-by-design} \newacronym{aws}{AWS}{amazon web services} \newacronym{qpcr}{qPCR}{quantitative polymerase chain reaction} \newacronym{cstr}{CSTR}{continuously stirred tank bioreactor} %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% % SI units for uber nerds % NOTE the \SI macro is depreciated but the arch repo (!!!) hasn't been updated % with the latest package yet (texlive-science) \sisetup{per-mode=symbol,list-units=single} \DeclareSIUnit\IU{IU} \DeclareSIUnit\rpm{RPM} \DeclareSIUnit\carrier{carrier} \DeclareSIUnit\dms{DMS} \DeclareSIUnit\cell{cells} \DeclareSIUnit\ab{mAb} \DeclareSIUnit\normal{N} \DeclareSIUnit\molar{M} \DeclareSIUnit\mM{\milli\molar} \DeclareSIUnit\uM{\micro\molar} \DeclareSIUnit\gforce{\times{} g} %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% % commands for lazy farts like me % gatech format conformity \newcommand{\mytitle}{ \Large{ \textbf{ Optimizing T Cell Manufacturing and Quality Using Functionalized Degradable Microscaffolds } } } \newcommand{\mycommitteemember}[3]{ \begin{flushleft} \noindent #1 \\ #2 \\ \textit{#3} \end{flushleft} } % a BME's best friend \newcommand{\invivo}{\textit{in vivo}} \newcommand{\invitro}{\textit{in vitro}} \newcommand{\exvivo}{\textit{ex vivo}} % various CD-whatever crap \newcommand{\cd}[1]{CD{#1}} \newcommand{\anti}[1]{anti-{#1}} \newcommand{\antih}[1]{anti-human {#1}} \newcommand{\antim}[1]{anti-mouse {#1}} \newcommand{\acd}[1]{\anti{\cd{#1}}} \newcommand{\ahcd}[1]{\antih{\cd{#1}}} \newcommand{\amcd}[1]{\antim{\cd{#1}}} \newcommand{\pos}[1]{#1+} \newcommand{\cdp}[1]{\pos{\cd{#1}}} \newcommand{\cdn}[1]{\cd{#1}-} \newcommand{\ptmem}{\cdp{62L}\pos{CCR7}} \newcommand{\ptmemp}{\ptmem{}~\si{\percent}} \newcommand{\pth}{\cdp{4}} \newcommand{\pthp}{\pth{}~\si{\percent}} \newcommand{\ptk}{\cdp{8}} \newcommand{\ptmemh}{\pth\ptmem} \newcommand{\ptmemk}{\ptk\ptmem} \newcommand{\dpthp}{$\Updelta$\pthp{}} \newcommand{\ptcar}{\gls{car}+} \newcommand{\ptcarp}{\ptcar~\si{\percent}} % so I don't need to worry about abbreviating all the different interleukins \newcommand{\il}[1]{\gls{il}-#1} % DOE responses I don't feel like typing ad-nauseam \newcommand{\pilII}{\gls{il2} concentration} \newcommand{\pdms}{\gls{dms} concentration} \newcommand{\pmab}{functional \gls{mab} surface density} % vendor and product stuff I don't feel like typing \newcommand{\catnum}[2]{(#1, #2)} \newcommand{\product}[3]{#1 \catnum{#2}{#3}} \newcommand{\thermo}{Thermo Fisher} \newcommand{\sigald}{Sigma Aldrich} \newcommand{\miltenyi}{Miltenyi Biotech} \newcommand{\bl}{Biolegend} \newcommand{\bd}{Becton Dickenson} % the obligatory misc category \newcommand{\inlinecode}{\texttt} \newcommand{\subcap}[2]{\subref{#1}) #2} \newcommand{\sigkey}{Significance test key: *p<0.1; **p < 0.05; ***p<0.01} %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% % ditto for environments \newenvironment{mytitlepage}{ \begin{singlespace} \begin{center} } { \end{center} \end{singlespace} } %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% % begin document (proceed with caution) \begin{document} \begin{titlepage} \begin{mytitlepage} \mytitle{} \vfill \Large{ A Dissertation \\ Presented to \\ The Academic Faculty \\ \vspace{1.5em} by \vspace{1.5em} Nathan John Dwarshuis, B.S. \\ \vfill In Partial Fulfillment \\ of the Requirements for the Degree \\ Doctor of Philosophy in Biomedical Engineering in the \\ Wallace H. Coulter Department of Biomedical Engineering \vfill Georgia Institute of Technology and Emory University \\ August 2021 \vfill COPYRIGHT \copyright{} BY NATHAN J. DWARSHUIS } \end{mytitlepage} \end{titlepage} \onecolumn \pagenumbering{roman} \clearpage \begin{mytitlepage} \mytitle{} \end{mytitlepage} \vfill \large{ \noindent Committee Members \begin{multicols}{2} \begin{singlespace} \mycommitteemember{Dr.\ Krishnendu\ Roy\ (Advisor)} {Department of Biomedical Engineering} {Georgia Institute of Technology and Emory University} \vspace{1.5em} \mycommitteemember{Dr.\ Madhav\ Dhodapkar} {Department of Hematology and Medical Oncology} {Emory University} \vspace{1.5em} \mycommitteemember{Dr.\ Melissa\ Kemp} {Department of Biomedical Engineering} {Georgia Institute of Technology and Emory University} \columnbreak{} \null{} \vfill \mycommitteemember{Dr.\ Wilbur\ Lam} {Department of Biomedical Engineering} {Georgia Institute of Technology and Emory University} \vspace{1.5em} \mycommitteemember{Dr.\ Sakis\ Mantalaris} {Department of Biomedical Engineering} {Georgia Institute of Technology and Emory University} \end{singlespace} \end{multicols} \vspace{1.5em} \hfill Date Approved: } \clearpage \chapter*{acknowledgements} \addcontentsline{toc}{chapter}{acknowledgements} Thank you to Lex Fridman and Devin Townsend for being awesome and inspirational. \clearpage \chapter*{summary} \addcontentsline{toc}{chapter}{summary} \Gls{act} using \gls{car} T cells have shown promise in treating cancer, but manufacturing large numbers of high quality cells remains challenging. Currently approved T cell expansion technologies involve \anti-cd{3} and \anti-cd{28} \glspl{mab}, usually mounted on magnetic beads. This method fails to recapitulate many key signals found \invivo{} and is also heavily licensed by a few companies, limiting its long-term usefulness to manufactures and clinicians. Furthermore, we understand that highly potent T cells are generally less-differentiated subtypes such as central memory and stem memory T cells. Despite this understanding, little has been done to optimize T cell expansion for generating these subtypes, including measurement and feedback control strategies that are necessary for any modern manufacturing process. The goal of this thesis was to develop a microcarrier-based \gls{dms} T cell expansion system as well as determine biologically-meaningful \glspl{cqa} and \glspl{cpp} that could be used to optimize for highly-potent T cells. In Aim 1, we develop and characterized the \gls{dms} system, including quality control steps. We also demonstrate the feasiblity of expanding highly-potent memory and CD4+ T cells, and showing compatibility with existing \gls{car} transduction methods. In aim 2, we use \gls{doe} methodology to optimize the \gls{dms} platform, and develop a computational pipeline to identify and model the effect of measurable \glspl{cqa} and \glspl{cpp} on the final product. In aim 3, we demonstrate the effectiveness of the \gls{dms} platform \invivo{}. This thesis lays the groundwork for a novel T cell expansion method which can be used in a clinical setting, and also provides a path toward optimizing for product quality in an industrial setting. \clearpage \tableofcontents \clearpage \listoffigures \clearpage \listoftables \clearpage % \twocolumn \chapter*{acronyms} \addcontentsline{toc}{chapter}{acronyms} \printglossary[type=\acronymtype] \clearpage \pagenumbering{arabic} \clearpage \chapter{introduction} \section*{overview} % TODO this is basically the same as the first part of the backgound, I guess I % can just trim it down T cell-based immunotherapies have received great interest from clinicians and industry due to their potential to treat, and often cure, cancer and other diseases\cite{Fesnak2016,Rosenberg2015}. In 2017, Novartis and Kite Pharma received FDA approval for \textit{Kymriah} and \textit{Yescarta} respectively, two genetically-modified \gls{car} T cell therapies against B cell malignancies. Despite these successes, \gls{car} T cell therapies are constrained by an expensive and difficult-to-scale manufacturing process with little control on cell quality and phenotype3,4. State-of-the-art T cell manufacturing techniques focus on \acd{3} and \acd{28} activation and expansion, typically presented on superparamagnetic, iron-based microbeads (Invitrogen Dynabead, Miltenyi MACS beads), on nanobeads (Miltenyi TransACT), or in soluble tetramers (Expamer)\cite{Roddie2019,Dwarshuis2017,Wang2016, Piscopo2017, Bashour2015}. These strategies overlook many of the signaling components present in the secondary lymphoid organs where T cells expand \invivo{}. Typically, T cells are activated under close cell-cell contact, which allows for efficient autocrine/paracrine signaling via growth-stimulating cytokines such as \gls{il2}. Additionally, the lymphoid tissues are comprised of \gls{ecm} components such as collagen, which provide signals to upregulate proliferation, cytokine production, and pro-survival pathways\cite{Gendron2003, Ohtani2008, Boisvert2007, Ben-Horin2004}. We hypothesized that culture conditions that better mimic these \invivo{} expansion conditions of T cells, can significantly improve the quality and quantity of manufactured T cells and provide better control on the resulting T cell phenotype. A variety of solutions have been proposed to make the T cell expansion process more physiological. One strategy is to use modified feeder cell cultures to provide activation signals similar to those of \glspl{dc}\cite{Forget2014}. While this has the theoretical capacity to mimic many components of the lymph node, it is hard to reproduce on a large scale due to the complexity and inherent variability of using cell lines in a fully \gls{gmp}-compliant manner. Others have proposed biomaterials-based solutions to circumvent this problem, including lipid-coated microrods\cite{Cheung2018}, 3D-scaffolds via either Matrigel\cite{Rio2018} or 3d-printed lattices\cite{Delalat2017}, ellipsoid beads\cite{meyer15_immun}, and \gls{mab}-conjugated \gls{pdms} beads\cite{Lambert2017} that respectively recapitulate the cellular membrane, large interfacial contact area, 3D-structure, or soft surfaces T cells normally experience \invivo{}. While these have been shown to provide superior expansion compared to traditional microbeads, none of these methods has been able to show preferential expansion of functional naïve/memory and CD4 T cell populations. Generally, T cells with a lower differentiation state such as naïve and memory cells have been shown to provide superior anti-tumor potency, presumably due to their higher potential to replicate, migrate, and engraft, leading to a long-term, durable response\cite{Xu2014, Fraietta2018, Gattinoni2011, Gattinoni2012}. Likewise, CD4 T cells are similarly important to anti-tumor potency due to their cytokine release properties and ability to resist exhaustion\cite{Wang2018, Yang2017}. Therefore, methods to increase naïve/memory and CD4 T cells in the final product are needed, a critical consideration being ease of translation to industry and ability to interface with scalable systems such as bioreactors. % TODO probably need to address some of the modeling stuff here as well This thesis describes a novel degradable microscaffold-based method derived from porous microcarriers functionalized with \acd{3} and \acd{28} \glspl{mab} for use in T cell expansion cultures. Microcarriers have historically been used throughout the bioprocess industry for adherent cultures such as stem cells and \gls{cho} cells, but not with suspension cells such as T cells\cite{Heathman2015, Sart2011}. The microcarriers chosen to make the DMSs in this study have a microporous structure that allows T cells to grow inside and along the surface, providing ample cell-cell contact for enhanced autocrine and paracrine signaling. Furthermore, the carriers are composed of gelatin, which is a collagen derivative and therefore has adhesion domains that are also present within the lymph nodes. Finally, the 3D surface of the carriers provides a larger contact area for T cells to interact with the \glspl{mab} relative to beads; this may better emulate the large contact surface area that occurs between T cells and \glspl{dc}. These microcarriers are readily available in over 30 countries and are used in an FDA fast-track-approved combination retinal pigment epithelial cell product (Spheramine, Titan Pharmaceuticals)\cite{purcellmain}. This regulatory history will aid in clinical translation. We show that compared to traditional microbeads, \gls{dms}-expanded T cells not only provide superior expansion, but consistently provide a higher frequency of naïve/memory and CD4 T cells (CCR7+CD62L+) across multiple donors. We also demonstrate functional cytotoxicity using a CD19 \gls{car} and a superior performance, even at a lower \gls{car} T cell dose, of \gls{dms}-expanded \gls{car}-T cells \invivo{} in a mouse xenograft model of human B cell \gls{all}. Our results indicate that \glspl{dms} provide a robust and scalable platform for manufacturing therapeutic T cells with higher naïve/memory phenotype and more balanced CD4+ T cell content. \section*{hypothesis} The hypothesis of this dissertation was that using \glspl{dms} created from off-the-shelf microcarriers and coated with activating \glspl{mab} would lead to higher quantity and quality T cells as compared to state-of-the-art bead-based expansion. The objective of this dissertation was to develop this platform, test its effectiveness both \invivo{} and \invivo{}, and develop computational pipelines that could be used in a manufacturing environment. \section*{specific aims} The specific aims of this dissertation are outlined in \cref{fig:graphical_overview}. \begin{figure*}[ht!] \begingroup \includegraphics[width=\textwidth]{../figures/overview.png} \endgroup \caption[Project Overview]{High-level overview.} \label{fig:graphical_overview} \end{figure*} \subsection*{aim 1: develop and optimize a novel T cell expansion process that mimics key components of the lymph nodes} In this first aim, we demonstrated the process for manufacturing \glspl{dms}, including quality control steps that are necessary for translation of this platform into a scalable manufacturing setting. We also demonstrate that the \gls{dms} platform leads to higher overall expansion of T cells and higher overall fractions of potent memory and CD4+ subtypes desired for T cell therapies. Finally, we demonstrate \invitro{} that the \gls{dms} platform can be used to generate functional \gls{car} T cells targeted toward CD19. \subsection*{aim 2: develop methods to control and predict T cell quality} For this second aim, we investigated methods to identify and control \glspl{cqa} and glspl{cpp} for manufacturing T cells using the \gls{dms} platform. This was accomplished through two sub-aims: \begin{itemize} \item[A --] Develop computational methods to control and predict T cell expansion and quality \item[B --] Perturb \gls{dms} expansion to identify additional mechanistic controls for expansion and quality \end{itemize} \subsection*{aim 3: confirm potency of T cells from novel T cell expansion process using \invivo{} xenograft mouse model} In this final aim, we demonstrate the effectiveness of \gls{dms}-expanded T cells compared to state-of-the-art beads using \invivo{} mouse models for \gls{all}. \section*{outline} In Chapter~\ref{background}, we provide additional background on the current state of T cell manufacturing and how the work in this dissertation moves the field forward. In Chapters~\ref{aim1},~\ref{aim2a},~\ref{aim2b}, and~\ref{aim3} we present the work pertaining to Aims 1, 2, and 3 respectively. Finally, we present our final conclusions in Chapter~\ref{conclusions}. \chapter{background and significance}\label{background} \section*{background} \subsection{quality by design in cell manufacturing} The challenges facing the cell manufacturing field at large are significant. Unlike other industries which manufacture inanimate products such as automobiles and semiconductors, the cell manufacturing industry needs to contend with the fact that cells are living entities which can change with every process manipulation\cite{Kirouac2008, Little2006, Pirnay2012, Rousseau2013}. This is further compounded by the lack of standardization and limited regulation. In order to overcome these barriers, adopting a systemic approach to cell manufacturing using \gls{qbd} principles will be extremely important\cite{Kirouac2008}. In \gls{qbd}, the objective is to reproducibly manufacturing products which minimizes risk for downstream stakeholders (in this case, the patient). This requires identification of \glspl{cqa}, which are measurable properties of the product that can be used to define its functionality and hence quality. \glspl{cqa} are important for defining the characteristics of a `good' product (release criteria) but also for ensuring that a process is on track to making such a product (process control). In the space of cell manufacturing, examples of \glspl{cqa} include markers on the surface of cells and readouts from functional assays such as killing assays. In general, these are poorly understood if they exist at all. In addition to \glspl{cqa}, the \glspl{cpp} pertinent to the manufacturing process are poorly understood. \glspl{cpp} are parameters which may be tuned and varied to control the outcome of process and the quality of the final product. Examples in the cell manufacturing space include the type of media used and the amount of \il{2} added. Once \glspl{cpp} are known, they can be optimized to ensure that costs are minimized and potency of the cellular product is maximized. The topic of discovering novel \glspl{cpp} and \glspl{cqa} in the context of this work are discussed further in \cref{sec:background_doe} and \cref{sec:background_quality}/\cref{sec:background_cqa} respectively. \subsection{T cells for immunotherapies} One of the first successful T cell-based immunotherapies against cancer is \glspl{til}\cite{Rosenberg2015}. This method works by taking tumor specimens from a patient, allowing the tumor-reactive lymphocytes to expand \exvivo{}, and then administered back to the patient along with a high dose of \il{2} [44]. In particular, \gls{til} therapy has shown robust results in treating melanoma [1], although \gls{til} have been found in other solid tumors such as gastointestinal, cervical, lung, and ovarian\cite{Rosenberg2015, Wang2014, Foppen2015, Solinas2017, June2007, Santoiemma2015}, and their presence is generally associate with favorable outcomes\cite{Clark1989}. \glspl{til} are heterogenous cell mixtures and generally are comprised of CD3 T cells and $\upgamma\updelta$ T cells\cite{Nishimura1999, Cordova2012}. To date, there are over 250 open clinical trials using \glspl{til}. Besides \gls{til}, the other broad class of T cell immunotherapies that has achieved great success in treating cancer in recent decades are gene-modified T cells. Rather than expand T cells that are present natively (as is the case with \gls{til} therapy), gene-modified T cell therapies entail extracting T cells from either the cancer patient (autologous) or a healthy donor (allogeneic) and reprogramming them genetically to target a tumor antigen (see \cref{sec:background_source}). In theory this offers much more flexibility\cite{Rosenberg2015}. T cells with transduced \glspl{tcr} were first designed to overcome the limitations of \gls{til}\cite{Rosenberg2015, Wang2014}. In this case, T cells are transduced \exvivo{} with a lentiviral vector to express a \gls{tcr} targeting a tumor antigen. T cells transduced with \glspl{tcr} have shown robust results in melanoma patients\cite{Robbins2011}, synovial sarcoma\cite{Morgan2006}, and others\cite{Ikeda2016}. To date, there are over 200 clinical trials using T cells with transduced \glspl{tcr}. While transduced \glspl{tcr} offer some flexibility in retargeting T cells toward relevant tumor antigens, they are still limited in that they can only target antigens that are presented via \gls{mhc} complexes. \gls{car} T cells overcome this limitation by using a the heavy and light chains (scFv) from a \gls{mab} which can target any antigen recognizable by antibodies. \gls{car} T cells were first demonstrated in 1989, where the author swapped the antigen-recognition domains of a native \gls{tcr} with a that of a foreign \gls{tcr}\cite{Gross1989}. Since then, this method has progressed to using an scFv with a CD3$\upzeta$ stimulatory domain along with the CD28, OX-40, or 4-1BB domains for costimulation. Since these can all be expressed with one protein sequence, \gls{car} T cells are relatively simple to produce and require only a single genetic transduction step (usually a lentiviral vector) to reprogram a batch T cells \exvivo{} toward the desired antigen. \gls{car} T cells have primarily found success in against CD19- and CD20-expressing tumors such as \gls{all} and \gls{cll} (eg B-cell malignancies)\cite{Kalos2011, Brentjens2011, Kochenderfer2010, Maude2014, Till2012, Till2008}. % BACKGROUND where else have they been approved? Out of all the T cell therapies discussed thus far, \gls{car} T cells have experienced the most commercial success and excitement. In 2017, Novartis and Kite Pharma acquired FDA approval for \textit{Kymriah} and \textit{Yescarta} respectively, both of which are \gls{car} T cell therapies against B-cell malignancies. % BACKGROUND beef this up, this is a big deal \gls{car} T cells are under further exploration for use in many other tumors, including multiple myeloma, mesothelioma, pancreatic cancer, glioblastoma, neuroblastoma, and prostate cancer, breast cancer, non-small-cell lung cancer, and others\cite{Rosenberg2015, Wang2014, Fesnak2016, Guo2016}. To date, there are almost 1000 clinical trials using \gls{car} T cells. % TODO there are other T cells like virus-specific T cells and gd T cells, not % that they matter... \subsection{cell sources in T cell manufacturing}\label{sec:background_source} T cells for cell manufacturing can be obtained broadly via two paradigms: autologous and allogeneic. The former involves obtaining T cells from a patient and giving them back to the same patient after \exvivo{} expansion and genetic modification. The latter involves taking T cells from a (usually) healthy donor, expanding them and manipulating them as desired, storing them long term, and then giving them to multiple patients. There are advantages and disadvantages to both, and in some cases such as \gls{til} therapy, the only option is to use autologous therapy. Autologous T cells by default are much safer. By definition, they will have no cross-reactivity with the patient and thus \gls{gvhd} is not a concern\cite{Decker2012}. However, there are numerous disadvantages. Autologous therapies are over 20X more costly as the process needs to be repeated for every patient\cite{Harrison2019}. To highlight how resource-intensive this can be, many cell products are manufactured at a centralized location, so patient T cells need to be shipped twice on dry ice from the hospital and back. In additional to being expensive, this can add days to the process, which is critical for patients with fast moving diseases. Manufacturing could be done on-site in a decentralized manner, but this requires more equipment and personnel overall. Using cells from a diseased patient has many drawbacks in itself. Cancer patients (especially those with chronic illnesses) often have exhausted T cells which expand far less readily and are consequently less potent\cite{Wherry2015, Ando2019, Zheng2017}. Additionally, they may have high frequencies of T\textsubscript{reg} cells which inhibitory\cite{Decker2012}. Removing these cells as well as purifying Th1 cells may enhance the potency of the final product\cite{Goldstein2012, Drela2004, Rankin2003, Luheshi2013, Grotz2015}; however, this would make the overall process more expensive as an additional step would be required. Allogeneic T cell therapies overcome nearly all of these disadvantages. Donor \glspl{pbmc} are easy to obtain, they can be processed in centralized locations, they can be stored easily under liquid nitrogen, and donors could be screened to find those with optimal anti-tumor cells. The key is overcoming \gls{gvhd}. Obviously this could be done the same way as done for transplants where patients find a `match' for their \gls{hla} type, but this severally limits options. This can be overcome by using gene-editing (eg \glspl{zfn}, \glspl{talen}, or \gls{crispr} to remove the native \gls{tcr} which would prevent the donor T cells from attacking host tissue\cite{Liu2019, Wiebking2020, Provasi2012, Berdien2014, Themeli2015}. To date there are about 10 open clinical trials utilizing allogeneic T cell therapies edited with \gls{crispr} to reduce the likelihood of \gls{gvhd}. \subsection{microcarriers in bioprocessing} Microcarriers have historically been used to grow a number of adherent cell types for a variety of applications. They were introduced in 1967 as a means to grow adherent cells `in suspension', effectively turning a 2D flask system into a 3D culture system\cite{WEZEL1967}. Microcarriers are generally spherical and are several hundred \si{\um} in diameter, which means they collectively have a much higher surface area than a traditional flask when matched for volume. Consequently, this means that microcarrier-based cultures can operate with much lower footprints than flask-like systems. Microcarriers also allow cell culture to operate more like a traditional chemical engineering process, wherein a \gls{cstr} may be employed to enhance oxygen transfer, maintain pH, and continuously supply nutrients\cite{Derakhti2019}. A variety of microcarriers have been designed, primarily differing in their choice of material and macroporous structure. Key concerns have been cell attachment at the beginning of culture and cell detachment at the harvesting step; these have largely driven the nature of the material and structures employed\cite{Derakhti2019}. Many microcarriers simply use polystyrene (the material used for tissue culture flasks and dishes in general) with no modification (SoloHill Plastic, Nunc Biosilon), with a cationic surface charge (SoloHill Hillex) or coated with an \gls{ecm} protein such as collagen (SoloHill Fact III). Other base materials have been used such as dextran (GE Healthcare Cytodex), cellulose (GE Healthcare Cytopore), and glass (\sigald{} G2767), all with none or similar surface modifications. Additionally, some microcarriers such as \gls{cus} and \gls{cug} are composed entirely out of protein (in these cases, porcine collagen) which also allows the microcarriers to be enzymatically degraded. In the case of non-protein materials, cells may still be detached using enzymes but these require similar methods to those currently used in flasks such as trypsin which target the cellular \gls{ecm} directly. Since trypsin and related enzymes tends to be harsh on cells, an advantage of using entirely protein-based microcarriers is that they can be degraded using a much safer enzyme such as collagenase, at the cost of being more expensive and also being harder to make \gls{gmp}-compliant\cite{Derakhti2019}. Going one step further, some microcarriers are composed of a naturally degrading scaffold such as alginate, which do not need an enzyme for degradation but are limited in that the degradation process is less controllable. Finally, microcarriers can differ in their overall structure. \gls{cug} and \gls{cus} microcarriers as well as the Cytopore microcarriers are macroporous, meaning they have a porous network in which cells can attach throughout their interior. This drastically increases the effective surface area and consequently the number of cells which may be grown per unit volume. Other microcarriers are microporous (eg only to small molecules) or not porous at all (eg polystyrene) in which case the cells can only grow on the surface. Microcarriers have seen the most use in growing \gls{cho} cells and hybridomas in the case of protein manufacturing (eg \gls{igg} production)\cite{Xiao1999, Kim2011} as well as pluripotent stem cells and mesenchymal stromal cells more recently in the case of cell manufacturing\cite{Heathman2015, Sart2011, Chen2013, Schop2010, Rafiq2016}. Interestingly, some groups have even explored using biodegradable microcarriers \invivo{} as a delivery vehicle for stem cell therapies in the context of regenerative medicine\cite{Zhang2016, Saltz2016, Park2013, Malda2006}. However, the characteristic shared by all the cell types in this application is the fact that they are adherent. In this work, we explore the use of microcarrier for T cells, which are naturally non-adherent. \subsection{methods to scale T cells} In order to scale T cell therapies to meet clinical demands, automation and bioreactors will be necessary. To this end, there are several choices that have found success in the clinic. The WAVE bioreactor (GE Healthcare) is the choice of expansion for many clinical applications\cite{Brentjens2011, Hollyman2009, Brentjens2013}. It is part of a broader class of bioreactors that consist of rocking platforms that agitate a bag filled with media and cells. Importantly, it has built-in sensors for measuring media flow rate, carbon dioxide, oxygen, pH, and nutrient consumption which enables automation. Unfortunately, in some settings this is not considered scalable as only one bag per bioreactor is allowed at once\cite{Roddie2019}. The other disadvantage with the WAVE system is that it keeps cells far apart by design, which could have negative impact on cross-talk, activation, and growth\cite{Somerville2012}. % BACKGROUND find clinical trials (if any) that use this Alternatively, the CliniMACS Prodigy (Miltenyi) is an all-in-one system that is a fully closed system that removes the need for expensive cleanrooms and associated personnel\cite{Kaiser2015, Bunos2015}. It contains modules to perform transduction, expansion, and washing. This setup also implies that fewer mistakes and handling errors will be made, since many of the steps are internal to the machine. Initial investigations have shown that it can yield T cells doses required for clinical use\cite{Zhu2018}. At the time of writing, several clinical trial are underway which use the CliniMACS, although mostly for stem-cell based cell treatments. Finally, another option that has been investigated for T cell expansion is the Grex bioreactor (Wilson Wolf). This is effectively a tall tissue-culture plate with a porous membrane at the bottom, which allows gas exchange to the active cell culture at the bottom of the plate while permitting large volumes of media to be loaded on top without suffocating the cells. While this is quite similar to plates and flasks normally used for small-scale research, the important difference is that its larger size requires fewer interactions and keeps the cells at a higher nutrient concentration for longer periods of time. However, it is still a an open system and requires manual (by default) interaction from an operator to load, feed, and harvest the cell product. Grex bioreactors have been using to grow \glspl{til}\cite{Jin2012} and virus-specific T cells\cite{Gerdemann2011}. \subsection{overview of T cell quality}\label{sec:background_quality} T cells are highly heterogeneous and can exist in a variety of states and subtypes, many of which can be measured (at least indirectly) though biomarkers such as cell surface proteins. Identifying and understanding these biomarkers are the basis for \glspl{cqa} which can be used to for process control, release criteria, and initial cell source screening. One of the most important dimensions of T cell quality is that of differentiation. T cells begin their life in circulation (eg after they exit the thymus) as naive T cells. When they become activated in the secondary lymph node organs, they differentiate from \gls{tn} to \gls{tscm}, \gls{tcm}, \gls{tem}, and finally \gls{teff}\cite{Gattinoni2012}. Subtypes earlier in this process are generally called `memory' or `memory-like' cells (eg \gls{tscm} and \gls{tcm}), and have been shown to have increased potency toward a variety of tumors, presumably due to their higher capacity for self-renewal and replication, enhanced migratory capacity, and/or increased engraftment potential\cite{Xu2014, Gattinoni2012, Fraietta2018, Gattinoni2011, Turtle2009}. The capacity for self-renewal is especially important for T cells therapies, as evidenced by the fact that \gls{til} therapies with longer telomeres tend to work better\cite{Donia2012}. Additionally, clonal diversity decreases following the infusion of \gls{car} T cell therapies, which demonstrates that only a few clones are self-renewing and therefore responsible for the overall response\cite{Sheih2020}. Memory T cells can be quantified easily using surface markers such as CD62L, CCR7, CD27, CD45RA, and CD45RO. Furthermore, memory markers are inversely related to exhaustion markers which are negatively associated with clinical outcomes\cite{Lee2013}. These cells in particular are seen in patients with chronic immune activation such as patients with chronic cancers. In addition to memory, the other major axis by which T cells may be classified is the CD4/CD8 ratio. CD4 (`helper') T cells are responsible for secreting cytokines which coordinate the immune response while CD8 (`killer') T cell responsible for killing tumor or infected cells using specialized lytic enzymes. Since CD8 T cells actually perform the killing function, it seems intuitive that CD8 T cells would be most important for anti-tumor immunotherapies. However, in mouse models with glioblastoma, survival was negatively impacted when CD4 T cells were removed\cite{Wang2018}. Furthermore, CD4 T cells have been shown to have cytotoxic properties on their own and also show resistance to T cell exhaustion compared to CD8 T cells\cite{Yang2017}. While T cell products with a defined ratio of CD4 and CD8 T cells have been utilized, they are more expensive than products with undefined ratios as the T cells need to be sorted and recombined, adding additional complexity\cite{Turtle2016}. While less of a focus in this dissertation, other quality markers exists to assess the overall killing potential and safety of the T cell product. Numerous methods exists to detect the killing capacity of \gls{car} T cells, many of which involve either measuring the lysis of a target cell using a dye or a radioactive tracer, by measuring the degranulation of the T cells themselves, or by measuring a cytokine that is secreted upon T cell activation and killing such as \gls{ifng}. Furthermore, the viability of T cells may be assessed using a number of methods, including exclusion dyes such as \gls{aopi} or a functional assay to detect metabolism. Finally, for the purposes of safety, T cell products using retro- or lentiviral vectors as their means of gene-editing must be tested for replication competent vectors\cite{Wang2013} and for contamination via bacteria or other pathogens. \subsection*{T cell activation} % Despite these success of T cell therapies (especially \gls{car} T cell % therapies) they are constrained by an expensive and difficult-to-scale % manufacturing process\cite{Roddie2019, Dwarshuis2017}. In order for T cells to be expanded \exvivo{} they must be activated with a stimulatory signal (Signal 1) and a costimulatory signal (Signal 2). \invivo{} Signal 1 is administered via the \gls{tcr} and the CD3 receptor when \glspl{apc} present a peptide via \gls{mhc} that the T cell in question is able to recognize. Signal 2 is administered via CD80 and CD86 which are also present on \glspl{apc} and is necessary to prevent the T cell from becoming anergic. While these two signal are the bare minimum to trigger a T cell to expand, there are many other potential signals present. T cells have many other costimulatory receptors such as OX40, 4-1BB and ICOS which are costimulatory along with CD28, and \glspl{apc} have corresponding ligands for these depending on the nature of the pathogen they have detected\cite{Azuma2019}. Furthermore, T cells exist in high cell density within the secondary lymphoid organs, which allows efficient cytokine cross-talk in an autocrine and paracrine manner. These cytokines are responsible for expansion (in the case of \il{2}) and subset differentiation (in the case of many others)\cite{Luckheeram2012}. By tuning the signal strength and duration of Signal 1, Signal 2, the various costimulatory signals, and the cytokine milieu, a variety of T cell phenotypes can be actualized. \invitro{}, T cells can be activated in a number of ways but the simplest and most common is to use \glspl{mab} that cross-link the CD3 and CD28 receptors, which supply Signal 1 and Signal 2 without the need for antigen (which also means all T cells are activated and not just a few specific clones). Additional signals may be supplied in the form of cytokines (eg \il{2}, \il{7}, or \il{15}) or feeder cells\cite{Forget2014}. As this is a critical unit operation in the manufacturing of T cell therapies, a number of commercial technologies exist to activate T cells\cite{Wang2016, Piscopo2017, Roddie2019, Bashour2015}. The simplest is to use \acd{3} and \acd{28} \gls{mab} bound to a 2D surface such as a plate, and this can be ackomplished in a \gls{gmp} manner as soluble \gls{gmp}-grade \glspl{mab} are commericially available. A similar but distinct method along these lines is to use multivalent activators such as ImmunoCult (StemCell Technologies) or Expamer (Juno Therapeutics) which may have increased cross-linking capacity compared to traditional \glspl{mab}. Beyond soluble protein, \glspl{mab} against CD3 and CD28 can be mounted on magnetic microbeads (\SIrange{3}{5}{\um} in diameter) such as DynaBeads (Invitrogen) and MACSbeads (\miltenyi{}), which are easier to separate using magnetic washing plates. Magnetic nanobeads such as TransAct (\miltenyi{}) work by a similar principle except they can be removed via centrifugation rather than a magnetic washing plate. Cloudz (RnD Systems) are another bead-based T cell expansion which mounts \acd{3} and \acd{28} \glspl{mab} on alginate microspheres, which are not only easily degradable but are also softer, which can have a positive impact on T cell activation and phenotype\cite{Lambert2017, OConnor2012}. A problem with all of these commercial solutions is that they only focus on Signal 1 and Signal 2 and ignore the many other physiological cues present in the secondary lymphoid organs. A variety of novel T cell activation and expansion solutions have been proposed to overcome this. One strategy is to use modified feeder cell cultures to provide activation signals similar to those of \glspl{dc}\cite{Forget2014}. While this has the theoretical capacity to mimic several key components of the lymph node, it is hard to reproduce on a large scale due to the complexity and inherent variability of using cell lines in a fully \gls{gmp}-compliant manner. Others have proposed biomaterials-based solutions to circumvent this problem, including lipid-coated microrods\cite{Cheung2018}, 3D-scaffolds via either Matrigel\cite{Rio2018} or 3d-printed lattices\cite{Delalat2017}, ellipsoid beads\cite{meyer15_immun}, and \gls{mab}-conjugated \gls{pdms} beads\cite{Lambert2017} that respectively recapitulate the cellular membrane, large interfacial contact area, 3D-structure, or soft surfaces T cells normally experience \textit{in vivo}. While these are in theory much easier to produce and \gls{qc} compared to feeder cells, none have been demonstrated to demonstrably expand high quality T cells as outlined in \cref{sec:background_quality}. \subsection*{integrins and T cell signaling} Because the microcarriers used in this work are derived from collagen, one key question is how these collagen domains may interact with the T cells during culture. This question is further explored in \cref{aim2b}. T cells naturally expand in the lymph nodes which have an \gls{ecm} composed of collagen\cite{Dustin2001, Ebnet1996, Ohtani2008}. Despite this, T cells don't interact with collagen fibers in the lymph node as the collagen fibers are sheathed with stromal fibroblasts\cite{Dustin2001, Ebnet1996}. However, the \gls{ecm} of peripheral tissues is dense with exposed collagen fibers are available to interact with T cells. Furthermore, T cells have been shown \invitro{} to crawl along collagen fibers in the presence of \glspl{apc}, facilitating short encounters with \glspl{apc}\cite{Gunzer2000}. While this may not be ideal \invivo{} due to the lack of cumulative signal received by \glspl{apc}\cite{Dustin2001}, it may be advantageous to include collagen domains \invitro{} as the mode of activation is not specific to any given clone. The major surface receptors for collagen are \gls{a2b1} and \gls{a2b2}\cite{Dustin2001, Hemler1990}. These receptors are not expressed on naive T cells and thus presence and stimulation of collagen alone is not sufficient to cause activation or expansion of T cells\cite{Hemler1990}. These receptors have been shown to lead to a number of functions that may be useful in the context of T cell expansion. First, they have been shown to act in a costimulatory manner which leads to increased proliferation\cite{Rao2000}. Furthermore, \gls{a2b1} and \gls{a2b2} have been shown to protect Jurkat cells against Fas-mediated apoptosis in the presence of collagen I\cite{Aoudjit2000, Gendron2003}. Finally, these receptors have been shown to increase \gls{ifng} production \invitro{} when T cells derived from human \glspl{pbmc} are stimulated in the presence of collagen I\cite{Boisvert2007}. % TODO there are other receptors I could name here that were not explored Other % integrins that interact with the environment include a4b1, which interacts % with fibronectin and has been shown to lead to higher IL2 production (Iwata et % al 2000). \subsection*{the role of IL15 in memory T cell proliferation} \il{15} is a cytokine that is involved with the proliferation and homeostasis of memory T cells. Its role in the work of this dissertation is the subject of further exploration in \cref{aim2b}. Functionally, mice lacking the gene for either \il{15}\cite{Kennedy2000} or its high affinity receptor \il{15R$\upalpha$}\cite{Lodolce1998} are generally healthy but show a deficit in memory CD8 T cells, thus underscoring its importance in manufacturing high-quality memory T cells for immunotherapies. T cells themselves express \il{15} and all of its receptor components\cite{MirandaCarus2005}. Additionally, blocking \il{15} itself or \il{15R$\upalpha$} \invitro{} has been shown to inhibit homeostatic proliferation of resting human T cells\cite{MirandaCarus2005}. \il{15} has been puzzling historically because it shares almost the same pathway as \il{2} yet has different functions\cite{Stonier2010, Osinalde2014, Giri1994, Giri1995}. In particular, both cytokines share the common gamma subchain (CD132) as well as the \il{2} $\upbeta$ receptor (CD122). The main difference in the heterodimeric receptors for \il{2} and \il{15} is the \il{2} $\upalpha$ chain (CD25) and the \il{15} $\upalpha$ chain respectively, both of which have high affinity for their respective ligands. The \il{2R$\upalpha$} chain itself does not have any signaling capacity, and therefore all the signaling resulting from \il{2} is mediated thought the $\upbeta$ and $\upgamma$ chains, namely via JAK1 and JAK3 leading to STAT5 activation consequently T cell activation. \il{15R$\upalpha$} itself has some innate signaling capacity, but this is poorly characterized in lymphocytes. Thus there is a significant overlap between the functions of \il{2} and \il{15} due to their receptors sharing the $\upbeta$ and $\upgamma$ chains in their heterodimeric receptors, and perhaps the main driver of their differential functions it the half life of each respective receptor\cite{Osinalde2014}. Where \il{15} is unique is that many (or possibly most) of its functions derive from being membrane-bound to its receptor\cite{Stonier2010}. Particularly, \il{15R$\upalpha$} binds to soluble \il{15} which produces a complex that can transmit signals to close neighboring cells (so called \textit{trans} presentation). This has been demonstrated in adoptive cell models, where T cells lacking \il{15R$\upalpha$} were able to generate memory T cells and proliferate only when other cells were present which expressed \il{15R$\upalpha$}\cite{Burkett2003, Schluns2004}. The implication of this mechanism is that cells expression \il{15R$\upalpha$} either need to express \il{15} themselves or be near other cells expressing \il{15}, and other cells in proximity require the $\upbeta$ and $\upgamma$ chains to receive the signal. In addition to \textit{trans} presentation, \il{15} may also work in a \textit{cis} manner, where \il{15R$\upalpha$}/\il{15} complexes may bind to the $\upbeta$ and $\upgamma$ chains on the same cell, assuming all receptors are expressed and soluble \il{15} is available\cite{Olsen2007}. Finally, \il{15R$\upalpha$} itself can exist in a soluble form, which can bind to \il{15} and signal to cells which are not adjacent to the source independent of the \textit{cis/trans} mechanisms already described\cite{Budagian2004}. \subsection*{overview of design of experiments}\label{sec:background_doe} The \gls{dms} system has a number of parameters that can be optimized, and a \gls{doe} is an ideal framework to test multiple parameters simultaneously. The goal of \gls{doe} is to answer a data-driven question with the least number of resources\cite{Wu2009}. It was developed in many non-biological industries throughout the \nth{20} century such as the automotive and semiconductor industries where engineers needed to minimize downtime and resource consumption on full-scale production lines. At its core, a \gls{doe} is simply a matrix of conditions to test where each row is usually called a `run' and corresponds to one experimental unit to which the conditions are applied, and each column represents a parameter of concern to be tested. The values in each cell represent the level at which each parameter is to be tested. When the experiment is performed using this matrix of conditions, the results are be summarized into one or more `responses' that correspond to each run. These responses are then be modeled (usually using linear regression) to determine the statistic relationship (also called an `effect') between each parameter and the response(s). Collectively, the space spanned by all parameters at their feasible ranges is commonly referred to as the `design space', and generally the goal of a \gls{doe} is to explore this design space using using the least number of runs possible. While there are many types of \glspl{doe} depending on the nature of the parameters and the goal of the experimenter, they all share common principles: \begin{description} \item [randomization --] The order in which the runs are performed should ideally be as random as possible. This is to mitigate against any confounding factors that may be present which depend on the order or position of the experimental runs. For an example in context, the evaporation rate of media in a tissue culture plate will be much faster at the perimeter of the plate vs the center. While randomization does not eliminate this bias, it will ensure the bias is `spread' evenly across all runs in an unbiased manner. \item [replication --] Since the analysis of a \gls{doe} is inherently statistical, replicates should be used to ensure that the underlying distribution of errors can be estimated. While this is not strictly necessary to conclude results using a \gls{doe}, failure to use replications requires strong assumptions about the model structure (particularly in the case of high-complexity models which could easily fit the data perfectly) and also precludes the use of statistical tests such as the lack-of-fit test which can be useful in rejecting or accepting a particular analysis. Note that the subject of replication is within but not the same as power analysis, which concerns the number of runs required to estimate a certain effect size. \item [orthogonality --] Orthogonality refers to the independence of each parameter in the design matrix. In other words, the levels tested in any given parameter add mutually-exclusive information about the response(s). Again, while not strictly necessary, orthogonality drastically simplifies the analysis of the experiment by allowing each parameter to be treated separately. In cases where orthogonality is impossible (which is often true in experiments with many categorical variables) strategies exist to maximize orthogonality. \item [blocking --] In the case where the experiment must be non-randomly spread over multiple groups, runs are assigned to `blocks' which are not necessarily relevant to the goals of the experiment but nonetheless could affect the response. A key assumption that is (usually) made in the case of blocking is that there is no interaction between the blocking variable and any of the experimental parameters. For example, in T cell expansion, if media lot were a blocking variable and expansion method were a parameter, we would by default assume that the effect of the expansion method does not depend on the media lot (even if the media lot itself might change the mean of the response). \end{description} \Glspl{doe} served three purposes in this dissertation. First, we used them as screening tools, which allowed us to test many input parameters and filter out the few that likely have the greatest effect on the response. Second, they were used to make a robust response surface model to predict optimums using relatively few resources, especially compared to full factorial or one-factor-at-a-time approaches. Third, we used \glspl{doe} to discover novel effects and interactions that generated hypotheses that could influence the directions for future work. To this end, the types of \glspl{doe} we generally used in this work were fractional factorial designs with three levels, which enable the estimation of both main effects and second order quadratic effects. \subsection*{identification and standardization of CPPs and CQAs}\label{sec:background_cqa} % BACKGROUND at least attempt to show that there is alot of work in the space % identifying signaling networks In the context of T cell manufacturing, ideally we would have a set of non-destructive biomarkers that could both identify functional T cells and predict when a process is on track to deliver such functional T cells. T cells secrete numerous cytokines and metabolites in the media, which may reflect the internal state accurately and thus serve as a potential set of \glspl{cqa}. The complexity of these pathways dictates that we take a big-data approach to this problem. To this end, there are several pertinent multi-omic (or simply `omic') techniques that can be used to collect such datasets, which can then be mined, modeled, and correlated to relevent responses (such as an endpoint quantification of memory T cells) to identify pertinent \glspl{cqa}. An overview of the techniques used in this work are: \begin{description} \item[Luminex --] This is a multiplexed bead-based assay similar to \gls{elisa} that can measure many bulk (not single cell) cytokine concentrations simultaneously in a media sample. This is a destructive assay but does not require cells to obtain a measurement. \item[\gls{nmr} --] It is well known that T cells of different lineages have different metabolic profiles; for instance memory T cells have larger aerobic capacity and fatty acid oxidation\cite{Buck2016, van_der_Windt_2012}. \gls{nmr} is a technique that can non-destructively quantify small molecules in a media sample, and thus is an attractive method that could be used for inline, real-time monitoring. \item[Flow and Mass Cytometry --] Flow cytometry using fluorophores has been used extensively for immune cell analysis, but has a practical limit of approximately 18 colors\cite{Spitzer2016}. Mass cytometry is analogous to traditional flow cytometry except that it uses heavy-metal \gls{mab} conjugates, which has a practical limit of over 50 markers. While mass cytometry is less practical than simple flow cytometers such as the BD Accuri, we may find that only a few markers are required to accurately predict performance, and thus this could easily translate to industry using relatively cost-effective equipment. Both of these destructively analyze the cells themselves, but they have the advantage in that they are measuring a direct property of the cells and not a secreted product. \end{description} % BACKGROUND what about ssRNAseq? Upon collecting these omic datasets, determining the \glspl{cqa} becomes a computational problem. Predictions of the final product using data collected earlier in time can be made using any number of supervised learning techniques (linear and non-linear regression in all its forms) which in turn can be used to develop process control models. Unsupervised learning and dimensionality reduction techniques such as \gls{tsne}, \gls{umap}, and \gls{spade}\cite{Qiu2011, Qiu2017} can be performed to delineate clusters of interesting cell types and the markers that define them. Ultimately, identifying \glspl{cqa} will likely be an iterative process, wherein putative \glspl{cqa} will be identified, the corresponding \glspl{cpp} will be set and optimized to maximize products with these \glspl{cpp} and then additional data will be collected in the clinic as the product is tested on various patients with different indications. Additional \glspl{cqa} may be identified which better predict specific clinical outcomes, which can be fed back into the process model and optimized again. \section{Innovation} \subsection{Innovation} Several aspects of this work are novel considering the state-of-the-art technology for T cell manufacturing: \begin{itemize} \item \Glspl{dms} offers a compelling alternative to state-of-the-art magnetic bead technologies (e.g. DynaBeads, MACS-Beads), which is noteworthy because the licenses for these techniques is controlled by only a few companies (Invitrogen and Miltenyi respectively). Because of this, bead-based expansion is more expensive to implement and therefore hinders companies from entering the rapidly growing T cell manufacturing arena. Providing an alternative as we are doing will add more options, increase competition among both raw material and T cell manufacturers, and consequently drive down cell therapy market prices and increase innovation throughout the industry. \item This is the first technology for T cell immunotherapies that selectively expands memory T cell populations with greater efficiency relative to bead-based expansion Others have demonstrated methods that can achieve greater expansion of T cells, but not necessarily specific populations that are known to be potent. \item We propose to optimize our systems using \gls{doe} methodology, which is a strategy commonly used in other industries and disciplines but has yet to gain wide usage in the development of cell therapies. \Glspl{doe} are advantageous as they allow the inspection of multiple parameters simultaneously, allowing efficient and comprehensive analysis of the system vs a one-factor-at-a-time approach. We believe this method is highly relevant to the development of cell therapies, not only for process optimization but also hypotheses generation. Of further note, most \textit{in vivo} experiments are not done using a \gls{doe}-based approach; however, a \gls{doe} is perfectly natural for a large mouse study where one naturally desires to use as few animals as possible. \item The \gls{dms} system is be compatible with static bioreactors such as the G-Rex which has been adopted throughout the cell therapy industry. Thus this technology can be easily incorporated into existing cell therapy process that are performed at scale. \item We analyzed our system using a multiomics approach, which will enable the discovery of novel biomarkers to be used as \glspl{cqa}. While this approach has been applied to T cells previously, it has not been done in the context of a large \gls{doe}-based model. This approach is aware of the whole design space, and thus enables greater understanding of process parameters and their effect on cell phenotype. \end{itemize} \chapter{aim 1}\label{aim1} \section{introduction} The first aim was to develop a microcarrier system that mimics several key aspects of the \invivo{} lymph node microenvironment. We compared compare this system to state-of-the-art T cell activation technologies for both expansion potential and memory cell formation. The governing hypothesis was that microcarriers functionalized with \acd{3} and \acd{28} \glspl{mab} will provide superior expansion and memory phenotype compared to state-of-the-art bead-based T cell expansion technology. % TODO this doesn't flow that well and is repetitive with what comes above Microcarriers have been used throughout the bioprocess industry for adherent cell cultures such as \gls{cho} cells and stem cells, as they are able to achieve much greater surface area per unit volume than traditional 2D cultures\cite{Heathman2015, Sart2011}. Adding adhesive \glspl{mab} to the microcarriers will adapt them for suspension cell cultures such as T cells. Consequently, the large macroporous structure will allow T cells to cluster more closely, which in turn will enable better autocrine and paracrine signaling. Specifically, two cytokines that are secreted by T cells, IL-2 and IL-15, are known to drive expansion and memory phenotype respectively\cite{Buck2016}. Therefore, the proposed microcarrier system should enable greater expansion and better retention of memory phenotype compared to current bead-based methods. \section{methods} \subsection{dms functionalization}\label{sec:dms_fab} \begin{figure*}[ht!] \begingroup \includegraphics{../figures/dms_flowchart.png} \endgroup \caption[\gls{dms} Flowchart]{Overview of \gls{dms} manufacturing process.} \label{fig:dms_flowchart} \end{figure*} Gelatin microcarriers (\gls{cus} or \gls{cug}, GE Healthcare, DG-2001-OO and DG-0001-OO) were suspended at \SI{20}{\mg\per\ml} in 1X \gls{pbs} and autoclaved. All subsequent steps were done aseptically, and all reactions were carried out at \SI{20}{\mg\per\ml} carriers at room temperature and agitated using an orbital shaker with a \SI{3}{\mm} orbit diameter. After autoclaving, the microcarriers were washed using sterile \gls{pbs} three times in a 10:1 volume ratio. \product{\Gls{snb}}{\thermo}{21217} was dissolved at approximately \SI{10}{\uM} in sterile ultrapure water, and the true concentration was then determined using the \gls{haba} assay (see below). \SI{5}{\ul\of{\ab}\per\mL} \gls{pbs} was added to carrier suspension and allowed to react for \SI{60}{\minute} at \SI{700}{\rpm} of agitation. After the reaction, the amount of biotin remaining in solution was quantified using the \gls{haba} assay (see below). The carriers were then washed three times, which entailed adding sterile \gls{pbs} in a 10:1 volumetric ratio, agitating at \SI{900}{\rpm} for \SI{10}{\minute}, adding up to a 15:1 volumetric ratio (relative to reaction volume) of sterile \gls{pbs}, centrifuging at \SI{1000}{\gforce} for \SI{1}{\minute}, and removing all liquid back down to the reaction volume. To coat with \gls{stp}, \SI{40}{\ug\per\mL} \product{\gls{stp}}{Jackson Immunoresearch}{016-000-114} was added and allowed to react for \SI{60}{\minute} at \SI{700}{RPM} of agitation. After the reaction, supernatant was taken for the \product{\gls{bca} assay}{\thermo}{23225}, and the carriers were washed analogously to the previous wash step to remove the biotin, except two washes were done and the agitation time was \SI{30}{\minute}. Biotinylated \glspl{mab} against human CD3 \catnum{\bl}{317320} and CD28 \catnum{\bl}{302904} were combined in a 1:1 mass ratio and added to the carriers at \SI{0.2}{\ug\of{\ab}\per\mg\of{\dms}}. Along with the \glspl{mab}, sterile \product{\gls{bsa}}{\sigald}{A9576} was added to a final concentration of \SI{2}{\percent} in order to prevent non-specific binding of the antibodies to the reaction tubes. \glspl{mab} were allowed to bind to the carriers for \SI{60}{\minute} with \SI{700}{\rpm} agitation. After binding, supernatants were sampled to quantify remaining \gls{mab} concentration using an \product{\anti{\gls{igg}} \gls{elisa} kit}{Abcam}{157719}. Fully functionalized \glspl{dms} were washed in sterile \gls{pbs} analogous to the previous washing step to remove excess \gls{stp}. They were washed once again in the cell culture media to be used for the T cell expansion. The concentration of the final \gls{dms} suspension was found by taking a \SI{50}{\uL} sample, plating in a well, and imaging the entire well. The image was then manually counted to obtain a concentration. Surface area for \si{\ab\per\um\squared} was calculated using the properties for \gls{cus} and \gls{cug} as given by the manufacturer {Table X}. \subsection{dms quality control assays} Biotin was quantified using the \product{\gls{haba} assay}{\sigald}{H2153-1VL}. In the case of quantifying \gls{snb} prior to adding it to the microcarriers, the sample volume was quenched in a 1:1 volumetric ratio with \SI{1}{\molar} NaOH and allowed to react for \SI{1}{\minute} in order to prevent the reactive ester linkages from binding to the avidin proteins in the \gls{haba}/avidin premix. All quantifications of \gls{haba} were performed on an Eppendorf D30 Spectrophotometer using \product{\SI{70}{\ul} cuvettes}{BrandTech}{759200}. The extinction coefficient at \SI{500}{\nm} for \gls{haba}/avidin was assumed to be \SI{34000}{\per\cm\per\molar}. \gls{stp} binding to the carriers was quantified indirectly using a \product{\gls{bca} kit}{\thermo}{23227} according to the manufacturer’s instructions, with the exception that the standard curve was made with known concentrations of purified \gls{stp} instead of \gls{bsa}. Absorbance at \SI{592}{\nm} was quantified using a Biotek plate reader. \Gls{mab} binding to the microcarriers was quantified indirectly using an \gls{elisa} assay per the manufacturer’s instructions, with the exception that the same antibodies used to coat the carriers were used as the standard for the \gls{elisa} standard curve. Open biotin binding sites on the \glspl{dms} after \gls{stp} coating was quantified indirectly using \product{\gls{fitcbt}}{\thermo}{B10570}. Briefly, \SI{400}{\pmol\per\ml} \gls{fitcbt} were added to \gls{stp}-coated carriers and allowed to react for \SI{20}{\minute} at room temperature under constant agitation. The supernatant was quantified against a standard curve of \gls{fitcbt} using a Biotek plate reader. \Gls{stp} binding was verified after the \gls{stp}-binding step visually by adding \gls{fitcbt} to the \gls{stp}-coated \glspl{dms}, resuspending in \SI{1}{\percent} agarose gel, and imaging on a \product{lightsheet microscope}{Zeiss}{Z.1}. \Gls{mab} binding was verified visually by first staining with \product{\anti{\gls{igg}}-\gls{fitc}}{\bl}{406001}, incubating for \SI{30}{\minute}, washing with \gls{pbs}, and imaging on a confocal microscope. \subsection{t cell culture}\label{sec:tcellculture} % TODO verify countess product number Cryopreserved primary human T cells were either obtained as sorted \product{\cdp{3} T cells}{Astarte Biotech}{1017} or isolated from \product{\glspl{pbmc}}{Zenbio}{SER-PBMC} using a negative selection \product{\cdp{3} \gls{macs} kit}{\miltenyi}{130-096-535}. T cells were activated using \glspl{dms} or \product{\SI{3.5}{\um} CD3/CD28 magnetic beads}{\miltenyi}{130-091-441}. In the case of beads, T cells were activated at the manufacturer recommended cell:bead ratio of 2:1. In the case of \glspl{dms}, cells were activated using \SI{2500}{\dms\per\cm\squared} unless otherwise noted. Initial cell density was \SIrange{2e6}{2.5e6}{\cell\per\ml} to in a 96 well plate with \SI{300}{\ul} volume. Serum-free media was either \product{OpTmizer}{\thermo}{A1048501} or \product{TexMACS}{\miltenyi}{170-076-307} supplemented with \SIrange{100}{400}{\IU\per\ml} \product{\gls{rhil2}}{Peprotech}{200-02}. Cell cultures were expanded for \SI{14}{\day} as counted from the time of initial seeding and activation. Cell counts and viability were assessed using \product{trypan blue}{\thermo}{T10282} or \product{\gls{aopi}}{Nexcelom Bioscience}{CS2-0106-5} and a \product{Countess Automated Cell Counter}{Thermo Fisher}{Countess 3 FL}. Media was added to cultures every \SIrange{2}{3}{\day} depending on media color or a \SI{300}{\mg\per\deci\liter} minimum glucose threshold. Media glucose was measured using a \product{GlucCell glucose meter}{Chemglass}{CLS-1322-02}. Cells on the \glspl{dms} were visualized by adding \SI{0.5}{\ul} \product{\gls{stppe}}{\bl}{405204} and \SI{2}{ul} \product{\acd{45}-\gls{af647}}{\bl}{368538}, incubating for \SI{1}{\hour}, and imaging on a spinning disk confocal microscope. In the case of Grex bioreactors, we either used a \product{24 well plate}{Wilson Wolf}{P/N 80192M} or a \product{6 well plate}{P/N 80240M}. \subsection{Quantifying cells on DMS interior} % TODO add a product number to MTT (if I can find it) Cells were stained and visualized using \gls{mtt}. \glspl{dms} with attached and loosely attached cells were sampled as desired and filtered through a \SI{40}{\um} cell strainer. While still in the cell strainer, \glspl{dms} were washed twice with \gls{pbs} and then dried by pulling liquid through the bottom of the cell strainer via a micropipette and dabbing with a KimWipe. \glspl{dms} were transferred to a 24 well plate with \SI{400}{\ul} media. \SI{40}{\ul} \gls{mtt} was added to each well and allowed to incubate for \SI{3}{\hour}, after which \glspl{dms} with cell were visualized via a brightfield microscope. To quantify cells on the interior of \glspl{dms}, cells and \glspl{dms} were isolated analogously to those for the \gls{mtt} stain up until the drying step. Cells were then transferred to a tube containing \SI{400}{\ul} at \SI{5}{\mg\per\ml} dispase solution. \glspl{dms} were incubated and rotated for \SI{45}{\minute} at \SI{37}{\degreeCelsius}, after which cells were counted as already described in \cref{sec:tcellculture}. \subsection{quantification of apoptosis using Annexin-V} Apoptosis was quantified using \gls{anv} according to the manufacturer's instructions. Briefly, cells were transferred to flow tubes and washed twice with \gls{pbs} by adding \SI{3}{\ml} to each tube, centrifuging for \SI{400}{\gforce}, and aspirating the liquid down to \SI{200}{\ul}. The cells were analogously washed a third time with staining buffer (\SI{10}{\mM} HEPES, \SI{140}{\mM} NaCl, \SI{2.5}{\mM} CaCl\textsubscript{2}) and aspirated down to a final volume of \SI{100}{\ul}. Cells were stained in this volume with \SI{1}{\ul} \product{\gls{anv}-\gls{fitc}}{\bl}{640906} and \SI{5}{\ul} \product{\gls{pi}}{\thermo}{P3566} and incubated for \SI{15}{\minute} at gls{rt} in the dark. After incubation, \SI{400}{\ul} staining buffer was added to each tube. Each tube was then analyzed via flow cytometry. \subsection{quantification of Caspase-3/7} \Gls{cas37} was quantified using \product{CellEvent dye}{\thermo}{C10723} according the manufacturer's instructions. Briefly, a 2X (\SI{8}{\mM}) working solution of CellEvent dye was added to \SI{100}{\ul} cell suspension (at least \num{5e4} cells) and incubated at \SI{37}{\degreeCelsius} for \SI{30}{\minute}. After incubation, cells were immediately analyzed via flow cytometry. \subsection{quantification of BCL-2} \Gls{bcl2} was quantified using an \product{Human Total Bcl-2 DuoSet \gls{elisa} kit}{Rnd Systems}{DYC827B-2} according to the manufacturer's instructions and supplemented with \product{5X diluent buffer}{\bl}{421203}, \product{\gls{tmb} substrate solution}{eBioscience}{00-4201-56}, and \SI{2}{\normal} H\textsubscript{2}SO\textsubscript{4} stop solution made in house. Briefly, cells were lysed using \product{10X lysis buffer}{Cell Signaling}{9803S}, and the lysate was quantified for protein using a \product{\gls{bca} assay}{\thermo}{23225} as directed. Standardized lysates were measured using the \gls{elisa} kit as directed. \subsection{chemotaxis assay} % TODO not sure about the transwell product number Migratory function was assayed using a transwell chemotaxis assay as previously described\cite{Hromas1997}. Briefly, \SI{3e5}{\cell} were loaded into a \product{transwell plate with \SI{5}{\um} pore size}{Corning}{3421} with the basolateral chamber loaded with \SI{600}{\ul} media and 0, 250, or \SI{1000}{\ng\per\mL} \product{CCL21}{Peprotech}{250-13}. The plate was incubated for \SI{4}{\hour} after loading, and the basolateral chamber of each transwell was quantified for total cells using \product{countbright beads}{\thermo}{C36950}. The final readout was normalized using the \SI{0}{\ng\per\mL} concentration as background. \subsection{degranulation assay} Cytotoxicity of expanded \gls{car} T cells was assessed using a degranulation assay as previously described\cite{Schmoldt1975}. Briefly, \num{3e5} T cells were incubated with \num{1.5e5} target cells consisting of either \product{K562 wild type cells}{ATCC}{CCL-243} or CD19- expressing K562 cells transformed with \gls{crispr} (kindly provided by Dr.\ Yvonne Chen, UCLA)\cite{Zah2016}. Cells were seeded in a flat bottom 96 well plate with \SI{1}{\ug\per\ml} \product{\acd{49d}}{eBioscience}{16-0499-81}, \SI{2}{\micro\molar} \product{monensin}{eBioscience}{ 00-4505-51}, and \SI{1}{\ug\per\ml} \product{\acd{28}}{eBioscience}{302914} (all functional grade \glspl{mab}) with \SI{250}{\ul} total volume. After \SI{4}{\hour} incubation at \SI{37}{\degreeCelsius}, cells were stained for CD3, CD4, and CD107a and analyzed on a BD LSR Fortessa. Readout was calculated as the percent \cdp{107a} cells of the total \cdp{8} fraction. \subsection{car expression} \gls{car} expression was quantified as previously described\cite{Zheng2012}. Briefly, cells were washed once and stained with \product{biotinylated \gls{ptnl}}{\thermo}{29997}. After a subsequent wash, cells were stained with \product{\gls{pe}-\gls{stp}}{\bl}{405204}, washed again, and analyzed on a BD Accuri. Readout was percent \gls{pe}+ cells as compared to secondary controls (\gls{pe}-\gls{stp} with no \gls{ptnl}). \subsection{car plasmid and lentiviral transduction} The anti-CD19-CD8-CD137-CD3$\upzeta$ \gls{car} with the EF1$\upalpha$ promotor\cite{Milone2009} was synthesized (Aldevron) and subcloned into a \product{FUGW}{Addgene}{14883} kindly provided by the Emory Viral Vector Core. Lentiviral vectors were synthesized by the Emory Viral Vector Core or the Cincinnati Children's Hospital Medical Center Viral Vector Core. RNA titer was calculated using a \product{Lenti-X \gls{qpcr} titer kit}{Takara}{631235}. To transduce primary human T cells, \product{retronectin}{Takara}{T100A} was coated onto non-TC treated 96 well plates and used to immobilize lentiviral vector particles according to the manufacturer's instructions. Briefly, retronectin solution was adsorbed overnight at \SI{4}{\degreeCelsius} and blocked the next day using \gls{bsa}. Prior to transduction, lentiviral supernatant was spinoculated at \SI{2000}{\gforce} for \SI{2}{\hour} at \SI{4}{\degreeCelsius}. T cells were activated in 96 well plates using beads or \glspl{dms} for \SI{24}{\hour}, and then cells and beads/\glspl{dms} were transferred onto lentiviral vector coated plates and incubated for another \SI{24}{\hour}. Cells and beads/\glspl{dms} were removed from the retronectin plates using vigorous pipetting and transferred to another 96 well plate wherein expansion continued. % METHOD fill in missing product numbers \gls{bcma} \gls{car} lentiviral vector was synthesized in house as follows\footnote{lentiviral synthesis was performed by Ritika Jain in our laboratory and included here for reference}. \SI{10}{\ng} of \anti{\gls{bcma}}-CD8-CD137-CD3$\upzeta$ plasmid (generously provided by Jim Kochenderfer at the NIH)\cite{Lam2020} was added to \SI{50}{\ul} \product{DH5$\upalpha$ cells}{\thermo}{18265017} and incubated for \SI{30}{\minute} on ice. The cell mixture was then heat-shocked at \SI{42}{\degreeCelsius} for \SI{20}{\minute} before being placed on ice for another \SI{2}{\minute}. \SI{950}{\ul} \product{LB Broth}{TODO}{TODO} was added to the cells which were then centrifuged for \SI{1}{\hour} at \SI{225}{\rpm}. \SI{20}{\ul} of the cell mixture was then spread over selection plates and incubated overnight at \SI{37}{\degreeCelsius}. Colonies were selected the following day and incubated in \product{LB Broth}{TODO}{TODO} with \product{ampicillin}{\sigald{}}{A9518-5G} at \SI{37}{\degreeCelsius} for \SIrange{12}{16}{\hour} prior to using the \product{miniprep kit}{Qiagen}{27104} as per the manufacturer's instructions to isolate the plasmid DNA. Transfer plasmid along with \product{pMDLg/pRRE}{Addgene}{12251}, \product{pRSV-Rev}{Addgene}{12253}, and \product{pMD2.G}{Addgene}{12259} (generously provided by the Sloan lab at Emory University) in \product{Opti-Mem}{\thermo}{31-985-070} with \product{lipfectamine 2000}{\thermo}{11668019} were added dropwise to HEK 293T cells and incubated for \SI{6}{\hour}, after which all media was replaced with fresh fresh media. After \SI{24}{\hour} and \SI{48}{\hour}, supernatent was collected, pooled, and concentrated using a \product{Lenti-X concentrator}{Takara}{631231} prior to storing at \SI{-80}{\degreeCelsius}. \subsection{sulfo-NHS-biotin hydrolysis quantification} The equation for hydrolysis of \gls{snb} was assumed to follow \cref{chem:snb_hydrolysis}. % TODO make this look prettier \begin{equation} \label{chem:snb_hydrolysis} \ce{NHS-CO-Biotin + OH- -> NHS- + Biotin-COOH} \end{equation} The hydrolysis of \gls{snb} was performed spectroscopically. \gls{snb} was added to either \gls{di} water or \gls{pbs} in a UV-transparent 96 well plate. Kinetic analysis using a Biotech Plate Reader began immediately after prep, and readings at \SI{260}{\nm} were taken every minute for \SI{2}{\hour}. \subsection{reaction kinetics quantification} The diffusion of \gls{stp} into biotin-coated microcarriers was determined experimentally. \SI{40}{\ug\per\ml} \gls{stp} was added to multiple batches of biotin-coated microcarriers, and supernatents were taken at fixed intervals and quantified for \gls{stp} protein using the \gls{bca} assay. % TODO defend why the microcarriers were saturated with stp The effective diffusivity of the microcarriers was determined using a pseudo-steady-state model. Each microcarrier was assumed to be a porous sphere with a fixed number of `\gls{stp} binding sites' equal to the number of \gls{stp} molecules experimentally determined to bind to the microcarriers. Because the reaction rate between biotin and \gls{stp} was so fast, we assumed that the interface of free biotin shrunk as a function of \gls{stp} bound until the center of the microcarriers was reached. We also assumed that the pores in the microcarriers were large enough that the interactions between the \gls{stp} and surfaces would be small, thus the apparent diffusivity could be represented as a fraction of the diffusion coefficient of \gls{stp} in water. This model was given by \cref{eqn:stp_diffision_1,eqn:stp_diffision_2}: % TODO actually derive these equations, eg state the initial conditions and % governing equation \begin{equation} \label{eqn:stp_diffision_1} \frac{dr}{dt} = \frac{-D_{app}C}{Br(1-r/R)} \end{equation} \begin{equation} \label{eqn:stp_diffision_2} \frac{dC}{dt} = \frac{-4 \pi n D_{app} C}{V(1/r-1/R)} \end{equation} \noindent where \begin{itemize}[label={}] \item $D_{app}$ is the apparent diffusion rate which is equal to $D_{STP}\beta$ \item $D_{STP}$ the diffusion rate of \gls{stp} in water \item $\beta$ a fractional parameter representing the tortuousity and void fraction of the microcarriers (here called the `geometric diffusivity') \item $r$ is the interfatial radius of the unbound biotin within a microcarrier \item $t$ is the reaction time \item $C$ is the concentration of \gls{stp} in the bulk solution \item $V$ is the volume of the bulk medium \item $R$ is the average radius of the microcarriers \item $n$ is the number of microcarriers in the reaction volume \end{itemize} The diffusion rate of \gls{stp} was assumed to be \SI{6.2e-7}{\cm\squared\per\second}\cite{Kamholz2001}. Since all but $\beta$ was known, the experimental data was fit using these equations using \inlinecode{ode45} in MATLAB and least squares as the fitting error. These equations were then used analogously to describe the reaction profile of \glspl{mab} assuming a diffusion rate of \SI{4.8e-7}{\cm\squared\per\second}\cite{Sherwood1992}. These same coefficients were used in determining the kinetics of the washing steps, and \SI{5.0e-6}{\cm\squared\per\second}\cite{Niether2020} was used as the diffusion coefficient for free biotin (which should be the only species left in solution after all the \gls{snb} has hydrolyzed). All diffusion coefficients were taken to be valid at \gls{rt} and in \gls{di} water, which is a safe assumption given that our reaction medium was 1X \gls{pbs}. See \cref{sec:appendix_binding} and \cref{sec:appendix_washing} for the MATLAB code (and output in the case of the washing steps) used. % METHOD add the equation governing the washing steps \subsection{Luminex Analysis}\label{sec:luminex_analysis} Luminex was performed using a \product{ProcartaPlex kit}{\thermo}{custom} for the markers outlined in \cref{tab:luminex_panel} with modifications (note that some markers were run in separate panels to allow for proper dilutions). Briefly, media supernatents from cells were sampled as desired and immediately placed in a \SI{-80}{\degreeCelsius} freezer until use. Before use, samples were thawed at \gls{rt} and vortexed to ensure homogeneity. To run the plate, \SI{25}{\ul} of magnetic beads were added to the plate and washed 3X using \SI{300}{\ul} of wash buffer. \SI{25}{\ul} of samples or standard were added to the plate and incubated for \SI{120}{\minute} at \SI{850}{\rpm} at \gls{rt} before washing analogously 3X with wash. \SI{12.5}{\ul} detection \glspl{mab} and \SI{25}{\ul} \gls{stppe} were sequentially added, incubated for \SI{30}{\minute} and vortexed, and washed analogously to the sample step. Finally, samples were resuspended in \SI{120}{\ul} reading buffer and analyzed via a BioRad Bioplex 200 plate reader. An 8 point log2 standard curve was used, and all samples were run with single replicates. Luminex data was preprocessed using R for inclusion in downstream analysis as follows. Any cytokine level that was over-range (`OOR >' in output spreadsheet) was set to the maximum value of the standard curve for that cytokine. Any value that was under-range (`OOR \SI{95}{\percent} complete}. Finally, we calculated the number of wash steps needed to remove the reagents between each step, including the time for each wash which required the geometric diffusivity of the microcarriers as calculated above. This is important, as failing to wash out residual free \gls{snb} (for example) could occupy binding sites on the \gls{stp} molecules, lowering the effective binding capacity of the \gls{mab} downstream. Each wash was a 1:15 dilution (\SI{1}{\ml} reaction volume in a \SI{15}{\ml} conical tube), and in the case of \gls{snb} we wished to wash out enough biotin such that less than \SI{1}{\percent} of the binding sites in \gls{stp} would be occupied. Given this dilution factor, a maximum of \SI{20}{\nmol} of biotin remaining \cref{fig:biotin_coating} \SI{2.9}{\nmol} biotin binding sites on \SI{40}{\ug} \gls{stp} (assuming 4 binding sites per \gls{stp} protein), this turned out to be 3 washes. By similar logic, using 2 washes after the \gls{stp} binding step will ensure that the number of free \gls{stp} binding sites is less than 20X the number of \gls{mab} molecules added\footnote{This step may benefit from an additional wash, as the number of washes used here was develop when \SI{40}{\ug} rather than \SI{4}{\ug} \gls{mab} was used to coat the \gls{dms}, yielding a much wider margin. However, it is also not clear to what extent this matters, as the \gls{mab} have multiple biotin molecules per \gls{mab} protein, and thus one \gls{mab} would require binding to several \gls{stp} molecules to be prevented from binding at all.} To determine the length of time required for each wash, we again assumed the microcarriers to be porous spheres, this time with an initial concentration of \gls{snb}, \gls{stp}, or \glspl{mab} equal to the final concentration of the bulk concentration of the previous binding step, and calculated the amount of time it would take for the concentration profile inside the microcarriers to equilibrate to the bulk in the wash step. Using this model, we found that the wash times for \gls{snb}, \gls{stp}, and \glspl{mab} was \SI{3}{\minute}, \SI{15}{\minute}, and \SI{17}{\minute} respectively. We verified that the \gls{snb} was totally undetectable after washing (\cref{fig:dms_biotin_washed}). The other two species need to be verified in a similar manner; however, we should not that the washing time for both the \gls{stp} and \gls{mab} coating steps were \SI{30}{\minute}, which is a significant margin of safety (albeit one that could be optimized). \subsection{DMSs can efficiently expand T cells compared to beads} % FIGURE make sure the day on these is correct \begin{figure*}[ht!] \begingroup \includegraphics{../figures/cells_on_dms.png} \phantomsubcaption\label{fig:dms_cells_phase} \phantomsubcaption\label{fig:dms_cells_fluor} \endgroup \caption[T cells growing on \glspl{dms}] {Cells grow in tight clusters in and around functionalized \gls{dms}. \subcap{fig:dms_cells_phase}{Phase-contrast image of T cells growing on \glspl{dms} on day 7} \subcap{fig:dms_cells_fluor}{Confocal images of T cells in varying z-planes growing on \glspl{dms} on day 9. \Glspl{dms} were stained using \gls{stppe} (red) and T cells were stained using \acd{45}-\gls{af647}.} } \label{fig:dms_cells} \end{figure*} \begin{figure*}[ht!] \begingroup \includegraphics{../figures/dms_expansion.png} \phantomsubcaption\label{fig:dms_expansion_bead} \phantomsubcaption\label{fig:dms_expansion_isotype} \endgroup \caption[\glspl{dms} selectively expand T cells] {T cells are selectively expanded on \gls{dms}. \subcap{fig:dms_expansion_bead}{T cells expanded with either \glspl{dms} or bead for 12 days. Significance was assessed using a two-tailed heteroschodastic T test.} \subcap{fig:dms_expansion_isotype}{T cells grown on \glspl{dms} coated with either activating \glspl{mab} or \gls{igg} isotype control \glspl{mab}.} } \label{fig:dms_expansion} \end{figure*} % DISCUSSION krish seems concerned about this isotype control figure, add some % discussion saying that IL2 does not spontaneously activate T cells to appease % him We next sought to determine how our \glspl{dms} could expand T cells compared to state-of-the-art methods used in industry. All bead expansions were performed as per the manufacturer’s protocol, with the exception that the starting cell densities were matched between the beads and carriers to ~\SI{2.5e6}{\cell\per\ml}. Throughout the culture we observed that T cells in \gls{dms} culture grew in tight clumps on the surface of the \glspl{dms} as well as inside the pores of the \glspl{dms} (\cref{fig:dms_cells_phase,fig:dms_cells_fluor}). Furthermore, we observed that the \glspl{dms} conferred greater expansion compared to traditional beads, and significantly greater expansion after \SI{12}{\day} of culture (\cref{fig:dms_expansion_bead}). We also observed no T cell expansion using \glspl{dms} coated with an isotype control mAb compared to \glspl{dms} coated with \acd{3}/\acd{28} \glspl{mab} (\cref{fig:dms_expansion_isotype}), confirming specificity of the expansion method. \begin{figure*}[ht!] \begingroup \includegraphics{../figures/apoptosis.png} \phantomsubcaption\label{fig:apoptosis_annV} \phantomsubcaption\label{fig:apoptosis_cas} \phantomsubcaption\label{fig:apoptosis_bcl2} \endgroup \caption[Apoptosis Quantification for \glspl{dms}] {\glspl{dms} produce cells with lower apoptosis marker expression on average compared to bead. \subcap{fig:apoptosis_annV}{Quantification of apoptosis and necrosis by \gls{anv} and \gls{pi}.} \subcap{fig:apoptosis_cas}{Quantification of Caspase-3/7 expression using CellEvent dye.} \subcap{fig:apoptosis_bcl2}{Quantification of BCL-2 expression using \gls{elisa}. All statistical tests shown are two-tailed homoschodastic t-tests. All cells were harvested at day 8.} } \label{fig:dms_apoptosis} \end{figure*} Given that the \gls{dms} system seemed to expand T cells more effectively, we asked if this difference was due to a reduction in apoptosis or an increase in proliferation rate (or both). We assessed the apoptotic state of T cells grown using either bead or \gls{dms} harvested on day 8 using \gls{pi} and \gls{anv}. \gls{anv} is a marker which stains phospholipid phosphatidylserine, which is usually present only on the cytoplasmic surface of the cell membrane, but flips to the outside when the cell becomes apoptotic. \gls{pi} stains the nucleus of the cell, but only penetrates necrotic cells which have a perforated cell membrane. When staining for these two markers and assessing via flow cytometry, we observe that the \gls{dms}-expanded T cells have lower frequencies of apoptotic and necrotic cells (\cref{fig:apoptosis_annV}). Furthermore, we stained our cultures with CellEvent dye, which is an indicator of \gls{cas37}, which is activated in apoptotic cells. In line with the \gls{pi}/\gls{anv} results, we observed that the \gls{dms} T cells had lower frequency of \gls{cas37} expression, indicating less apoptosis for our method (\cref{fig:apoptosis_cas}). Finally, we lysed our cells and stained for \gls{bcl2}, which is also upregulated in apoptosis. In this case, some (but not all) of the bead-expanded cultures showed higher \gls{bcl2} expression, which could indicate more apoptosis in those groups (\cref{fig:apoptosis_bcl2}). None of the \gls{dms} cultures showed similar heightened expression. Taken together, these data suggest that the \gls{dms} platform at least in part achieves higher expansion by lowering apoptosis of the cells in culture. % FIGURE double check the timing of this experiment (it might not be day 14) \begin{figure*}[ht!] \begingroup \includegraphics{../figures/dms_inside.png} \phantomsubcaption\label{fig:dms_inside_bf} \phantomsubcaption\label{fig:dms_inside_regression} \endgroup \caption[A subset of T cells grow in interior of \glspl{dms}] {A percentage of T cells grow in the interior of \glspl{dms}. \subcap{fig:dms_inside_bf}{T cells stained dark with \gls{mtt} after growing on either coated or uncoated \glspl{dms} for 14 days visualized with brightfield microscope.} \subcap{fig:dms_inside_regression}{Linear regression performed on T cell percentages harvested on the interior of the \glspl{dms} vs the initial starting cell density.} } \label{fig:dms_inside} \end{figure*} \begin{table}[!h] \centering \caption{Regression for fraction of cells in \gls{dms} at day 14} \label{tab:inside_regression} \input{../tables/inside_fraction_regression.tex} \end{table} % RESULT state the CI of what are inside the carriers We also asked how many cells were inside the \glspl{dms} vs. free-floating in suspension and/or loosely attached to the surface. We qualitatively verified the presence of cells inside the \glspl{dms} using a \gls{mtt} stain to opaquely mark cells and enable visualization on a brightfield microscope (\cref{fig:dms_inside_bf}). After seeding \glspl{dms} at different densities and expanding for \SI{14}{\day}, we filtered the \glspl{dms} out of the cell suspension and digested them using dispase to free any cells attached on the inner surface. We observed that approximately \SI{15}{\percent} of the total cells after \SI{14}{\day} were on the interior surface of the \glspl{dms} (\cref{fig:dms_inside_regression,tab:inside_regression}). Performing linear regression on this data revealed that the percentage of T cells inside the \glspl{dms} does not depend on the initial starting cell density (at least when harvested after \SI{14}{\day}) (\cref{tab:inside_regression}). \subsection{DMSs lead to greater expansion and memory and CD4+ phenotypes} \begin{figure*}[ht!] \begingroup \includegraphics{../figures/dms_vs_bead_expansion.png} \phantomsubcaption\label{fig:dms_exp_fold_change} \phantomsubcaption\label{fig:dms_exp_mem} \phantomsubcaption\label{fig:dms_exp_cd4} \phantomsubcaption\label{fig:dms_exp_mem4} \phantomsubcaption\label{fig:dms_exp_mem8} \endgroup \caption[\gls{dms} vs bead expansion] {\gls{dms} lead to superior expansion of T cells compared to beads across multiple donors. \subcap{fig:dms_exp_fold_change}{Longitudinal fold change of T cells grown using either \glspl{dms} or beads. Significance was evaulated using t tests at each timepoint} Fold change of subpopulations expanded using either \gls{dms} or beads at day 14, including \subcap{fig:dms_exp_mem}{\ptmem{} cells}, \subcap{fig:dms_exp_cd4}{\pth{} cells}, \subcap{fig:dms_exp_mem4}{\ptmemh{} cells}, and \subcap{fig:dms_exp_mem8}{\ptmemk{} cells}. \sigkey{} } \label{fig:dms_exp} \end{figure*} After observing differences in expansion, we further hypothesized that the \gls{dms} cultures could lead to a different T cell phenotype. In particular, we were interested in the formation of naïve and memory T cells, as these represent a subset with higher replicative potential and therefore improved clinical prognosis\cite{Gattinoni2011, Wang2018}. We measured naïve and memory T cell frequency staining for CCR7 and CD62L (both of which are present on lower differentiated T cells such as naïve, central memory, and stem memory cells\cite{Gattinoni2012}). Using three donors, we noted again \glspl{dms} produced more T cells over a \SI{14}{\day} expansion than beads, with significant differences in number appearing as early after \SI{5}{\day} (\cref{fig:dms_exp_fold_change}). Furthermore, we noted that \glspl{dms} produced more memory/naïve cells after \SI{14}{\day} when compared to beads for all donors (\cref{fig:dms_exp_mem,fig:dms_exp_cd4}) showing that the \gls{dms} platform is able to selectively expand potent, early differentiation T cells. Of additional interest was the preservation of the CD4+ compartment. In healthy donor samples (such as those used here), the typical CD4:CD8 ratio is 2:1. We noted that \glspl{dms} produced more CD4+ T cells than bead cultures as well as naïve/memory, showing that the \gls{dms} platform can selectively expand CD4 T cells to a greater degree than beads (Figure 2c). The trends held true when observing the CD4+ and CD8+ fractions of the naïve/memory subset (\ptmem{}) (\cref{fig:dms_exp_mem4,fig:dms_exp_mem8}). % FIGURE this figure has weird proportions % FIGURE this figure was not produced with the same donors as the figure above, % which is really confusing \begin{figure*}[ht!] \begingroup \includegraphics{../figures/dms_phenotypes.png} \phantomsubcaption\label{fig:dms_phenotype_mem} \phantomsubcaption\label{fig:dms_phenotype_cd4} \endgroup \caption[Representative flow plots of \ptmem{} and \pth{} T cells] {Representative flow plots of \ptmem{} and \pth{} T cells at day 14 of expansion using either beads or \glspl{dms}. For three representative donor samples, phenotypes are shown for \subcap{fig:dms_phenotype_mem}{\ptmem{}} and \subcap{fig:dms_phenotype_cd4}{\pth}. Each population was also gated on \cdp{3} T cells. } \label{fig:dms_phenotype} \end{figure*} We also observed that, at least with the donors and conditions tested in these experiments\footnote{these results were not always consistent, see the metaanalysis at the end of this aim for an in-depth quantification of this observation} that the fraction of \ptmem{} and \pth{} T cells was higher in the \gls{dms} groups compared to the bead groups (\cref{fig:dms_phenotype}). This result was seen for multiple donors. We should not that in the case of \pthp{}, the donors we used had an initial \pthp{} that was much higher (healthy donors generally have a CD4:CD8 ratio of 2:1), so the proper interpretation of this is that the \pthp{} decreases less over the culture period with the \gls{dms} platform as opposed to the beads (or alternatively, the \gls{dms} has less preferential expansion for CD8 T cells). We cannot say the same about the \ptmemp{} since we did not have the initial data for this phenotype; however (although it should be the vast majority of cells given that cryopreserved T cells from a healthy donor should generally be composed of circulated memory and naive T cells). Taken together, these data indicate the \gls{dms} platform has the capacity to expand higher numbers and percentages of highly potent \ptmem{} and \pth{} T cells compared to state-of-the-art bead technology. \subsection*{DMSs can be used to produce functional CAR T cells} After optimizing for naïve/memory and CD4 yield, we sought to determine if the \glspl{dms} were compatible with lentiviral transduction protocols used to generate \gls{car} T cells27,28. We added a \SI{24}{\hour} transduction step on day 1 of the \SI{14}{\day} expansion to insert an anti-CD19 \gls{car}29 and subsequently measured the surface expression of the \gls{car} on day 14 \cref{fig:car_production_flow_pl,fig:car_production_endpoint_pl}. We noted that there was robust \gls{car} expression in over \SI{25}{\percent} of expanded T cells, and there was no observable difference in \gls{car} expression between beads and \glspl{dms}. We also verified the functionality of expanded \gls{car} T cells using a degranulation assay\cite{Zheng2012}. Briefly, T cells were cocultured with target cells (either wild-type K562 or CD19-expressing K562 cells) for \SI{4}{\hour}, after which the culture was analyzed via flow cytometry for the appearance of CD107a on CD8+ T cells. CD107a is found on the inner-surface of cytotoxic granules and will emerge on the surface after cytotoxic T cells are activated and degranulate. Indeed, we observed degranulation in T cells expanded with both beads and \glspl{dms}, although not to an observably different degree \cref{fig:car_production_flow_degran,fig:car_production_endpoint_degran}. Taken together, these results indicated that the \glspl{dms} provide similar transduction efficiency compared to beads. We also verified that expanded T cells were migratory using a chemotaxis assay for CCL21; since \glspl{dms} produced a larger percentage of naïve and memory T cells (which have CCR7, the receptor for CCL21) we would expect higher migration in \gls{dms}-expanded cells vs.\ their bead counterparts. Indeed, we noted a significantly higher migration percentage for T cells grown using \glspl{dms} versus beads (\cref{fig:car_production_migration}). Interestingly, there also appeared to be a decrease in CCL21 migration between transduced and untransduced T cells expanded using beads, but this interaction effect was only weakly significant (p = 0.068). No such effect was seen for \gls{dms}-expanded T cells, showing that migration was likely independent of \gls{car} transduction. \begin{figure*}[ht!] \begingroup \includegraphics{../figures/car_production.png} \phantomsubcaption\label{fig:car_production_flow_pl} \phantomsubcaption\label{fig:car_production_endpoint_pl} \phantomsubcaption\label{fig:car_production_flow_degran} \phantomsubcaption\label{fig:car_production_endpoint_degran} \phantomsubcaption\label{fig:car_production_migration} \endgroup \caption[\glspl{dms} produce functional \gls{car} T cells] {\glspl{dms} produce functional \gls{car} T cells. \subcap{fig:car_production_flow_pl}{Representative flow cytometry plot for transduced or untransduced T cells stained with \gls{ptnl}.} \subcap{fig:car_production_endpoint_pl}{Endpoint plots with \gls{anova} for transduced or untransduced T cells stained with \gls{ptnl}.} \subcap{fig:car_production_flow_degran}{Representative flow plot for degenerating T cells.} \subcap{fig:car_production_endpoint_degran}{Endpoint plots for transduced or untransduced T cells stained with \cd{107a} for the degranulation assay.} \subcap{fig:car_production_migration}{Endpoint plot for transmigration assay with \gls{anova}.} All data is from T cells expanded for \SI{14}{\day}. } \label{fig:car_production} \end{figure*} In addition to CD19 \gls{car} T cells, we also demonstrated that the \gls{dms} platform can be used to expand \gls{car} T cells against \gls{bcma}. Analogously to the case with CD19, \gls{dms} and bead produced similar fractions of \ptcar{} cells (albeit in this case at day 7 and with an undefined \gls{moi}) (\cref{fig:car_bcma_percent}). Also consistent with CD19 and non-\gls{car} data, we also found that the number of \ptcar{} T cells was greater for \gls{dms} than for bead (\cref{fig:car_bcma_total}). % FIGURE the right half if bigger than the left half \begin{figure*}[ht!] \begingroup \includegraphics{../figures/car_bcma.png} \phantomsubcaption\label{fig:car_bcma_percent} \phantomsubcaption\label{fig:car_bcma_total} \endgroup \caption[BMCA Transduction Results] {\glspl{dms} produce larger numbers of \gls{bcma} \gls{car} T cells compared to beads. \subcap{fig:car_bcma_percent}{\ptcarp{} at day 14.} \subcap{fig:car_bcma_total}{Total number of \ptcarp{} cells at day 14.} } \label{fig:car_bcma} \end{figure*} \subsection{DMSs efficiently expand T cells in Grex bioreactors} \begin{figure*}[ht!] \begingroup \includegraphics{../figures/grex_results.png} \phantomsubcaption\label{fig:grex_results_fc} \phantomsubcaption\label{fig:grex_results_viability} \phantomsubcaption\label{fig:grex_mem} \phantomsubcaption\label{fig:grex_cd4} \endgroup \caption[Grex bioreactor results] {\glspl{dms} expand T cells robustly in Grex bioreactors. \subcap{fig:grex_results_fc}{Fold change of T cells over time.} \subcap{fig:grex_results_viability}{Viability of T cells over time.} \subcap{fig:grex_mem}{\ptmemp{}} and \subcap{fig:grex_cd4}{\pthp{}} of T cells after \SI{14}{\day} of expansion. Significance tests were performed using the Wilcoxon non-parametric test. } \label{fig:grex_results} \end{figure*} We also asked if the \gls{dms} platform could expand T cells in a static bioreactor such a Grex. We incubated T cells in a Grex analogously to that for plates and found that T cells in Grex bioreactors expanded as efficiently as bead over \SI{14}{\day} and had similar viability (\cref{fig:grex_results_fc,fig:grex_results_viability}). Furthermore, consistent with past results, \glspl{dms}-expanded T cells had higher \pthp{} compared to beads and higher \ptmemp{} compared to beads (\cref{fig:grex_mem,fig:grex_cd4}). Overall the \ptmemp{} was much lower than that seen from cultures grown in tissue-treated plates (\cref{fig:dms_phenotype_mem}). These discrepancies might be explained in light of our other data as follows. The Grex bioreactor has higher media capacity relative to its surface area, and we did not move the T cells to a larger bioreactor as they grew in contrast with our plate cultures. This means that the cells had higher growth area constraints, which may have nullified any advantage to the expansion that we seen elsewhere (\cref{fig:dms_exp_fold_change}). Furthermore, the higher growth area could mean higher signaling and higher differentiation rate to effector T cells, which was why the \ptmemp{} was so low compared to other data (\cref{fig:dms_phenotype_mem}). \begin{figure*}[ht!] \begingroup \includegraphics{../figures/grex_luminex.png} \endgroup \caption[Grex luminex results] {\gls{dms} lead to higher cytokine production in Grex bioreactors.} \label{fig:grex_luminex} \end{figure*} We also quantified the cytokines released during the Grex expansion using Luminex. We noted that in nearly all cases, the \gls{dms}-expanded T cells released higher concentrations of cytokines compared to beads (\cref{fig:grex_luminex}). This included higher concentrations of pro-inflammatory cytokines such as GM-CSF, \gls{ifng}, and \gls{tnfa}. This demonstrates that \gls{dms} could lead to more robust activation and fitness. Taken together, these data suggest that \gls{dms} also lead to robust expansion in Grex bioreactors, although more optimization may be necessary to maximize the media feed rate and growth area to get comparable results to those seen in tissue-culture plates. \subsection{DMSs do not leave antibodies attached to cell product} \begin{figure*}[ht!] \begingroup \includegraphics{../figures/nonstick.png} \endgroup \caption[\glspl{mab} do not detach from \glspl{dms}] {\glspl{mab} do not detach from microcarriers onto T cells in a detectable manner. Plots are representative manufacturing runs harvest after \SI{14}{\day} of expansion and stained with \anti{\gls{igg}}. } \label{fig:nonstick} \end{figure*} % DISCUSSION alude to this figure We asked if \glspl{mab} from the \glspl{dms} detached from the \gls{dms} surface and could be detected on the final T cell product. This test is important for clinical translation as any residual \glspl{mab} on T cells injected into the patient could elicit an undesirable \antim{\gls{igg}} immune response. We did not detect the presence of either \ahcd{3} or \ahcd{28} \glspl{mab} (both of which were \gls{igg}) on the final T cell product after \SI{14}{\day} of expansion (\cref{fig:nonstick}). \subsection{DMSs consistently outperform bead-based expansion compared to beads in a variety of conditions} In order to establish the robustness of our method, we combined all experiments performed in our lab using beads or \glspl{dms} and combined them into one dataset. Since each experiment was performed using slightly different process conditions, we hypothesized that performing causal inference on such a dataset would not only indicate if the \glspl{dms} indeed led to better results under a variety of conditions, but would also indicate other process parameters that influence the outcome. The dataset was curated by compiling all experiments and filtering those that ended at day 14 and including flow cytometry results for the \ptmem{} and \pth{} populations. We further filtered our data to only include those experiments where the surface density of the CD3 and CD28 \gls{mab} were held constant (since some of our experiments varied these on the \glspl{dms}). This ultimately resulted in a dataset with 162 runs spanning 15 experiments between early 2017 and early 2021. % FIGURE add some correlation analysis to this Since the aim of the analysis was to perform causal inference, we determined 6 possible treatment variables which we controlled when designing the experiments included in this dataset. Obviously the principle treatment parameter was ‘activation method’ which represented the effect of activating T cells with either beads or our DMS method. We also included ‘bioreactor’ which was a categorical for growing the T cells in a Grex bioreactor vs polystyrene plates, ‘feed criteria’ which represented the criteria used to feed the cells (using media color or a glucose meter), ‘IL2 Feed Conc’ as a continuous parameter for the concentration of IL2 added each feed cycle, and ‘CD19-CAR Transduced’ representing if the cells were lentivirally transduced or not. Unfortunately, many of these parameters correlated with each other highly despite the large size of our dataset, so the only two parameters for which causal relationships could be evaluated were ‘activation method’ and ‘bioreactor’. We should also note that these were not the only set of theoretical treatment parameters that we could have used. For example, media feed rate is an important process parameter, but this was dependent on the feeding criteria and the growth rate of the cells, which in turn is determined by activation method. Therefore, ‘media feed rate’ (or similar) is a ‘post-treatment parameter’ and would have violated the backdoor criteria and severely biased our estimates of the treatment parameters themselves. In addition to these treatment parameters, we also included covariates to improve the precision of our model. Among these were donor parameters including age, \gls{bmi}, demographic, and gender, as well as the initial viability and CD4/CD8 ratio of the cryopreserved cell lots used in the experiments. We also included the age of key reagents such as IL2, media, and the anti-aggregate media used to thaw the T cells prior to activation. Each experiment was performed by one of three operators, so this was included as a three-level categorical parameter. Lastly, some of our experiments were sampled longitudinally, so we included a boolean categorical to represented this modification as removing conditioned media as the cell are expanding could disrupt signaling pathways. % TABLE these tables have extra crap in them that I don't need to show \begin{table}[!h] \centering \caption{Causal Inference on treatment variables only} \label{tab:ci_treat} \input{../tables/causal_inference_treat.tex} \end{table} \begin{table}[!h] \centering \caption{Causal Inference on treatment variables and control variables} \label{tab:ci_controlled} \input{../tables/causal_inference_control.tex} \end{table} \begin{figure*}[ht!] \begingroup \includegraphics{../figures/metaanalysis_effects.png} \phantomsubcaption\label{fig:metaanalysis_fx_exp} \phantomsubcaption\label{fig:metaanalysis_fx_mem} \phantomsubcaption\label{fig:metaanalysis_fx_cd4} \endgroup \caption[Meta-analysis effect sizes] {\glspl{dms} exhibit superior performance compared to beads controlling for many experimental and process conditions. Effect sizes for \subcap{fig:metaanalysis_fx_exp}{fold change}, \subcap{fig:metaanalysis_fx_mem}{\ptmemp{}}, and \subcap{fig:metaanalysis_fx_cd4}{\dpthp{}}. The dotted line represents the mean of the bead population. The red and blue dots represent the effect size of using \gls{dms} instead of beads only considering treatment variables (\cref{tab:ci_treat}) or treatment and control variables (\cref{tab:ci_controlled}) respectively. } \label{fig:metaanalysis_fx} \end{figure*} % TODO the real reason we log-transformed was because box-cox and residual plots We first asked what the effect of each of our treatment parameters was on the responses of interest, which were fold change of the cells, the \ptmemp{}, and \dpthp{} (the shift in \pthp{} at day 14 compared to the initial \pthp{}). We performed a linear regression using activation method and bioreactor as predictors (the only treatments that were shown to be balanced) (\cref{tab:ci_treat}). Note that fold change was log transformed to reflect the exponential nature of T cell growth. We observe that the treatments are significant in all cases except for the \dpthp{}; however, we also observe that relatively little of the variability is explained by these simple models ($R^2$ between 0.17 and 0.44). % RESULT add the regression diagnostics to this We then included all covariates and unbalanced treatment parameters and performed linear regression again (\cref{tab:ci_controlled,fig:metaanalysis_fx}). We observe that after controlling for additional noise, the models explained much more variability ($R^2$ between 0.76 and 0.87) and had relatively constant variance and small deviations for normality as per the assumptions of regression analysis {Figure X}. Furthermore, the coefficient for activation method in the case of fold change changed very little but still remained quite high (note the log-transformation) with \SI{143}{\percent} increase in fold change compared to beads. Furthermore, the coefficient for \ptmemp{} dropped to about \SI{2.7}{\percent} different and almost became non-significant at $\upalpha$ = 0.05, and the \dpthp{} response increased to almost a \SI{9}{\percent} difference and became highly significant. Looking at the bioreactor treatment, we see that using the bioreactor in the case of fold change and \ptmemp{} is actually harmful to the response, while at the same time it seems to increase the \dpthp{} response. We should note that this parameter merely represents whether or not the choice was made experimentally to use a bioreactor or not; it does not indicate why the bioreactor helped or hurt a certain response. For example, using a Grex entails changing the cell surface and feeding strategy for the T cells, and any one of these ‘mediating variables’ might actually be the cause of the responses. \section{discussion} % DISCUSSION this is fluffy We have developed a T cell expansion system that recapitulates key features of the in vivo lymph node microenvironment using DMSs functionalized with activating mAbs. This strategy provided superior expansion with higher number of naïve/memory and CD4+ T cells compared to state-of-the-art microbead technology (Figure 2). Other groups have used biomaterials approaches to mimic the \invivo{} microenvironment\cite{Cheung2018, Rio2018, Delalat2017, Lambert2017, Matic2013}; however, to our knowledge this is the first system that specifically drives naïve/memory and CD4+ T cell formation in a scalable, potentially bioreactor-compatible manufacturing process. % DISCUSSION assuage krish by showing that in the isotype control fig that IL2 % doesn't activation T cells: https://www.jimmunol.org/content/jimmunol/191/12/5822.full.pdf Memory and naïve T cells have been shown to be important clinically. Compared to effectors, they have a higher proliferative capacity and are able to engraft for months; thus they are able to provide long-term immunity with smaller doses\cite{Gattinoni2012, Joshi2008}. Indeed, less differentiated T cells have led to greater survival both in mouse tumor models and human patients\cite{Fraietta2018, Adachi2018, Rosenberg2011}. Furthermore, clinical response rates have been positively correlated with T cell expansion, implying that highly-proliferative naïve and memory T cells are a significant contributor\cite{Xu2014, Besser2010}. Circulating memory T cells have also been found in complete responders who received CAR T cell therapy\cite{Kalos2011}. Similarly, CD4 T cells have been shown to play an important role in CAR T cell immunotherapy. It has been shown that CAR T doses with only CD4 or a mix of CD4 and CD8 T cells confer greater tumor cytotoxicity than only CD8 T cells\cite{Wang2018, Sommermeyer2015}. There are several possible reasons for these observations. First, CD4 T cells secrete proinflammatory cytokines upon stimulation which may have a synergistic effect on CD8 T cells. Second, CD4 T cells may be less prone to exhaustion and may more readily adopt a memory phenotype compared to CD8 T cells\cite{Wang2018}. Third, CD8 T cells may be more susceptible than CD4 T cells to dual stimulation via the CAR and endogenous T Cell Receptor (TCR), which could lead to overstimulation, exhaustion, and apoptosis\cite{Yang2017}. Despite evidence for the importance of CD4 T cells, more work is required to determine the precise ratios of CD4 and CD8 T cell subsets to be included in CAR T cell therapy given a disease state. % DISCUSSION this mentions the DOE which is in the next aim When analyzing all our experiments comprehensively using causal inference, we found that all three of our responses were significantly increased when controlling for covariates (Figure 3, Table 2). By extension, this implies that not only will DMSs lead to higher fold change overall, but also much higher fold change in absolute numbers of memory and CD4+ T cells. Furthermore, we found that using a Grex bioreactor is detrimental to fold change and memory percent while helping CD4+. Since there are multiple consequences to using a Grex compared to tissue-treated plates, we can only speculate as to why this might be the case. Firstly, when using a Grex we did not expand the surface area on which the cells were growing in a comparable way to that of polystyrene plates. In conjunction with our DOE data {Figure X} which shows that high DMS concentrations favor CD4+ and don’t favor memory fraction, one possible explanation is that the T cells spent longer times in highly activating conditions (since the beads and DMSs would have been at higher per-area concentrations in the Grex vs polystyrene plates). Furthermore, the simple fact that the T cells spent more time at high surface densities could simply mean that the T cells didn’t expands as much due to spacial constraints. This would all be despite the fact that Grex bioreactors are designed to lead to better T cell expansion due to their gas-permeable membranes and higher media-loading capacities. If anything, our data suggests we were using the bioreactor sub-optimally, and the hypothesized causes for why our T cells did not expand could be verified with additional experiments varying the starting cell density and/or using larger bioreactors. A key question in the space of cell manufacturing is that of donor variability. To state this precisely, this is a second order interaction effect that represents the change in effect of treatment (eg bead vs DMS) given the donor. While our meta-analysis was relatively large compared to many published experiments usually seen for technologies at this developmental stage, we have a limited ability in answering this question. We can control for donor as a covariate, and indeed our models show that many of the donor characteristics are strongly associated with each response on average, but these are first order effects and represent the association of age, gender, demographic, etc given everything else in the model is held constant. Second order interactions require that our treatments be relatively balanced and random across each donor, which is a dubious assumption for our dataset. However, this can easily be solved by performing more experiments with these restrictions in mind, which will be a subject of our future work. Furthermore, this dataset offers an interesting insight toward novel hypothesis that might be further investigated. One limitation of our dataset is that we were unable to investigate the effects of time using a method such as autoregression, and instead relied on aggregate measures such as the total amount of a reagent added over the course of the expansion. Further studies should be performed to investigate the temporal relationship between phenotype, cytokine concentrations, feed rates, and other measurements which may perturb cell cultures, as this will be the foundation of modern process control necessary to have a fully-automated manufacturing system. In addition to larger numbers of potent T cells, other advantages of our DMS approach are that the DMSs are large enough to be filtered (approximately 300 µm) using standard 40 µm cell filters or similar. If the remaining cells inside that DMSs are also desired, digestion with dispase or collagenase may be used. Collagenase D may be selective enough to dissolve the DMSs yet preserve surface markers which may be important to measure as critical quality attributes CQAs {Figure X}. Furthermore, our system should be compatible with large-scale static culture systems such as the G-Rex bioreactor or perfusion culture systems, which have been previously shown to work well for T cell expansion\cite{Forget2014, Gerdemann2011, Jin2012}. The microcarriers used to create the DMSs also have a regulatory history in human cell therapies that will aid in clinical translation.; they are already a component in an approved retinal pigment epithelial cell product for Parkinson’s patients, and are widely available in 30 countries\cite{purcellmain}. It is important to note that all T cell cultures in this study were performed up to 14 days. Others have demonstrated that potent memory T cells may be obtained simply by culturing T cells as little as 5 days using traditional beads\cite{Ghassemi2018}. It is unknown if the naïve/memory phenotype of our DMS system could be further improved by reducing the culture time, but we can hypothesize that similar results would be observed given the lower number of doublings in a 5 day culture. We should also note that we investigated one subtype (\ptmem{}) in this study. Future work will focus on other memory subtypes such as tissue resident memory and stem memory T cells, as well as the impact of using the DMS system on the generation of these subtypes. % DISCUSSION this sounds sketchy Another advantage is that the DMS system appears to induce a faster growth rate of T cells given the same IL2 concentration compared to beads (Supplemental Figure 8) along with retaining naïve and memory phenotype. This has benefits in multiple contexts. Firstly, some patients have small starting T cell populations (such as infants or those who are severely lymphodepleted), and thus require more population doublings to reach a usable dose. Our data suggests the time to reach this dose would be reduced, easing scheduling a reducing cost. Secondly, the allogeneic T cell model would greatly benefit from a system that could create large numbers of T cells with naïve and memory phenotype. In contrast to the autologous model which is currently used for Kymriah and Yescarta, allogeneic T cell therapy would reduce cost by spreading manufacturing expenses across many doses for multiple patients\cite{Harrison2019}. Since it is economically advantageous to grow as many T cells as possible in one batch in the allogeneic model (reduced start up and harvesting costs, fewer required cell donations), the DMSs offer an advantage over current technology. % DISCUSSION this is already stated in the innovation section It should be noted that while we demonstrate a method providing superior performance compared to bead-based expansion, the cell manufacturing field would tremendously benefit from simply having an alternative to state-of-the-art methods. The patents for bead-based expansion are owned by few companies and licensed accordingly; having an alternative would provide more competition in the market, reducing costs and improving access for academic researchers and manufacturing companies. % DISCUSSION this isn't relevent to this aim but should be said somewhere Finally, while we have demonstrated the DMS system in the context of CAR T cells, this method can theoretically be applied to any T cell immunotherapy which responds to anti-CD3/CD28 mAb and cytokine stimulation. These include \glspl{til}, virus-specific T cells (VSTs), T cells engineered to express $\upgamma\updelta$TCR (TEGs), $\upgamma\updelta$ T cells, T cells with transduced-TCR, and CAR-TCR T cells\cite{Cho2015, Straetemans2018, Robbins2011, Brimnes2012, Baldan2015, Walseng2017}. Similar to CD19-CARs used in liquid tumors, these T cell immunotherapies would similarly benefit from the increased proliferative capacity, metabolic fitness, migration, and engraftment potential characteristic of naïve and memory phenotypes\cite{Blanc2018, Lalor2016, Rosato2019}. Indeed, since these T cell immunotherapies are activated and expanded with either soluble mAbs or bead-immobilized mAbs, our system will likely serve as a drop-in substitution to provide these benefits. \chapter{aim 2a}\label{aim2a} \section{introduction} The purpose of this sub-aim was to develop computational methods to identify novel \glspl{cqa} and \glspl{cpp} that could be used for release criteria, process control, and process optimization for the \gls{dms} platform. We hypothesized that T cells grown using the \gls{dms} system would produce detectable biological signatures in the media supernatent which corresponded to clinically relevent responses such as the fold expansion of the T cells or the resulting phenotype. We tested this hypothesis by activating T cells under a variety of conditions using a \gls{doe}, sampling the media at intermediate timepoints, and creating models to predict the outcome of the cultures. We should stress that the specific \glspl{cpp} and \glspl{cqa} determined by this aim are not necessarily universal, as this was not performed with equipment that would normally be used at scale. However, the process outlined here is one that can easily be adaptable to any system, and the specific findings themselves offer interesting insights that warrant further study. \section{methods} \subsection{study design} \begin{figure*}[ht!] \begingroup \includegraphics{../figures/modeling_overview.png} \phantomsubcaption\label{fig:mod_overview_flow} \phantomsubcaption\label{fig:mod_overview_doe} \endgroup \caption[Modeling Overview] {Overview of modeling experiments. \subcap{fig:mod_overview_flow}{Relationship between \gls{doe} experiments and AI driven prediction. \glspl{doe} will be used to determine optimal process input conditions, and longitudinal multiomics data will be used to fit predictive models. Together, these will reveal predictive species that may be used for \glspl{cqa} and \glspl{cpp}.} \subcap{fig:mod_overview_doe}{Overview of the two \gls{doe} experiments; the initial \gls{doe} is given by the blue points and the augmented \gls{doe} is given by the blue points.} } \label{fig:mod_overview} \end{figure*} The first DOE resulted in a randomized 18-run I-optimal custom design where each DMS parameter was evaluated at three levels: IL2 concentration (10, 20, and 30 U/uL), DMS concentration (500, 1500, 2500 carrier/uL), and functionalized antibody percent (60\%, 80\%, 100\%). These 18 runs consisted of 14 unique parameter combinations where 4 of them were replicated twice to assess prediction error. Process parameters for the ADOE were evaluated at multiple levels: IL2 concentration (30, 35, and 40 U/uL), DMS concentration (500, 1000, 1500, 2000, 2500, 3000, 3500 carrier/uL), and functionalized antibody percent (100\%) as depicted in Fig.1b. To further optimize the initial region explored (DOE) in terms of total live CD4+ TN+TCM cells, a sequential adaptive design-of-experiment (ADOE) was designed with 10 unique parameter combinations, two of these replicated twice for a total of 12 additional samples (Fig.1b). The fusion of cytokine and NMR profiles from media to model these responses included 30 cytokines from a custom Thermo Fisher ProcartaPlex Luminex kit and 20 NMR features. These 20 spectral features from NMR media analysis were selected out of approximately 250 peaks through the implementation of a variance-based feature selection approach and some manual inspection steps. \subsection{DMS fabrication} \glspl{dms} were fabricated as described in \cref{sec:dms_fab} with the following modifications in order to obtain a variable functional \gls{mab} surface density. During the \gls{mab} coating step, the anti-CD3/anti-CD28 mAb mixture was further combined with a biotinylated isotype control to reduce the overall fraction of targeted \glspl{mab} (for example the \SI{60}{\percent} \gls{mab} surface density corresponded to 3 mass parts \acd{3}, 3 mass parts \acd{28}, and 4 mass parts isotype control). \subsection{T cell culture} T cell culture was performed as described in \cref{sec:tcellculture} with the following modifications. At days 4, 6, 8, and 11, \SI{100}{\ul} media were collected for the Luminex assay and \gls{nmr} analysis. The volume of removed media was equivalently replaced during the media feeding step, which took place immediately after sample collection. Additionally, the same media feeding schedule was followed for the DOE and ADOE to improve consistency, and the same donor lot was used for both experiments. All cell counts were performed using \gls{aopi}. \subsection{flow cytometry} Flow cytometry was performed analogously to \cref{sec:flow_cytometry}. \subsection{Cytokine quantification} Cytokines were quantified via Luminex as described in \cref{sec:luminex_analysis}. \subsection{NMR metabolomics} Prior to analysis, samples were centrifuged at \SI{2990}{\gforce} for \SI{20}{\minute} at \SI{4}{\degreeCelsius} to clear any debris\footnote{all \gls{nmr} analysis was done by our collaborators at the University of Georgia}. 5 uL of 100/3 mM DSS-D6 in deuterium oxide (Cambridge Isotope Laboratories) were added to 1.7 mm NMR tubes (Bruker BioSpin), followed by 45 uL of media from each sample that was added and mixed, for a final volume of 50 uL in each tube. Samples were prepared on ice and in predetermined, randomized order. The remaining volume from each sample in the rack (approx. 4 uL) was combined to create an internal pool. This material was used for internal controls within each rack as well as metabolite annotation. \gls{nmr} spectra were collected on a Bruker Avance III HD spectrometer at 600 MHz using a 5-mm TXI cryogenic probe and TopSpin software (Bruker BioSpin). One-dimensional spectra were collected on all samples using the noesypr1d pulse sequence under automation using ICON NMR software. Two-dimensional \gls{hsqc} and TOCSY spectra were collected on internal pooled control samples for metabolite annotation. One-dimensional spectra were manually phased and baseline corrected in TopSpin. Two-dimensional spectra were processed in NMRpipe37. One dimensional spectra were referenced, water/end regions removed, and normalized with the PQN algorithm38 using an in-house MATLAB (The MathWorks, Inc.) toolbox. % TODO add the supplemental figure alluded to here? To reduce the total number of spectral features from approximately 250 peaks and enrich for those that would be most useful for statistical modeling, a variance-based feature selection was performed within MATLAB. For each digitized point on the spectrum, the variance was calculated across all experimental samples and plotted. Clearly-resolved features corresponding to peaks in the variance spectrum were manually binned and integrated to obtain quantitative feature intensities across all samples (Supp.Fig.S24). In addition to highly variable features, several other clearly resolved and easily identifiable features were selected (glucose, BCAA region, etc). Some features were later discovered to belong to the same metabolite but were included in further analysis. Two-dimensional spectra collected on pooled samples were uploaded to COLMARm web server10, where \gls{hsqc} peaks were automatically matched to database peaks. \gls{hsqc} matches were manually reviewed with additional 2D and proton spectra to confirm the match. Annotations were assigned a confidence score based upon the levels of spectral data supporting the match as previously described11. Annotated metabolites were matched to previously selected features used for statistical analysis. % I'm pretty sure this isn't relevant % Using the list of annotated metabolites obtained above, an approximation of a % representative experimental spectrum was generated using the GISSMO mixture % simulation tool.39,40 With the simulated mixture of compounds, generated at 600 % MHz to match the experimental data, a new simulation was generated at 80 MHz to % match the field strength of commercially available benchtop NMR spectrometers. % The GISSMO tool allows visualization of signals contributed from each individual % compound as well as the mixture, which allows annotation of features in the % mixture belonging to specific compounds. Several low abundance features selected for analysis did not have database matches and were not annotated. Statistical total correlation spectroscopy41 suggested that some of these unknown features belonged to the same molecules (not shown). Additional multidimensional NMR experiments will be required to determine their identity. \subsection{machine learning and statistical analysis} Linear regression analysis of the \glspl{doe} was performed as described in \cref{sec:statistics}. Seven \gls{ml} techniques were implemented to predict three responses related to the memory phenotype of the cultured T cells under different process parameters conditions (i.e. Total Live CD4+ TN and TCM, Total Live CD8+ TN+TCM, and Ratio CD4+/CD8+ TN+TCM). The \gls{ml} methods executed were \gls{rf}, \gls{gbm}, \gls{cif}, \gls{lasso}, \gls{plsr}, \gls{svm}, and DataModeler’s \gls{sr}\footnote{of these seven methods, all except \gls{lasso} were performed by collaborators}. Primarily, \gls{sr} models were used to optimize process parameter values based on TN+TCM phenotype and to extract early predictive variable combinations from the multi-omics experiments. Furthermore, all regression methods were executed, and the high-performing models were used to perform a consensus analysis of the important variables to extract potential critical quality attributes and critical process parameters predictive of T-cell potency, safety, and consistency at the early stages of the manufacturing process. \gls{sr} was done using Evolved Analytics’ DataModeler software (Evolved Analytics LLC, Midland, MI). DataModeler utilizes genetic programming to evolve symbolic regression models (both linear and non-linear) rewarding simplicity and accuracy. Using the selection criteria of highest accuracy (R2>90\% or noise-power) and lowest complexity, the top-performing models were identified. Driving variables, variable combinations, and model dimensionality tables were generated. The top-performing variable combinations were used to generate model ensembles. In this analysis, DataModeler’s SymbolicRegression function was used to develop explicit algebraic (linear and nonlinear) models. The fittest models were analyzed to identify the dominant variables using the VariablePresence function, the dominant variable combinations using the VariableCombinations function, and the model dimensionality (number of unique variables) using the ModelDimensionality function. CreateModelEnsemble was used to define trustable model ensembles using selected variable combinations and these were summarized (model expressions, model phenotype, model tree plot, ensemble quality, model quality, variable presence map, \gls{anova} tables, model prediction plot, exportable model forms) using the ModelSummaryTable function. Ensemble prediction and residual performance were respectively assessed via the EnsemblePredictionPlot and EnsembleResidualPlot subroutines. Model maxima (ModelMaximum function) and model minima (ModelMinimum function) were calculated and displayed using the ResponsePlotExplorer function. Trade-off performance of multiple responses was explored using the MultiTargetResponseExplorer and ResponseComparisonExplorer with additional insights derived from the ResponseContourPlotExplorer. Graphics and tables were generated by DataModeler. These model ensembles were used to identify predicted response values, potential optima in the responses, and regions of parameter values where the predictions diverge the most. Non-parametric tree-based ensembles were done through the \inlinecode{randomForest}, inlinecode{gbm}, and \inlinecode{cforest} regression functions in R, for \gls{rf}, \gls{gbm}, and \gls{cif} models, respectively. Both \gls{rf} and \gls{cif} construct multiple decision trees in parallel, by randomly choosing a subset of features at each decision tree split, in the training stage. Random forest individual decision trees are split using the Gini Index, while conditional inference forest uses a statistical significance test procedure to select the variables at each split, reducing correlation bias. In contrast, \gls{gbm} construct regression trees in series through an iterative procedure that adapts over the training set. This model learns from the mistakes of previous regression trees in an iterative fashion to correct errors from its precursors’ trees (i.e. minimize \gls{mse}). Prediction performance was evaluated using \gls{loocv} and permutation-based variable importance scores assessing \% increase of \gls{mse}, relative influence based on the increase of prediction error, coefficient values for \gls{rf}, \gls{gbm}, and \gls{cif}, respectively. \gls{plsr} was executed using the \inlinecode{plsr} function from the \inlinecode{pls} package in R while \gls{lasso} regression was performed using the \inlinecode{cv.glmnet} R package, both using leave-one-out cross-validation. Finally, the \inlinecode{kernlab} R package was used to construct the \gls{svm} models. Parameter tuning was done for all models in a grid search manner using the train function from the \inlinecode{caret} R package using \gls{loocv} as the optimization criteria. Specifically, the number of features randomly sampled as candidates at each split (\inlinecode{mtry}) and the number of trees to grow (\inlinecode{ntree}) were tuned parameters for random forest and conditional inference forest. In particular, minimum sum of weights in a node to be considered for splitting and the minimum sum of weights in a terminal node were manually tuned for building the \gls{cif} models. Moreover, \gls{gbm} parameters such as the number of trees to grow, maximum depth of each tree, learning rate, and the minimal number of observations at the terminal node, were tuned for optimum \gls{loocv} performance as well. For \gls{plsr}, the optimal number of components to be used in the model was assessed based on the standard error of the cross-validation residuals using the function \inlinecode{selectNcomp} from the \inlinecode{pls} package. Moreover, \gls{lasso} regression was performed using the \inlinecode{cv.glmnet} package with alpha = 1. The best lambda for each response was chosen using the minimum error criteria. Lastly, a fixed linear kernel (i.e. \inlinecode{svmLinear}) was used to build the \gls{svm} regression models evaluating the cost parameter value with best \gls{loocv}. Prediction performance was measured for all models using the final model with \gls{loocv} tuned parameters. % TODO do I need this? % Table M2 shows the parameter values evaluated per model % at the final stages of results reporting. \subsection{consensus analysis} Consensus analysis of the relevant variables extracted from each machine learning model was done to identify consistent predictive features of quality at the early stages of manufacturing. First importance scores for all features were measured across all \gls{ml} models using \inlinecode{varImp} with \inlinecode{caret} R package except for scores for \gls{svm} which \inlinecode{rminer} R package was used. These importance scores were percent increase in \gls{mse}, relative importance through average increase in prediction error when a given predictor is permuted, permuted coefficients values, absolute coefficient values, weighted sum of absolute coefficients values, and relative importance from sensitivity analysis determined for \gls{rf}, \gls{gbm}, \gls{cif}, \gls{lasso}, \gls{plsr}, and \gls{svm}, respectively. Using these scores, key predictive variables were selected if their importance scores were within the 80th percentile ranking for the following \gls{ml} methods: \gls{rf}, \gls{gbm}, \gls{cif}, \gls{lasso}, \gls{plsr}, \gls{svm} while for \gls{sr} variables present in >30\% of the top-performing \gls{sr} models from DataModeler (R2>= 90\%, Complexity >= 100) were chosen to investigate consensus except for \gls{nmr} media models at day 4 which considered a combination of the top-performing results of models excluding lactate ppms, and included those variables which were in > 40\% of the best performing models. Only variables with those high percentile scoring values were evaluated in terms of their logical relation (intersection across \gls{ml} models) and depicted using a Venn diagram from the \inlinecode{venn} R package. \section{results} \subsection{T cells can be grown on DMSs with lower IL2 concentrations} Prior to the main experiments in this aim, we performed a preliminary experiment to assess the effect of lowering the \gls{il2} concentration on the T cells grown with either bead or \gls{dms}. One of the hypotheses for the \gls{dms} system was that the higher cell density would enable more efficient cross-talk between T cells. Since \gls{il2} is secreted by activated T cells themselves, T cells in the \gls{dms} system may need less or no \gls{il2} if this hypothesis were true. % FIGURE this plots proportions look dumb % FIGURE take out the NLS lines since I don't feel like defending them \begin{figure*}[ht!] \begingroup \includegraphics{../figures/il2_modulation.png} \phantomsubcaption\label{fig:il2_mod_timecourse} \phantomsubcaption\label{fig:il2_mod_total} \phantomsubcaption\label{fig:il2_mod_mem} \phantomsubcaption\label{fig:il2_mod_flow} \endgroup \caption[T cells grown at varying IL2 concentrations] {\glspl{dms} grow T cells effectively at lower IL2 concentrations. \subcap{fig:il2_mod_timecourse}{Longitudinal cell counts of T cells grown with either bead or \glspl{dms} using varying IL2 concentrations} Day 14 counts of either \subcap{fig:il2_mod_total}{total cells} or \subcap{fig:il2_mod_mem}{\ptmem{} cells} plotted against \gls{il2} concentration. \subcap{fig:il2_mod_flow}{Flow cytometry plots of the \ptmem{} gated populations at day 14 of culture for each \gls{il2} concentration.} } \label{fig:il2_mod} \end{figure*} We varied the concentration of \gls{il2} from \SIrange{0}{100}{\IU\per\ml} and expanded T cells as described in \cref{sec:tcellculture}. T cells grown with either method expanded robustly as \gls{il2} concentration was increased (\cref{fig:il2_mod_timecourse}). Surprisingly, neither the bead or the \gls{dms} group expanded at all with \SI{0}{\IU\per\ml} \gls{il2}. When examining the endpoint fold change after \SI{14}{\day}, we observe that the difference between the bead and \gls{dms} appears to be greater at lower \gls{il2} concentrations (\cref{fig:il2_mod_total}). % This is further supported by fitting a non-linear % least squares equation to the data following a hyperbolic curve (which should be % a plausible model given that this curve describes receptor-ligand kinetics, % which we can assume \gls{il2} to follow). Furthermore, the same trend can be seen when only examining the \ptmem{} cell expansion at day 14 (\cref{fig:il2_mod_mem}). In this case, the \ptmemp{} of the T cells seemed to be relatively close at higher \gls{il2} concentrations, but separated further at lower concentrations (\cref{fig:il2_mod_flow}) Taken together, these data do not support the hypothesis that the \gls{dms} system does not need \gls{il2} at all; however, it appears to have a modest advantage at lower \gls{il2} concentrations compared to beads. For this reason, we decided to investigate the lower range of \gls{il2} concentrations starting at \SI{10}{\IU\per\ml} throughout the remainder of this aim. % RESULT this is not consistent with the next section since the responses are % different \subsection{DOE shows optimal conditions for expanded potent T cells} % TABLE not all of these were actually used, explain why by either adding columns % or marking with an asterisk \begin{table}[!h] \centering \caption{DOE Runs} \label{tab:doe_runs} \input{../tables/doe_runs.tex} \end{table} % RESULT integrate this figure into the results paragraph \begin{figure*}[ht!] \begingroup \includegraphics{../figures/doe_responses_first.png} \phantomsubcaption\label{fig:doe_response_first_mem} \phantomsubcaption\label{fig:doe_response_first_cd4} \endgroup \caption[Response plots for first DOE] {Response plots from the first \gls{doe} experiment for \subcap{fig:doe_response_first_mem}{\ptmemp{}} and \subcap{fig:doe_response_first_cd4}{\pthp{}}. Each point is one run. } \label{fig:doe_response_first} \end{figure*} % RESULT maybe add regression tables to this, although it doesn't really matter % since we end up doing regression on the full thing later anyways. We conducted two consecutive \glspl{doe} to optimize the \pth{} and \ptmem{} responses for the \gls{dms} system. In the first \gls{doe} we, tested \pilII{} in the range of \SIrange{10}{30}{\IU\per\ml}, \pdms{} in the range of \SIrange{500}{2500}{\dms\per\ml}, and \pmab{} in the range of \SIrange{60}{100}{\percent}. When looking at the total \ptmemp{} output, we observed that \pilII{} showed a positive linear trend with the \pdms{} and \pmab{} showing possible second-order effects with maximums and minimums at the intermediate level (\cref{fig:doe_response_first_mem}). In the case of \pth{}, we observed that all parameters seemed to have a positive linear response, with \pilII{} and \pdms{} showing slight second order effects that suggest a maximum might exist at a higher value for each. After performing the first \gls{doe} we augmented the original design matrix with an \gls{adoe} which was built with three goals in mind. Firstly we wished to validate the first \gls{doe} by assessing the strength and responses of each effect. Secondly, we wished to improve our confidence in regions that showed high complexity, such as the peak in the \gls{dms} concentration for the total \ptmem{} cell response. Thirdly, we wished to explore additional ranges of each response. Since \pilII{} and \pdms{} appeared to continue positively influence multiple responses beyond our tested range, we were curious if there was an optimum at some higher setting of either of these values. For this reason, we increased the \pilII{} to include \SI{40}{\IU\per\ml} and the \pdms{} to \SI{3500}{\dms\per\ml}. Note that it was impossible to go beyond \SI{100}{\percent} for the \pmab{}, so runs were positioned for this parameter with validation and confidence improvements in mind. The runs for each \gls{doe} were shown in \cref{tab:doe_runs}\footnote{Not all runs in this table were used. It was determined later that the total \glspl{mab} surface density may not be consistent across each batch of \gls{dms} used, primarily due to the fact that a subset were created at different scale and with a different operator. To remove this bias in our data, these runs were not used.}. \begin{figure*}[ht!] \begingroup \includegraphics{../figures/doe_responses.png} \phantomsubcaption\label{fig:doe_responses_mem} \phantomsubcaption\label{fig:doe_responses_cd4} \phantomsubcaption\label{fig:doe_responses_mem4} \phantomsubcaption\label{fig:doe_responses_ratio} \endgroup \caption[T cell optimization through Design of Experiments] {\gls{doe} methodology reveals optimal conditions for expanding T cell subsets. Responses vs IL2 concentration, \gls{dms} concentration, and functional \gls{mab} percentage are shown for \subcap{fig:doe_responses_mem}{total \ptmem{} T cells}, \subcap{fig:doe_responses_cd4}{total \pth{} T cells}, \subcap{fig:doe_responses_mem4}{total \ptmemh{} T cells}, and \subcap{fig:doe_responses_ratio}{ratio of CD4 and CD8 T cells in the \ptmem{} compartment}. Each point represents one run. } \label{fig:doe_responses} \end{figure*} \begin{table}[!h] \centering \caption{Total CD62L+CCR7+ T cell response (first order regression)} \label{tab:doe_mem1.tex} \input{../tables/doe_mem1.tex} \end{table} \begin{table}[!h] \centering \caption{Total CD62L+CCR7+ T cell response (third order regression)} \label{tab:doe_mem2.tex} \input{../tables/doe_mem2.tex} \end{table} \begin{table}[!h] \centering \caption{Total CD4+ T cell response} \label{tab:doe_cd4.tex} \input{../tables/doe_cd4.tex} \end{table} \begin{table}[!h] \centering \caption{Linear regression for total \ptmemh{} cells} \label{tab:doe_mem4.tex} \input{../tables/doe_mem4.tex} \end{table} \begin{table}[!h] \centering \caption{Linear regression for CD4:CD8 ratio in the \ptmem{} compartment} \label{tab:doe_ratio.tex} \input{../tables/doe_ratio.tex} \end{table} The response plots from both \glspl{doe} are shown in \cref{fig:doe_responses} for total \ptmem{} cells, total \pth{} cells, total \ptmemh{} cells, and CD4:CD8 ratio in the \ptmem{} compartment. In general, the responses for the first and second \gls{doe} seemed to overlap, although not perfectly. Interestingly, only the \ptmem{} response seemed to have anything more complex than a linear relationship, particularly in the case of \pilII{} and \pdms{}, which showed intermediate optimums (\cref{fig:doe_responses_mem}). In the case of \pilII{}, it was not clear if this optimum was simply due to a batch effect of being from the first or second \gls{doe}. The optimum for \pdms{} appeared in the same location albeit more pronounced in the second \gls{doe} so, giving more confidence to the location of this second order feature. The remainder of the responses showed mostly linear relationships in all parameter cases (\cref{fig:doe_responses_cd4,fig:doe_responses_mem4,fig:doe_responses_ratio}). % RESULT it seems arbitrary that I went straight to a third order model, the real % reason is because it seemed weird that a second order model didn't find % anything to be significant We performed linear regression on the three input parameters as well as a binary parameter representing if a given run came from the first or second \gls{doe} (called `dataset'). Starting with the total \ptmem{} cells response, we fit a first order regression model using these four parameters (\cref{tab:doe_mem1.tex}). While \pilII{} was found to be a significant predictor, the model fit was extremely poor ($R^2$ of 0.331). This was not surprising given the apparent complexity of this response (\cref{fig:doe_responses_mem}). To obtain a better fit, we added second and third degree terms (\cref{tab:doe_mem2.tex}). Note that the dataset parameter was not included in the second order interaction as this was treated as a blocking variable, which are typically not assumed to have interaction effects. Also note that the response was log-transformed, which yielded a better fit. In this model many more parameters emerged as being significant, including the quadratic terms for \pdms{} and \pilII{}, in agreement with what can be qualitatively observed in the response plot (\cref{fig:doe_responses_mem}). Furthermore, the dataset parameter was weakly significant, indicating a possible batch effect between the \glspl{doe}. We should also note that despite many parameters being significant, this model was still only mediocre in describing this response; the $R^2$ was 0.741 but the adjusted $R^2$ was 0.583, indicating that our data might be underpowered for a model this complex. Further experiments beyond what was performed here may be needed to fully describe this response. % TABLE combine these tables into one We performed linear regression on the other three responses, all of which performed much better than the \ptmem{} response as expected given the much lower apparent complexity in the response plots (\cref{fig:doe_responses_cd4,fig:doe_responses_mem4,fig:doe_responses_ratio}). All these models appeared to fit will, with $R^2$ and adjusted $R^2$ upward of 0.8. In all but the CD4:CD8 \ptmem{} ratio, the dataset parameter emerged as significant, indicating a batch effect between the \glspl{doe}. All other parameters except \pilII{} in the case of CD4:CD8 \ptmem{} ratio were significant predictors. \begin{figure*}[ht!] \begingroup \includegraphics{../figures/doe_sr_contour.png} \phantomsubcaption\label{fig:doe_sr_contour_mem4} \phantomsubcaption\label{fig:doe_sr_contour_ratio} \endgroup \caption[Contour plots for DOE responses] {Symbolic regression and contour plots reveal optimal conditions for \subcap{fig:doe_sr_contour_mem4}{\ptmemh{} cells} and \subcap{fig:doe_sr_contour_ratio}{CD4:CD8 ratio in the \ptmem{} compartment}. } \label{fig:doe_sr_contour} \end{figure*} We then visualized the total \ptmemh{} cells and CD4:CD8 \ptmem{} ratio using the response explorer in DataModeler to create contour plots around the maximum responses. For both, it appeared that maximizing all three input parameters resulted in the maximum value for either response (\cref{fig:doe_responses}). While not all combinations at and around this optimum were tested, the model nonetheless showed that there were no other optimal values or regions elsewhere in the model. % TODO this section header sucks \subsection{AI modeling reveals highly predictive species} \begin{figure*}[ht!] \begingroup \includegraphics{../figures/doe_luminex.png} \endgroup \caption[Cytokine release profile of T cells from DOE] {T cells show robust and varying cytokine responses over time} \label{fig:doe_luminex} \end{figure*} Due to the heterogeneity of the multivariate data collected and knowing that no single model structure is perfect for all applications, we implemented an agnostic modeling approach to better understand these TN+TCM responses. To achieve this, a consensus analysis using seven machine learning (ML) techniques, Random Forest (RF), Gradient Boosted Machine (GBM), Conditional Inference Forest (CIF), Least Absolute Shrinkage and Selection Operator (LASSO), Partial Least-Squares Regression (PLSR), Support Vector Machine (SVM), and DataModeler’s Symbolic Regression (SR), was implemented to molecularly characterize TN+TCM cells and to extract predictive features of quality early on their expansion process (Fig.1d-e). % TABLE this table looks like crap, break it up into smaller tables \begin{table}[!h] \centering \caption{Results for data-driven modeling} \label{tab:mod_results} \input{../tables/model_results.tex} \end{table} SR models achieved the highest predictive performance (R2>93\%) when using multi-omics predictors for all endpoint responses (\cref{tab:mod_results}). SR achieved R2>98\% while GBM tree-based ensembles showed leave-one-out cross-validated R2 (LOO-R2) >95\% for CD4+ and CD4+/CD8+ TN+TCM responses. Similarly, LASSO, PLSR, and SVM methods showed consistent high LOO-R2, 92.9\%, 99.7\%, and 90.5\%, respectively, to predict the CD4+/CD8+ TN+TCM. Yet, about 10\% reduction in LOO-R2, 72.5\%-81.7\%, was observed for CD4+ TN+TCM with these three methods. Lastly, SR and PLSR achieved R2>90\% while other ML methods exhibited exceedingly variable LOO-R2 (0.3\%,RF-51.5\%,LASSO) for CD8+ TN+TCM cells. \begin{figure*}[ht!] \begingroup \includegraphics{../figures/sr_omics.png} \endgroup \caption[Symbolic Regression Cytokine Dependencies] {Multi-omics culturing media prediction profiles at day 6 using symbolic regression.} \label{fig:sr_omics} \end{figure*} The top-performing technique, SR, showed that the median aggregated predictions for CD4+ and CD8+ TN+TCM cells increases when IL2 concentration, IL15, and IL2R increase while IL17a decreases in conjunction with other features. These patterns combined with low values of DMS concentration and GM-CSF uniquely characterized maximum CD8+ TN+TCM. Meanwhile, higher glycine but lower IL13 in combination with others showed maximum CD4+ TN+TCM predictions (\cref{fig:sr_omics}). \begin{figure*}[ht!] \begingroup \includegraphics{../figures/modeling_flower.png} \phantomsubcaption\label{fig:mod_flower_48r} \phantomsubcaption\label{fig:mod_flower_cd4} \endgroup \caption[Data-Driven \gls{cqa} identification] {Data-driven modeling using techniques with regularization reveals species predictive species which are candidates for \glspl{cqa}. Flower plots are shown for \subcap{fig:mod_flower_48r}{CD4:CD8 ratio} and \subcap{fig:mod_flower_cd4}{total \ptmemh{} cells}. The left and right columns includes models that were trained only on the secretome and metabolome respectively. Each flower on each plot represents one model, moving toward the center indicates higher agreement between models.} \label{fig:mod_flower} \end{figure*} Selecting CPPs and CQAs candidates consistently for T cell memory is desired. Here, \gls{tnfa} was found in consensus across all seven ML methods for predicting CD4+/CD8+ TN+TCM when considering features with the highest importance scores across models (Fig.3a;Methods). Other features, IL2R, IL4, IL17a, and DMS concentration, were commonly selected in >=5 ML methods (Fig.3a,c). Moreover, IL13 and IL15 were found predictive in combination with these using SR (Supp.Table.S4). \begin{figure*}[ht!] \begingroup \includegraphics{../figures/nmr_cors.png} \phantomsubcaption\label{fig:nmr_cors_lactate} \phantomsubcaption\label{fig:nmr_cors_formate} \phantomsubcaption\label{fig:nmr_cors_glucose} \phantomsubcaption\label{fig:nmr_cors_matrix} \endgroup \caption[NMR Day 4 correlations] {\gls{nmr} features at day 4 are strongly correlated with each other and the response variables. Highly correlated relationships are shown for \subcap{fig:nmr_cors_lactate}{lactate}, \subcap{fig:nmr_cors_formate}{formate}, and \subcap{fig:nmr_cors_glucose}{glucose}. Blue and blue connections indicate positive and negative correlations respectively. The threshold for visualizing connections in all cases was 0.8. \subcap{fig:nmr_cors_matrix}{The correlation matrix for all predictive features and the total \ptmemh{} response.} } \label{fig:nmr_cors} \end{figure*} \section{discussion} % optimization of process features % TODO this sounds like total fluff % DISCUSSION integrate figures CPPs modeling and understanding are critical to new product development and in cell therapy development, it can have life-saving implications. The challenges for effective modeling grow with the increasing complexity of processes due to high dimensionality, and the potential for process interactions and nonlinear relationships. Another critical challenge is the limited amount of available data, mostly small DOE datasets. SR has the necessary capabilities to resolve the issues of process effects modeling and has been applied across multiple industries12. SR discovers mathematical expressions that fit a given sample and differs from conventional regression techniques in that a model structure is not defined a priori13. Hence, a key advantage of this methodology is that transparent, human-interpretable models can be generated from small and large datasets with no prior assumptions\cite{Kotancheka}. Since the model search process lets the data determine the model, diverse and competitive (e.g., accuracy, complexity) model structures are typically discovered. An ensemble of diverse models can be formed where its constituent models will tend to agree when constrained by observed data yet diverge in new regions. Collecting data in these regions helps to ensure that the target system is accurately modeled, and its optimum is accurately located\cite{Kotancheka}. Exploiting these features allows adaptive data collection and interactive modeling. Consequently, this adaptive-DOE approach is useful in a variety of scenarios, including maximizing model validity for model-based decision making, optimizing processing parameters to maximize target yields, and developing emulators for online optimization and human understanding\cite{Kotancheka}. % predictive features An in-depth characterization of potential DMS-based T-cell CQAs includes a list of cytokine and NMR features from media samples that are crucial in many aspects of T cell fate decisions and effector functions of immune cells. Cytokine features were observed to slightly improve prediction and dominated the ranking of important features and variable combinations when modeling together with NMR media analysis and process parameters (Fig.3b,d). Predictive cytokine features such as \gls{tnfa}, IL2R, IL4, IL17a, IL13, and IL15 were biologically assessed in terms of their known functions and activities associated with T cells. T helper cells secrete more cytokines than T cytotoxic cells, as per their main functions, and activated T cells secrete more cytokines than resting T cells. It is possible that some cytokines simply reflect the CD4+/CD8+ ratio and the activation degree by proxy proliferation. However, the exact ratio of expected cytokine abundance is less clear and depends on the subtypes present, and thus examination of each relevant cytokine is needed. IL2R is secreted by activated T cells and binds to IL2, acting as a sink to dampen its effect on T cells\cite{Witkowska2005}. Since IL2R was much greater than IL2 in solution, this might reduce the overall effect of IL2, which could be further investigated by blocking IL2R with an antibody. In T cells, TNF can increase IL2R, proliferation, and cytokine production\cite{Mehta2018}. It may also induce apoptosis depending on concentration and alter the CD4+ to CD8+ ratio\cite{Vudattu2005}. Given that TNF has both a soluble and membrane-bound form, this may either increase or decrease CD4+ ratio and/or memory T cells depending on the ratio of the membrane to soluble TNF\cite{Mehta2018}. Since only soluble TNF was measured, membrane TNF is needed to understand its impact on both CD4+ ratio and memory T cells. Furthermore, IL13 is known to be critical for Th2 response and therefore could be secreted if there are significant Th2 T cells already present in the starting population\cite{Wong2011}. This cytokine has limited signaling in T cells and is thought to be more of an effector than a differentiation cytokine\cite{Junttila2018}. It might be emerging as relevant due to an initially large number of Th2 cells or because Th2 cells were preferentially expanded; indeed, IL4, also found important, is the conical cytokine that induces Th2 cell differentiation (Fig.3). The role of these cytokines could be investigated by quantifying the Th1/2/17 subsets both in the starting population and longitudinally. Similar to IL13, IL17 is an effector cytokine produced by Th17 cells\cite{Amatya2017} thus may reflect the number of Th17 subset of T cells. GM-CSF has been linked with activated T cells, specifically Th17 cells, but it is not clear if this cytokine is inducing differential expansion of CD8+ T cells or if it is simply a covariate with another cytokine inducing this expansion\cite{Becher2016}. Finally, IL15 has been shown to be essential for memory signaling and effective in skewing CAR-T cells toward the Tscm phenotype when using membrane-bound IL15Ra and IL15R\cite{Hurton2016}. Its high predictive behavior goes with its ability to induce large numbers of memory T cells by functioning in an autocrine/paracrine manner and could be explored by blocking either the cytokine or its receptor. Moreover, many predictive metabolites found here are consistent with metabolic activity associated with T cell activation and differentiation, yet it is not clear how the various combinations of metabolites relate with each other in a heterogeneous cell population. Formate and lactate were found to be highly predictive and observed to positively correlate with higher values of total live CD4+ TN+TCM cells (Fig.5a-b;Supp.Fig.28-S30,S38). Formate is a byproduct of the one-carbon cycle implicated in promoting T cell activation\cite{RonHarel2016}. Importantly, this cycle occurs between the cytosol and mitochondria of cells and formate excreted\cite{Pietzke2020}. Mitochondrial biogenesis and function are shown necessary for memory cell persistence\cite{van_der_Windt_2012, Vardhana2020}. Therefore, increased formate in media could be an indicator of one-carbon metabolism and mitochondrial activity in the culture. In addition to formate, lactate was found as a putative CQA of TN+TCM. Lactate is the end-product of aerobic glycolysis, characteristic of highly proliferating cells and activated T cells\cite{Lunt2011, Chang2013}. Glucose import and glycolytic genes are immediately upregulated in response to T cell stimulation, and thus generation of lactate. At earlier time-points, this abundance suggests a more robust induction of glycolysis and higher overall T cell proliferation. Interestingly, our models indicate that higher lactate predicts higher CD4+, both in total and in proportion to CD8+, seemingly contrary to previous studies showing that CD8+ T cells rely more on glycolysis for proliferation following activation\cite{Cao2014}. It may be that glycolytic cells dominate in the culture at the early time points used for prediction, and higher lactate reflects more cells. % TODO not sure how much I should include here since I didn't do this analysis % AT ALL % Ethanol patterns are difficult to interpret since its production in mammalian % cells is still poorly understood31. Fresh media analysis indicates ethanol % presence in the media used, possibly utilized as a carrier solvent for certain % formula components. However, this does not explain the high variability and % trend of ethanol abundance across time (Supp.Fig.S25-S27). As a volatile % chemical, variation could be introduced by sample handling throughout the % analysis process. Nonetheless, it is also possible that ethanol excreted into % media over time, impacting processes regulating redox and reactive oxygen % species which have previously been shown to be crucial in T cell signaling and % differentiation32. % this looks fine since it is just parroting sources, just need to paraphrase a % little Metabolites that consistently decreased over time are consistent with the primary carbon source (glucose) and essential amino acids (BCAA, histidine) that must be continually consumed by proliferating cells. Moreover, the inclusion of glutamine in our predictive models also suggests the importance of other carbon sources for certain T cell subpopulations. Glutamine can be used for oxidative energy metabolism in T cells without the need for glycolysis\cite{Cao2014}. Overall, these results are consistent with existing literature that show different T cell subtypes require different relative levels of glycolytic and oxidative energy metabolism to sustain the biosynthetic and signaling needs of their respective phenotypes\cite{Almeida2016,Wang_2012}. It is worth noting that the trends of metabolite abundance here are potentially confounded by the partial replacement of media that occurred periodically during expansion (Methods), thus likely diluting some metabolic byproducts (i.e. formate, lactate) and elevating depleted precursors (i.e. glucose, amino acids). More definitive conclusions of metabolic activity across the expanding cell population can be addressed by a closed system, ideally with on-line process sensors and controls for formate, lactate, along with ethanol and glucose. \chapter{aim 2b}\label{aim2b} \section{introduction} The purpose of this sub-aim was to further explore the \gls{dms} platform, specifically for mechanisms and pathways that could be the basis for additional \glspl{cpp} that could be optimized to yield higher quantity and quality of T cells. Our strategy in general was to perturb the \gls{dms} system from the normal operating conditions at which it was used up until this point either through temporal modulation of activation signal or by blocking pathways of interest using \glspl{mab}. \section{methods} \subsection{DMSs temporal modulation} % METHOD The concentration for the surface marker cleavage experiment was much % higher, if that matters \glspl{dms} were digested in active T cell cultures via addition of sterile \product{\gls{colb}}{\sigald}{11088807001} or \product{\gls{cold}}{\sigald}{11088858001}. Collagenase was dissolved in \product{\gls{hbss}}{Gibco}{14025-076} or \product{TexMACS}{\miltenyi}{170-076-307} at approximately \SI{100}{\ug\per\ml}. This solution was added to T cell cultures at a 1:1 ratio in place of plain media normally used to feed the cells during the regular media addition cycle at day 4. Cultures were then incubated as described in \cref{sec:tcellculture}, and the \glspl{dms} were verified to have been digested after \SI{24}{\hour}. Adding \gls{dms} was relatively much simpler; the number of \gls{dms} used per area on day 0 was scaled up by 3 on day 4 to match the change from a 96 well plate to a 24 well plate, effectively producing a constant activation signal. \subsection{mass cytometry and clustering analysis} T cells were stained using a \product{34 \gls{cytof} marker panel}{Fluidigm}{201322} and \product{cisplatin}{Fluidigm}{201064} which were used according to the manufacturer’s instructions. \numrange{2e6}{3e6} stained cells per group were analyzed on a Fluidigm Helios. Unbiased cell clusters were obtained using \gls{spade} analysis by pooling three representative \gls{fcs} files and running the \gls{spade} pipeline with k-means clustering (k = 100), arcsinh transformation with cofactor 5, density calculation neighborhood size of 5 and local density approximation factor of 1.5, target density of 20000 cells, and outlier density cutoff of \SI{1}{\percent}. All markers in the \gls{cytof} panel were used in the analysis \subsection{integrin blocking experiments} To block \gls{a2b1} and \gls{a2b2}, active T cell cultures with \gls{dms} were supplemented with \product{\anti{\gls{a2b1}}}{\sigald}{MAB1973Z} and \product{\anti{\gls{a2b2}}}{\sigald}{MAB1950Z} (both \gls{leaf}) at indicated concentrations and timepoints. T cells were grown as described in \cref{sec:tcellculture}. \gls{a2b1} and \gls{a2b2} were verified to be present on active T cell cultures by staining with \product{\anti{\gls{a2b1}}-\gls{apc}}{\bl}{328313} and \product{\anti{\gls{a2b2}}-\gls{fitc}}{\bl}{359305} on day 6 of culture and analyzing via a BD Accuri flow cytometer. \subsection{IL15 blocking experiments} To block the \gls{il15r}, we supplemented T cell cultures activated with \gls{dms} with either \product{\anti{\gls{il15r}}}{Rnd}{AF247} or \product{\gls{igg} isotype control}{RnD}{AB-108-C} at the indicated timepoints and concentrations. T cells were grown as otherwise described in \cref{sec:tcellculture} with the exception that volumes were split by $\frac{1}{3}$ to keep the culture volume constant and minimize the amount of \gls{mab} required. To block soluble \gls{il15}, we supplemented analogously with \product{\anti{\gls{il15}}}{RnD}{EEP0419081} or \product{\gls{igg} isotype control}{\bl}{B236633}. \section{results} \subsection{adding or removing DMSs alters expansion and phenotype} We hypothesized that adding or removing \gls{dms} in the middle of an active culture would alter the activation signal and hence the growth trajectory and phenotype of T cells. While adding \glspl{dms} was simple, the easiest way to remove \glspl{dms} was to use enzymatic digestion. Collagenase is an enzyme that specifically targets collagen proteins. Since our \glspl{dms} are composed of porcine-derived collagen, this enzyme should target the \gls{dms} while sparing the cells along with any markers we wish to analyze. We tested this specific hypothesis using either \gls{colb}, \gls{cold} or \gls{hbss}, and stained the cells using a typical marker panel to assess if any of the markers were cleaved off by the enzyme which would bias our final readout. We observed that the marker histograms in the \gls{cold} group were similar to that of the buffer group, while the \gls{colb} group visibly lowered CD62L and CD4, indicating partial enzymatic cleavage (\cref{fig:collagenase_fx}). Based on this result, we used \gls{cold} moving forward. % FIGURE this figure is tall and skinny like me \begin{figure*}[ht!] \begingroup \includegraphics{../figures/collagenase.png} \endgroup \caption[Effects Collagenase Treatment on T cells] {T cells treated with either \gls{colb}, \gls{cold}, or buffer and then stained for various surface markers and analyzing via flow cytometry.} \label{fig:collagenase_fx} \end{figure*} When either adding more \glspl{dms}, removing \glspl{dms} using \gls{cold}, or doing nothing, we observed that, counterintuitively, cell growth seemed to be inhibited in the \textit{added} group while the cells seemed to grow faster in the \textit{removed} group relative to the \textit{no change} group (\cref{fig:add_rem_growth}). Additionally, the \textit{removed} group seemed to have a negative growth rate in the final \SI{4}{\day} of culture, indicating that either the lack activation signal had slowed the cell growth down or that the cells were growing fast enough to outpace the media feeding schedule. The viability was the same between all groups, indicating that this negative growth rate and the lower growth rate in the \textit{added} group were likely not due to cell death (\cref{fig:add_rem_viability}). Interestingly, the \textit{added} group had significantly higher \pth{} cells compared to the \textit{no change} group, and the inverse was true for the \textit{removed} group (\cref{fig:add_rem_cd4}). These results show that the growth rate and phenotype are fundamentally altered by changing the number of \glspl{dms} temporally. \begin{figure*}[ht!] \begingroup \includegraphics{../figures/add_remove_endpoint.png} \phantomsubcaption\label{fig:add_rem_growth} \phantomsubcaption\label{fig:add_rem_viability} \phantomsubcaption\label{fig:add_rem_cd4} \endgroup \caption[Endpoint results from adding/removing \gls{dms} on day 4] {Changing \gls{dms} concentration on day 4 has profound effects on phenotype and growth. \subcap{fig:add_rem_growth}{Longitudinal fold change}, \subcap{fig:add_rem_viability}{longitudinal viability}, and \subcap{fig:add_rem_cd4}{day 14 \pthp{}} of T cell cultures with \glspl{dms} added, removed, or kept the same on day 4. } \label{fig:add_rem} \end{figure*} \begin{figure*}[ht!] \begingroup \includegraphics{../figures/spade_gates.png} \endgroup \caption[SPADE Gating Strategy] {Gating strategy for quantifying early-differentiated T cells via \gls{spade}.} \label{fig:spade_gates} \end{figure*} \begin{figure*}[ht!] \begingroup \includegraphics{../figures/add_remove_spade.png} \phantomsubcaption\label{fig:spade_msts} \phantomsubcaption\label{fig:spade_quant} \phantomsubcaption\label{fig:spade_tsne_all} \phantomsubcaption\label{fig:spade_tsne_stem} \endgroup \caption[SPADE and tSNE analysis temporally-modified DMS concentration] {Removing \glspl{dms} leads to a higher fraction of potent stem-memory T cells compared to both adding and not changing the \gls{dms} concentration at day 4. \subcap{fig:spade_msts}{SPADE plots of CD4, CD45RA, CD27, and CD45RO expression on T cells. All cells from the added, removed, or no change groups were pooled and clustered at once.} \subcap{fig:spade_quant}{T cells from SPADE plots clustered by expression in (\subref{fig:spade_msts}) quantified against total cell number from each group.} \subcap{fig:spade_tsne_all}{\gls{tsne} plots of all cells pooled from all groups.} \subcap{fig:spade_tsne_stem}{\gls{tsne} plots of T cells from all groups manually gated on \cdp{8}\cdp{27}\cdp{45RO}.} } \label{fig:spade} \end{figure*} We next asked what the effect of removing the \glspl{dms} would have on other phenotypes, specifically \gls{tcm} and \gls{tscm} cells. To this end we stained cells using a 34-marker mass cytometry panel and analyzed them using a Fluidigm Helios. After pooling the \gls{fcs} file events from each group and analyzing them via \gls{spade} we see that there is a strong bifurcation of CD4 and CD8 T cells. We also observe that among CD27, CD45RA, and CD45RO (markers commonly used to identify \gls{tcm} and \gls{tscm} subtypes) we see clear `metaclusters' composed of individual \gls{spade} clusters which are high for that marker (\cref{fig:spade_msts,fig:spade_gates}). We then gated each of these metaclusters according to their marker levels and assigned them to one of three phenotypes for both the CD4 and CD8 compartments: \gls{tcm} (high CD45RO, low CD45RA, high CD27), \gls{tscm} (low CD45RO, high CD45RA, high CD27), and `transitory' \gls{tscm} cells (mid CD45RO, mid CD45RA, high CD27). Together these represent low differentiated cells which should be highly potent as anti-tumor therapies. When quantifying the number of cells from each experimental group in these phenotypes, we clearly see that the number of lower differentiated cells is much higher in the \textit{no change} or \textit{removed} groups compared to the \textit{added} group (\cref{fig:spade_quant}). Furthermore, the \textit{removed} group had a much higher fraction of \gls{tscm} cells compared to the \textit{no change} group, which had more `transitory \gls{tscm} cells'. The majority of these cells were \cdp{8} cells. When analyzing the same data using \gls{tsne}, we observe a higher fraction of CD27 and lower fraction of CD45RO in the the \textit{removed} group (\cref{fig:spade_tsne_all}). When manually gating on the CD27+CD45RO- population, we see there is higher density in the \textit{removed} group, indicating more of this population (\cref{fig:spade_tsne_stem}). Together, these data indicate that removing \glspl{dms} at lower timepoints leads to potentially higher expansion, lower \pthp{}, and higher fraction of lower differentiated T cells such as \gls{tscm}, and adding \gls{dms} seems to do the inverse. \subsection{blocking integrin binding does not alter expansion or phenotype} % BACKGROUND add background into why integrins are important One of the reasons the \gls{dms} platform might be performing better than the beads is the fact that they are composed of gelatin, which is a collagen derivative. The beads are simply \gls{mab} attached to a polymer resin coated onto an iron oxide core, and thus have no analogue for collagen. Collagen domains present on the \gls{dms} group could be creating pro-survival and pro-expansion signals to the T cells through \gls{a2b1} and \gls{a2b2}, causing them to grow better in the \gls{dms} system. \begin{figure*}[ht!] \begingroup \includegraphics{../figures/integrin_1.png} \phantomsubcaption\label{fig:inegrin_1_overview} \phantomsubcaption\label{fig:inegrin_1_fc} \phantomsubcaption\label{fig:inegrin_1_mem} \phantomsubcaption\label{fig:inegrin_1_cd49} \endgroup \caption[Integrin blocking I] {Blocking with integrin does not lead to differences in memory or growth. \subcap{fig:inegrin_1_overview}{Experimental overview} \subcap{fig:inegrin_1_fc}{Fold change of \gls{dms}-activated T cell over time with each blocking condition.} \subcap{fig:inegrin_1_mem}{\ptmemp{} at day 14 for each blocked condition.} \subcap{fig:inegrin_1_cd49}{\gls{a2b1} and \gls{a2b2} expression over time.} `A' and `B' refer to the inclusion of \anti{\gls{a2b1}} or \anti{\gls{a2b2}} respectively. } \label{fig:integrin_1} \end{figure*} \begin{table}[!h] \centering \caption{Linear regression for day 14 phenotype shown in \cref{fig:integrin_1}} \label{tab:integrin_1_reg} \input{../tables/integrin_1_reg.tex} \end{table} We tested this hypothesis by adding blocking \glspl{mab} against \gls{a2b1} and/or \gls{a2b2} to running T cell cultures activated using the \glspl{dms}. These block \glspl{mab} were added at day 6 of culture when \gls{a2b1} and \gls{a2b2} were known to be expressed\cite{Hemler1990}. We found that the fold expansion was identical in all the blocked groups vs the unblocked control group (\cref{fig:inegrin_1_fc}). Furthermore, we observed that the \ptmemp{} (total and across the CD4/CD8 compartments) was not significantly different between any of the groups (\cref{fig:inegrin_1_mem,tab:integrin_1_reg}). We also noted that \gls{a2b1} and \gls{a2b2} were present on the surface of a significant subset of T cells at day 6, showing that the target we wished to block was present (\cref{fig:inegrin_1_cd49}). \begin{figure*}[ht!] \begingroup \includegraphics{../figures/integrin_2.png} \phantomsubcaption\label{fig:inegrin_2_overview} \phantomsubcaption\label{fig:inegrin_2_fc} \phantomsubcaption\label{fig:inegrin_2_mem} \endgroup \caption[Integrin blocking II] {Blocking with integrin does not lead to differences in memory or growth. \subcap{fig:inegrin_1_fc}{Fold change of \gls{dms}-activated T cell over time with each blocking condition.} \subcap{fig:inegrin_1_mem}{\ptmemp{} at day 14 for each blocked condition.} `A' and `B' refer to the inclusion of \anti{\gls{a2b1}} or \anti{\gls{a2b2}} respectively. } \label{fig:integrin_2} \end{figure*} \begin{table}[!h] \centering \caption{Linear regression for day 14 phenotype shown in \cref{fig:integrin_2}} \label{tab:integrin_2_reg} \input{../tables/integrin_2_reg.tex} \end{table} Since this last experiment gave a negative result, we decided to hit \gls{a2b1} and \gls{a2b2} harder by adding blocking \glspl{mab} at more timepoints between day 0 and day 6, hypothesizing that the majority of the signaling would be during the period of culture where the \gls{dms} surface concentration was at its maximum. Once again, we observed no difference between any of the blocked conditions and the unblocked controls in regard to expansion (\cref{fig:inegrin_2_fc}). Furthermore, none of the \ptmemp{} readouts (total, CD4, or CD8) were statistically different between groups (\cref{fig:inegrin_2_mem,tab:integrin_2_reg}). Taken together, these data suggest that the advantage of the \gls{dms} platform is not due to signaling through \gls{a2b1} or \gls{a2b2}. \subsection{blocking IL15 signaling does not alter expansion or phenotype} \gls{il15} is a cytokine responsible for memory T cell survival and maintenance. Furthermore, we observed in other experiments that it is secreted to a much greater extend in \gls{dms} compared to bead cultures (\cref{fig:doe_luminex}). One of our driving hypotheses in designing the \gls{dms} system was that the higher cell density would lead to greater local signaling. Since we observed higher \ptmemp{} across many conditions, we hypothesized that \gls{il15} may be responsible for this, and further that the unique \textit{cis/trans} activity of \gls{il15} may be more active in the \gls{dms} system due to higher cell density. \begin{figure*}[ht!] \begingroup \includegraphics{../figures/il15_blockade_1.png} \phantomsubcaption\label{fig:il15_1_overview} \phantomsubcaption\label{fig:il15_1_fc} \phantomsubcaption\label{fig:il15_1_viability} \phantomsubcaption\label{fig:il15_1_mem} \endgroup \caption[IL15 blocking I] {Blocking IL15Ra does not lead to differences in memory or growth. \subcap{fig:il15_1_overview}{Experimental overview} Longitudinal measurements of \subcap{fig:il15_1_fc}{fold change} and \subcap{fig:il15_1_viability}{viability} for blocked and unblocked conditions expanded with either beads or \glspl{dms}. \subcap{fig:il15_1_mem}{Flow cytometry markers for \gls{dms}-expanded T cells at day 14 for blocked and unblocked groups.}. } \label{fig:il15_1} \end{figure*} % RESULT how did I determine how much to add? % FIGURE just gate these as normal because this looks sketchy We first tested this hypothesis by blocking \gls{il15r} with either a specific \gls{mab} or an \gls{igg} isotype control. We observed no difference in the expansion rate of blocked or unblocked cells (this experiment also had bead-based groups but they did not expand well and thus were not included) (\cref{fig:il15_1_fc}). Furthermore, there were no differences in viability between any group (\cref{fig:il15_1_viability}). We also performed flow cytometry to asses the \ptmemp{} and \pthp{} outputs. Without even gating the samples, simply lining up their histograms showed no difference between any of the markers, and by extension showing no difference in phenotype (\cref{fig:il15_1_mem}). % FIGURE this should say ug not mg \begin{figure*}[ht!] \begingroup \includegraphics{../figures/il15_blockade_2.png} \phantomsubcaption\label{fig:il15_2_overview} \phantomsubcaption\label{fig:il15_2_fc} \phantomsubcaption\label{fig:il15_2_viability} \phantomsubcaption\label{fig:il15_2_mem} \endgroup \caption[IL15 blocking II] {Blocking soluble IL15 does not lead to differences in memory or growth. \subcap{fig:il15_2_overview}{Experimental overview} Longitudinal measurements of \subcap{fig:il15_2_fc}{fold change} and \subcap{fig:il15_2_viability}{viability} for blocked and unblocked conditions expanded with \glspl{dms}. \subcap{fig:il15_2_mem}{Flow cytometry markers for \gls{dms}-expanded T cells at day 14 for blocked and unblocked groups.}. } \label{fig:il15_2} \end{figure*} We next tried blocking soluble \gls{il15} itself using either a \gls{mab} or an \gls{igg} isotype control. \anti{\gls{il15}} or \gls{igg} isotype control was added at \SI{5}{\ug\per\ml}, which according to \cref{fig:doe_luminex} was in excess of the \gls{il15} concentration seen in past experiments by over 20000X. Similarly, we observed no difference between fold change, viability, or marker histograms between any of these markers, showing that blocking \gls{il15} led to no difference in growth or phenotype. % RESULT this can probably be worded more specifically in terms of the cis/trans % action of IL15 In summary, this data did not support the hypothesis that the \gls{dms} platform gains its advantages via the \gls{il15} pathway. \section{discussion} This work provides insight for how the \gls{dms} operates and may be optimized further. The data showing increased \pthp{} when \glspl{dms} are added and the reverse when removed is consistent with other data we produced via \gls{doe} showing that higher \gls{dms} concentrations lead to higher \pthp{} (\cref{fig:doe_responses_cd4,fig:add_rem_cd4}). The difference in this case is that we showed that altering activation signal analogously affects the \pthp{} in the dimension of time as well as space. A similar trend was observed with memory T cells in this aim. Our previous \gls{doe} data showed that, to a point, lower \gls{dms} concentration leads to higher \ptmemp{} (\cref{fig:doe_responses_mem}). In this aim, we showed that decreasing activation signal temporally by removing \glspl{dms} leads to the same effect in the \gls{tcm}, \gls{tscm} and `transitory' \gls{tscm} populations, (all of which are included in the \ptmem{} phenotype). Taken together, these imply that temporally or spatially altering the \gls{dms} concentration, and thus the activation signal, has similar effects. % BACKGROUND this sounds like background? % There are several plausible explanations for the observed phenotypic differences % between beads and DMSs. First, the DMSs are composed of a collagen derivative % (gelatin); collagen has been shown to costimulate activated T cells via % \gls{a2b1} and \gls{a2b2}, leading to enhanced proliferation, increased % \gls{ifng} production, and upregulated CD25 (IL2R$\upalpha$) surface % expression8,10,11,41,42. While we did not find support for our hypothesis that the \gls{dms} signal through the \gls{a2b1} and/or \gls{a2b2} receptors, we can speculate as to why either this experiment failed and may be done better in the future, or why these receptors may simply be irrelevant for our system. On the first point, we did not verify that these \glspl{mab} indeed blocked the receptor we were targeting. There has been evidence from other groups that these particular clones work at the concentrations we used\cite{MirandaCarus2005}. This does not necessarily mean that the \glspl{mab} we obtained were functional in blocking their intended targets (although they were from a reputable manufacturer, \bl). Furthermore, we can safely rule out the possibility that the \glspl{mab} never reached their targets, as they were added immediately after the T cells were resuspended as required for cell counting, hence their resting clustered state was disrupted. % TODO define Bite On the second point, the collagen domains may not even be relevant to our system depending on the nature of the \gls{stp} coating. We intended by design for the system to be fully coated or nearly fully-coated with \gls{stp} (\cref{fig:stp_coating}). Thus the domains that \gls{a2b1} and \gls{a2b2} may be targeting could be sterically hindered by a layer of \gls{stp}, and if not that, also a layer of CD3/CD28 \glspl{mab}. The other possibility is that these domains are simply denatured to beyond recognition due to the fabrication process for the microcarriers we used (which involves a proprietary cross-linking step to make the material autoclave-safe). Either of these could be tested and verified by staining the \glspl{dms} with a fluorescently-tagged \gls{mab} (or something smaller such as a BiTE to reduce the possibility of steric hindrance) and verifying binding via confocal microscopy or indirect protein quantification as we do for the \gls{qc} of the \gls{dms}. If this test came back negative, we would be fairly confident that the \gls{a2b1} and \gls{a2b1} domains are either unreachable or unrecognizable. % DISCUSSION not sure exactly how to explain this We also failed to uphold our hypothesis that the \gls{dms} system gains its advantage via \gls{il15} signaling. % DISCUSSION not sure if this belongs here, although it might make sense to offer % alternative explanations of why the DMSs "work" given this negative data % Second, there is evidence that providing a larger % contact area for T cell activation provides greater stimulation16,43; the DMSs % have a rougher interface than the 5 µm magnetic beads, and thus could facilitate % these larger contact areas. Third, the DMSs may allow the T cells to cluster % more densely compared to beads, as evidenced by the large clusters on the % outside of the DMSs (Figure 1f) as well as the significant fraction of DMSs % found within their interiors (Supplemental Figure 2a and b). This may alter the % local cytokine environment and trigger different signaling pathways. % Particularly, IL15 and IL21 are secreted by T cells and known to drive memory % phenotype44–46. We noted that the IL15 and IL21 concentration was higher in a % majority of samples when comparing beads and DMSs across multiple timepoints % (Supplemental Figure 18) in addition to many other cytokines. IL15 and IL21 are % added exogenously to T cell cultures to enhance memory frequency,45,47 and our % data here suggest that the DMSs are better at naturally producing these % cytokines and limiting this need. Furthermore, IL15 unique signals in a trans % manner in which IL15 is presented on IL15R to neighboring cells48. The higher % cell density in the DMS cultures would lead to more of these trans interactions, % and therefore upregulate the IL15 pathway and lead to more memory T cells. \chapter{aim 3}\label{aim3} \section{introduction} % DO NOT COMMENT OUT THIS LINE: the real purpose of this aim was to appease % Nature Biotech because they think that animal models are necessary for good % science. This entire aim exists because of their foolishness. The purpose of this aim was to verify that \gls{car} T cells produced using the \gls{dms} system will show potent anti-tumor properties in a complex \invivo{} system compared to state-of-the-art bead technology. We hypothesized that due to the increased \ptmem{} and \pth{} phenotypes as shown in \cref{aim1}, that \gls{dms}-expanded T cells would show longer survival and lower tumor burden than those expanded with beads. We explored the effect of dosing at different levels and the effect of harvesting T cells at early timepoints in the culture, which has been shown to produce lower-differentiated T cells with higher potency\cite{Ghassemi2018}. \section{methods} \subsection{CD19-CAR T cell generation} % METHOD describe how T cells were grown for this aim % METHOD describe how the luciferase cells were generated (eg the kwong lab) \subsection{\invivo{} therapeutic efficacy in NSG mice model} % METHOD use actual product numbers for mice All mice in this study were male \gls{nsg} mice from Jackson Laboratories. At day 0 (-7 day relative to T cell injection), 1e6 firefly luciferase-expressing \product{Nalm-6 cells}{ATCC}{CRL-3273} suspended in ice-cold PBS were injected via tail vein into each mouse. At day 7, saline or CAR T cells at the indicated doses from either bead or DMS-expanded T cell cultures (for 14 days) were injected into each mouse via tail vein. Tumor burden was quantified longitudinally via an \gls{ivis} Spectrum (Perkin Elmer). Briefly, 200ug/mice luciferin at 15 mg/ml in PBS was injected intraperitoneally under isoflurane anesthesia into each mouse and waited for at least 10 minutes before imaging. Mice were anesthetized again and imaged using the \gls{ivis}. Mice from each treatment group/dose were anesthetized, injected, and imaged together, and exposure time of the \gls{ivis} was limited to avoid saturation based on the signal from the saline group. \gls{ivis} images were processed by normalizing them to common minimum and maximum photon counts and total flux was estimated in terms of photons/second. Endpoint for each mouse was determined by \gls{iacuc} euthanasia criteria (hunched back, paralysis, blindness, lethargy, and weight loss). Mice were euthanized according to these endpoint criteria using carbon dioxide asphyxiation. \subsection{statistics} For the \invivo{} model, the survival curves were created and statistically analyzed using GraphPad Prism using the Mantel-Cox test to assess significance between survival groups. \section{results} We asked if the higher memory/naive phenotype and more balanced CD4/CD8 ratio of our \gls{dms}-expanded CAR T cells would lead to better anti-tumor potency in vivo compared to bead-expanded CAR T cells. We also asked if this superior anti-tumor potency would hold true at lower doses of CAR expressing T cells in the DMS group vs the bead group. To test this, we used a human xenograft model of B cell \gls{all} by intravenously injecting \gls{nsg} mice with \num{1e6} Nalm-6 tumor cells expression firefly luciferase\cite{Fraietta2018}. After \SI{7}{\day} of tumor cell growth (\cref{fig:mouse_dosing_overview}), we intravenously injected saline or three doses (high, medium, and low) of \gls{dms} T cells from either bead or DMS cultures expanded for \SI{14}{\day}. We quantified total \gls{dms} expressing T cell percentage for bead and \gls{dms} groups using the \gls{ptnl} assay (\cref{tab:mouse_dosing_results}). Before injecting the T cells into the mice, we quantified their phenotype and growth. We observed that for this expansion, the bead and \gls{dms} T cells produced similar numbers of \ptmem{} T cells, and the beads even had a higher fraction of CD45RA, which is present on lower-differentiated naive and stem-memory T cells (\cref{fig:mouse_dosing_qc_mem}). However, the \pthp{} of the final product was higher in \gls{dms} (\cref{fig:mouse_dosing_qc_cd4}). The \gls{dms} T cells also expanded more robustly than the beads (\cref{fig:mouse_dosing_qc_growth}). In the Nalm-6/\gls{nsg} xenograft model, we observed lower tumor burden and significantly longer survival of bead and \gls{dms}-treated mice at all doses compared to the saline groups (\cref{fig:mouse_dosing_ivis}). Importantly, at each dose we observed that the \gls{dms}-treated mice had much lower tumor burden and significantly higher survival than their bead-treated counterparts (\cref{fig:mouse_dosing_ivis_survival}). When factoring the percentage T cells in each dose that expressed the \gls{car}, we note that survival of the low \gls{dms} dose (which had similar total \gls{car} T cells compared to the bead medium dose and less than the bead high dose) is significantly higher than that of both the bead medium dose and the bead high dose (\cref{fig:mouse_dosing_ivis_survival_comp}). Overall, the Kaplan-Meier survival of Nalm-6 tumor bearing \gls{nsg} mice shown in the \cref{fig:mouse_dosing_ivis_survival} was up to day 40 as reported elsewhere\cite{Fraietta2018}. However, we also included a Kaplan-Meier figure up to day 46 (\cref{fig:mouse_dosing_ivis_survival_full}) where most of the mice euthanized from day 40 through day 46 from \gls{dms} groups showed no or very small fragment of spleen which was due to \gls{gvhd} responses. Similar \gls{gvhd} responses were reported earlier in \gls{nsg} mice where the mice injected with human \gls{pbmc} exhibited acute \gls{gvhd} between \SIrange{40}{50}{\day} post intravenous injection\cite{Ali2012}. Notably, both survival analyses (up to day 40 in \cref{fig:mouse_dosing_ivis_survival} and up to day 46 in \cref{fig:mouse_dosing_ivis_survival_full}) confirmed that \gls{dms}-expanded groups outperformed bead-expanded groups in terms of prolonging survival of Nalm-6 tumor challenged \gls{nsg} mice. Together, these data suggested that \glspl{dms} produce T cells that are not only more potent that bead-expanded T cells (even when accounting for differences in \gls{car} expression) but also showed that \gls{dms} expanded T cells are effective at lower doses. Given the quality control data of the T cells prior to injecting into the mice, it seems that this advantage is either due to the higher \pthp{} or the overall fitness of the T cells given the higher expansion in the case of \gls{dms} (\cref{fig:mouse_dosing_qc_cd4,fig:mouse_dosing_qc_growth}). It was likely not due to the memory phenotype given that it was actually slightly higher in the case of beads (\cref{fig:mouse_dosing_qc_mem}). \subsection{DMS-expanded T cells show greater anti-tumor activity \invivo{} compared to beads} \begin{figure*}[ht!] \begingroup \includegraphics{../figures/mouse_dosing_overview.png} \endgroup \caption[Mouse Dosing Experimental Overview] {Overview of \invivo{} experiment to test \gls{car} T cells expanded with either \glspl{dms} at different doses. } \label{fig:mouse_dosing_overview} \end{figure*} \begin{table}[!h] \centering \caption{Results for \gls{car} T cell \invivo{} dose study} \label{tab:mouse_dosing_results} \input{../tables/mouse_dose_car.tex} \end{table} % FIGURE put growth first in this figure \begin{figure*}[ht!] \begingroup \includegraphics{../figures/mouse_dosing_qc.png} \phantomsubcaption\label{fig:mouse_dosing_qc_mem} \phantomsubcaption\label{fig:mouse_dosing_qc_cd4} \phantomsubcaption\label{fig:mouse_dosing_qc_growth} \endgroup \caption[Mouse Dosing T cell Characteristics] {Characteristics of T cells harvested at day 14 injected into NSG mice at varying doses. Fractions of T cell subtypes in the day 14 product including \subcap{fig:mouse_dosing_qc_mem}{\ptmemp{}}. \subcap{fig:mouse_dosing_qc_cd4}{\pthp{}}, and \subcap{fig:mouse_dosing_qc_growth}{Fold change of T cells.} } \label{fig:mouse_dosing_qc} \end{figure*} % FIGURE explain what statistical test was used here \begin{figure*}[ht!] \begingroup \includegraphics{../figures/mouse_dosing_ivis.png} \phantomsubcaption\label{fig:mouse_dosing_ivis_images} \phantomsubcaption\label{fig:mouse_dosing_ivis_plots} \phantomsubcaption\label{fig:mouse_dosing_ivis_survival} \phantomsubcaption\label{fig:mouse_dosing_ivis_survival_comp} \phantomsubcaption\label{fig:mouse_dosing_ivis_survival_full} \endgroup \caption[Mouse Dosing IVIS and Survival Results] {T cells expanded with \glspl{dms} confer greater anti-tumor potency \invivo{} even at lower doses. \subcap{fig:mouse_dosing_ivis_images}{IVIS images of Nalm-6 tumor-bearing \gls{nsg} mice injected with varying doses of T cells} \subcap{fig:mouse_dosing_ivis_plots}{Plots showing quantified photon counts of the results from (\subref{fig:mouse_dosing_ivis_plots}).} \subcap{fig:mouse_dosing_ivis_survival}{Survival plots of mice} \subcap{fig:mouse_dosing_ivis_survival_comp}{Survival plots of mice showing only those that received a comparable number of \gls{car} T cells.} \subcap{fig:mouse_dosing_ivis_survival_full}{The same data as \subref{fig:mouse_dosing_ivis_survival} except showing the full time until euthanasia for all mice (including those that died via \gls{gvhd}).} } \label{fig:mouse_dosing_ivis} \end{figure*} \subsection{Beads and DMSs perform similarly at earlier timepoints} We then asked how T cells harvested using either beads or \gls{dms} performed when harvested at earlier timepoints\cite{Ghassemi2018}. We performed the same experiments as described in \cref{fig:mouse_dosing_overview} with the modification that T cells were only grown and harvested after \SI{6}{\day}, \SI{10}{\day}, or \SI{14}{\day} of expansion (\cref{fig:mouse_timecourse_overview}). T cells were frozen after harvest, and all timepoints were thawed at the same time prior to injection. The dose of T cells injected was \num{1.25e6} cells per mouse (the same as the high dose in the first experiment). All other characteristics of the experiment were the same. \begin{figure*}[ht!] \begingroup \includegraphics{../figures/mouse_timecourse_overview.png} \endgroup \caption[Mouse Timecourse Experimental Overview] {Overview of \invivo{} experiment to test \gls{car} T cells using either \glspl{dms} or bead harvested at varying timepoints. } \label{fig:mouse_timecourse_overview} \end{figure*} % RESULT find literature saying that CAR T cells grow slower As was the case with the first \invivo{} experiment, T cells activated with \glspl{dms} expanded much more efficiently compared to those expanded with beads (\cref{fig:mouse_timecourse_qc_growth}). When we quantified the \ptcarp{} of T cells harvested at each timepoint, we noted that the bead group had much higher \ptcar{} expression at earlier timpoints compared to \gls{dms}, while they equalized at later timepoints (\cref{fig:mouse_timecourse_qc_car}). In addition, overall \ptcar{} expression decreased at later timepoints, indicating that \gls{car} transduced T cells either grow slower or die faster compared to untransduced cells. The \pthp{} of the harvested T cells was higher overall in \gls{dms} expanded T cells but decreased with increasing timepoints (\cref{fig:mouse_timecourse_qc_cd4}). The \ptmemp{} was similar at day 6 between bead and \gls{dms} groups but the \gls{dms} group had higher \ptmemp{} at day 14 despite the overall \ptmemp{} decreasing with time as shown elsewhere (\cref{fig:mouse_timecourse_qc_mem})\cite{Ghassemi2018}. \begin{figure*}[ht!] \begingroup \includegraphics{../figures/mouse_timecourse_qc.png} \phantomsubcaption\label{fig:mouse_timecourse_qc_growth} \phantomsubcaption\label{fig:mouse_timecourse_qc_car} \phantomsubcaption\label{fig:mouse_timecourse_qc_cd4} \phantomsubcaption\label{fig:mouse_timecourse_qc_mem} \endgroup \caption[Mouse Timecourse T cell Characteristics] {Characteristics of T cells harvested at varying timepoints injected into NSG mice. \subcap{fig:mouse_timecourse_qc_growth}{Fold change of T cells (each timepoint only includes the runs that were harvested at day 14).} Fractions of T cell subtypes in the day 14 product including \subcap{fig:mouse_timecourse_qc_car}{\ptcarp{}}, \subcap{fig:mouse_timecourse_qc_cd4}{\pthp{}}, and \subcap{fig:mouse_timecourse_qc_mem}{\ptmemp{}}. } \label{fig:mouse_timecourse_qc} \end{figure*} We analyzed the tumor burden using \gls{ivis} which showed that mice that received T cells from any group performed better than those that received only saline (\cref{fig:mouse_timecourse_ivis}). Note that unlike the previous experiment, many of the mice survived until day 40 at which point \gls{gvhd} began to take effect (after euthanizing the mice at day 42, most had small or no spleen). When comparing bead and \gls{dms} groups, the \gls{dms} T cells still seemed superior to the bead group, at least initially (note that in this case they had similar numbers of \ptcar{} cells). At day 6, both \gls{dms} and bead groups seemed to eradicate the tumor initially, after which it came back after day 21 for the bead and day 28 for the \gls{dms} group. The day 10 groups performed somewhere in between, where they increased linearly unlike the day 6 groups but not as quickly as the day 14 groups. In the case of the \gls{dms} day 10 group, it also appeared like a few mice actually performed better than all other groups in regard to the final tumor burden. \begin{figure*}[ht!] \begingroup \includegraphics{../figures/mouse_timecourse_ivis.png} \phantomsubcaption\label{fig:mouse_timecourse_ivis_images} \phantomsubcaption\label{fig:mouse_timecourse_ivis_plots} \endgroup \caption[Mouse Timecourse IVIS Results] {\glspl{dms} exhibit superior anti-tumor activity \invivo{} at day 14 compared to beads but are similar to beads at lower timepoints. \subcap{fig:mouse_timecourse_ivis_images}{IVIS images for day 6 to day 42 of mice treated with varying doses of \gls{car} T cells grown with beads or \glspl{dms}.} \subcap{fig:mouse_timecourse_ivis_plots}{Quantified dotplots of the images in (\subref{fig:mouse_timecourse_ivis_images}). Numbers beneath each dot represent the number of mice at that timepoint.}, } \label{fig:mouse_timecourse_ivis} \end{figure*} \section{discussion} \begin{figure*}[ht!] \begingroup \includegraphics{../figures/mouse_summary.png} \phantomsubcaption\label{fig:mouse_summary_1} \phantomsubcaption\label{fig:mouse_summary_2} \endgroup \caption[Mouse Summary] {Summary of cells injected into mice during for \subcap{fig:mouse_summary_1}{the first mouse experiment} and \subcap{fig:mouse_summary_2}{the second mouse experiment}. The y axis maximum is set to the maximum number of cells injected between both experiments (\num{1.25e6}). Note that the \gls{car} was quantified using a separate panel than the rest of the markers. } \label{fig:mouse_summary} \end{figure*} The total number of T cells for each \invivo{} experiment are shown in \cref{fig:mouse_summary}. When we tested bead and DMS expanded \gls{car} T cells, we found that the \gls{dms} expanded CAR-T cells outperformed bead groups in prolonging survival of Nalm-6 tumor challenged (intravenously injected) \gls{nsg} mice. DMS expanded CAR-T cells were very effective in clearing tumor cells as early as 7 days post CAR-T injection even at low total T cell dose compared to the bead groups where tumor burden was higher than DMS groups across all the total T cell doses tested here. More interestingly, when only CAR-expressing T cell doses between bead and DMS groups were compared, DMS group had significantly higher survival effects over similar or higher CAR expression T cell doses from bead group. All these results suggest that the T cells in DMS groups (compared to bead group) resulted in highly effective CAR-T cells that can efficiently kill tumor cells. When comparing the total number of T cells of different phenotypes, we observed that when comparing low-dose \gls{dms} group to the mid- bead groups (which had similar numbers of \gls{car} T cells), the number of \ptmem{} (both with and without CD45RA) T cells injected was much lower in the \gls{dms} group (\cref{fig:mouse_summary_1}). This could mean several things. First, the \ptmem{} phenotype may have nothing to do with the results seen here, at least in this model. While this may have been the case in our hands, this would contradict previous evidence suggesting that \gls{tn} and \gls{tcm} cells work better in almost the same model (the only difference being Raji cells in place of Nalm-6 cells, both of which express CD19)\cite{Sommermeyer2015}. Second, the distribution of \gls{car} T cells across different subtypes of T cells was different between the \gls{dms} and bead groups (with possibly higher correlation of \gls{car} expression and the \ptmem{} phenotype). It is hard to assess this without strong assumptions as the \gls{car} was quantified using a separate flow panel relative to the other markers. We can also make a similar observation for the number of \pth{} T cells injected (\cref{fig:mouse_summary_1}). In this case, either the \pth{} phenotype doesn't matter in this model (or the \ptk{} population matters much more), or the distribution of \gls{car} is different between CD4 and CD8 T cells in a manner that favors the \gls{dms} group. While in a glioblastoma model and not a B-cell \gls{all} model, previous groups have shown that \pthp{} T cells are important for response\cite{Wang2018}. When testing \gls{car} T cells at earlier timepoints relative to day 14 as used in the first \invivo{} experiment, we noted that none of the \gls{car} treatments seemed to work as well as they did in the first experiment. However, the total number of \gls{car} T cells was generally much lower in this second experiment relative to the first (\cref{fig:mouse_summary}). Only the day 6 group had \gls{car} T cell numbers comparable to the weakest dose of bead cells given in the first experiment, and these T cells were harvested at earlier timepoints than the first mouse experiment and thus may not be safely comparable. The lower overall \gls{car} doses may explain why at best, the tumor seemed to be in remission only temporarily. Even so, the \gls{dms} group seemed to perform better at day 6 as it held off the tumor longer, and also slowed the tumor progression relative to the bead group at day 14 (\cref{fig:mouse_timecourse_ivis_plots}). Taken together, these data suggest that the \gls{dms} platform produces T cells that have an advantage \invivo{} over beads. While we may not know the exact mechanism, our data suggests that the responses are unsurprisingly influenced by the \ptcarp{} of the final product. Followup experiments would need to be performed to determine the precise phenotype responsible for these responses. \chapter{conclusions and future work}\label{conclusions} \section{conclusions} This dissertation describes the development of a novel T cell expansion platform, including the fabrication, quality control, and biological validation of its performance both \invitro{} and \invivo{}. Development of such a system would be meaningful even if it only performed as well as current methods, as adding another method to the arsenal of the growing T cell manufacturing industry would reduce the reliance on a small number of companies that currently license magnetic bead-based T cell expansion technology. However, we additionally show that the \gls{dms} platform expands more T cells on average, including highly potent \ptmem{} and \pth{} T cells, and produces higher percentages of both. If commercialized, this would be a compelling asset the T cell manufacturing industry. % TODO double check the numbers at the end In \cref{aim1}, we develop the \gls{dms} platform and verified its efficacy \invitro{}. Importantly, this included \gls{qc} steps at every critical step of the fabrication process to ensure that the \gls{dms} can be made within a targeted specification. These \gls{qc} steps all rely on common, relatively cost-effective assays such as the \gls{haba} assay, \gls{bca} assay, and \glspl{elisa}, thus other labs and commercial entities should be able to perform them. The microcarriers themselves are an off-the-shelf product available from reputable vendors, further enhancing translatability. On average, we demonstrated that the \gls{dms} outperforms state-of-the-art bead-based T cell expansion technology in terms of total fold expansion, \ptmemp{}, and \pthp{} by \SI{143}{\percent}, \SI{2.5}{\percent}, and \SI{9.8}{\percent} controlling for donor, operator, and a variety of process conditions. In \cref{aim2a}, we developed a modeling pipeline that can be used by commercial entities as the scale up this process to identify \glspl{cqa} and \gls{cpp}. These are highly important for a variety of reasons. First, understanding pertinent \glspl{cpp} allow manufacturers to operate their process at optimal conditions. This is important for anti-tumor cell therapies, where the prospects of a patient can urgently depend on receiving therapy in a timely manner. Optimal process conditions allow T cells to be expanded as quickly as possible for the patient, while also minimizing cost for the manufacturer. Second, \glspl{cqa} can be used to define process control schemes as well as release criteria. Process control, and with it the ability to predict future outcomes based on data obtained at the present, is highly important for cell therapies given that batch failures are extremely expensive\cite{Harrison2019}, and predicting a batch failure would allow manufacturers to restart the batch in a timely manner without wasting resources. Furthermore, \glspl{cqa} can be used to define what a `good' vs `bad' product is, which will important help anticipate dosing and followup procedures in the clinic if the T cells are administered. In the aim, we cannot claim to have found the ultimate set of \glspl{cqa} and \glspl{cpp}, as we used tissue culture plates instead of a bioreactor and we only used one donor. However, we have indeed outlined a process that others may use to find these for their process. In particular, the 2-phase modeling process we used (starting with a \gls{doe} and collecting data longitudinally) is a strategy that manufacturers can easily implement. Also, collecting secretome and metabolome is easily generalized to any setting and to most bioreactors and expansion systems, as they can be obtained with relatively inexpensive equipment (Luminex assay, benchtop \gls{nmr}, etc) without disturbing the cell culture. In \cref{aim2b}, we further explored additional tuning knobs that could be used to control and optimize the \gls{dms} system. We determined that altering the \gls{dms} concentration temporally has profound effects on the phenotype and expansion rate. This agrees with other data we obtained in \cref{aim2a} and with what others have generally reported about signal strength and T cell differentiation\cite{Gattinoni2012, Lozza2008, Lanzavecchia2005, Corse2011}. We did not find any mechanistic relationship between either integrin signaling or \gls{il15} signaling. In the case of the former, it may be more likely that the \glspl{dms} surfaces are saturated to the point of sterically hindering any integrin interactions with the collagen surface. In the case of \gls{il15} more experiments likely need to be done in order to plausibly rule out this mechanism and/or determine if it is involved at all. % TODO make this tighter and cite paper showing that this makes at least some % sense In \cref{aim3} we determined that the \glspl{dms} expand T cells that also performed better than beads \invivo{}. In the first experiment we performed, the results were very clearly in favor of the \glspl{dms}. In the second experiment, even the \gls{dms} group failed to fully control the tumor burden, but this is not surprising given the low \ptcarp{} across all groups. Also, despite this, the \gls{dms} group appeared to control the tumor better on average for early, mid, and late T cell harvesting timepoints. It was not clear if this effect was due to increased \cdp{} or overall increased fitness of the \gls{dms}-expanded T cells given their higher expansion rate. The \ptmemp{} did not seem to be a factor given that it was nearly the same in the first experiment between \gls{dms} and bead groups despite the clear advantage seen in the \gls{dms} group. \section{future directions} There are several important next steps to perform with this work, many of which will be relevent to using this technology in a clinical trial: \subsection{Translation to GMP process} While this work was done with translatability and \gls{qc} in mind, an important feature that is missing from the process currently is the use of \gls{gmp} methods and materials. The microcarriers themselves are made from porcine-derived collagen, which itself is not \gls{gmp}-compliant due to its non-human animal origins. However, using any other source of collagen should work so long as the structure of the microcarriers remains relatively similar and it has lysine groups that can react with the \gls{snb} to attach \gls{stp} and \glspl{mab}. Obviously these would need to be tested and verified, but they should not be insurmountable. Furthermore, the \gls{mab} binding step requires \gls{bsa} to prevent adsorption to the non-polar polymer walls of the reaction tubes. A human carrier protein such as \gls{hsa} could be used in its place to eliminate the non-human animal origin material, but this could be much more expensive. Alternatively, the use of protein could be replaced altogether by a non-ionic detergent such as Tween-20 or Tween-80, which are already used for commercial \gls{mab} formulations for precisely this purpose\cite{Kerwin2008}. Validating the process with Tween would be the best next step to eliminate \gls{bsa} from the process. The \gls{stp} and \glspl{mab} in this process were not \gls{gmp}-grade; however, they are commonly used in clinical technology such as dynabeads and thus the research-grade proteins used here could be easily replaced. The \gls{snb} is a synthetic small molecule and thus does not have any animal-origin concerns. \subsection{mechanistic investigation} Despite the improved outcomes in terms of expansion and phenotype relative to beads, we don't have a good understanding of why they \gls{dms} platform works as well as it does. Several broad areas remain to be investigated, including the role of the increased cytokine output (including \il{15} which was explored to some extent in this work), the role of cells on the interior of the \gls{dms} relative to those outside the \gls{dms}, and the role of the physical surface properties of the \gls{dms} (including the morphology and the stiffness). \subsection{additional ligands and signals on the DMSs} In this work we only explored the use of \acd{3} and \acd{28} \glspl{mab} coated on the surface of the \gls{dms}. The chemistry used for the \gls{dms} is very general, and any molecule or protein that could be engineered with a biotin ligand could be attached without any further modification. There are many other ligands that could have profound effects on the expansion and quality of T cells which may be utilized. The simplest next step is to simply vary the ratio of \acd{3} and \acd{28} signal. Another obvious example is to attach \il{15}/\il{15R$\upalpha$} complexes to the surface to mimic \textit{trans} presentation from other cell types\cite{Stonier2010}. Other adhesion ligands or peptides such as GFOGER could be used to stimulate T cells and provide more motility on the \glspl{dms}\cite{Stephan2014}. Finally, viral delivery systems could theoretically be attached to the \gls{dms}, greatly simplifying the transduction step. \subsection{assessing performance using unhealthy donors} All the work presented in this dissertation was performed using healthy donors. This was mostly due to the fact that it was much easier to obtain healthy donor cells and was much easier to control. However, it is indisputable that the most relevant test cases of the \gls{dms} will be for unhealthy patient T cells, at least in the case of autologous therapies. In particular, it will be interesting to see how the \gls{dms} performs when assessed head-to-head with bead-based expansion technology given that even in healthy donors, we observed the \gls{dms} platform to work where the beads failed (\cref{fig:dms_exp_fold_change}). \subsection{translation to bioreactors} In this work we performed some preliminary experiments demonstrating that the \gls{dms} platform can work in a Grex bioreactor. While an important first step, more work needs to be done to optimize how this system will or can work in a scalable environment using bioreactors. There are several paths to explore. Firstly, the Grex itself has additional automation accessories which could be tested, which would allow continuous media exchange and cytokine administration. While this is an improvement from the work done here, it is still a Grex and has all the disadvantages of an open system. Secondly, other static bioreactors such as the Quantum hollow fiber bioreactor (Terumo) could be explored. Essentially the \gls{dms} would be an additional matrix that could be supplied to this system which would enhance its compatibility with T cells. Finally, suspension bioreactors such as the classic \gls{cstr} or WAVE bioreactors could be tried. The caveat with these is that the T cells only seem to be loosely attached to the \gls{dms} throughout culture, so an initial activation/transduction step in static culture might be necessary before moving to a suspension system (alternatively the \gls{dms} could be coated with additional adhesion ligands to make the T cells attach more strongly). \onecolumn \clearpage \appendix \chapter{meta analysis database code}\label{sec:appendix_meta} The code used to aggregate all experimental data was written primarily in Python, with a subprocess running R in a Docker container to handle the flow cytometry data (\cref{fig:meta_overview}). The Postgres database itself was hosted using \gls{aws} using their proprietary Aurora implementation. % TODO explain what the colors mean \begin{figure*}[ht!] \begingroup \includegraphics{../figures/metaanalysis.png} \endgroup \caption[Meta-analysis overview] {Overview of strategy used for meta-analysis} \label{fig:meta_overview} \end{figure*} The code is available here: \url{https://github.gatech.edu/ndwarshuis3/mdma}. \chapter{binding kinetics code}\label{sec:appendix_binding} The \gls{stp} binding kinetic profile was fit and calculated using the following MATLAB code. Note that the \inlinecode{geometry} parameter was varied so as to minimize the \inlinecode{SSE} output. \lstinputlisting{../code/diffusion_stp.m} The geometric diffusivity from above (the \inlinecode{geometry} variable) was used in the below code to obtain the reaction profile for the \gls{mab} binding step. The model is the same except for the parameters which were changes to reflect the \gls{mab} coating process. \lstinputlisting{../code/diffusion_mab.m} \chapter{washing kinetics code}\label{sec:appendix_washing} The wash steps for the \gls{dms} were modeled using the following code: \lstinputlisting{../code/microcarrier_diffusion_washing.m} Complete output from this code is shown below: \input{../code/washing_out.tex} \chapter{references} \renewcommand{\chapter}[2]{} % noop the original bib section header \bibliography{references} \bibliographystyle{naturemag} \end{document}